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ABSTRACT 
The identification of novel cancer-associated biomarkers against which drugs can be developed is 
anticipated to be beneficial in multiple ways; including their use as monotherapies and in 
combination with current chemotherapeutic agents for improved anti-cancer treatment outcome. 
Recently, research in our own laboratory and others have reported elevated expression of the 
nuclear transporter Kpnβ1 in multiple cancers. Using the cervical cancer model, we showed that its 
inhibition using small-interfering RNA (siRNA) resulted in cancer cell death via apoptosis while 
sparing normal cells, suggesting it has potential as a target for anti-cancer therapy. An in silico screen 
for Kpnβ1 inhibitors identified several small molecules that showed inhibitory effects on nuclear 
import as well as cancer killing activity. 
 
In this study, we aimed to examine the potential of one such small molecule, the Inhibitor of Nuclear 
Import-43 (INI-43) as a lead compound with anti-cancer activities using multiple cancer models. 
Through culture-based in vitro assays, we demonstrated that INI-43 inhibited the proliferation of 
cancer cells grown anchorage-dependently and independently. These effects were similarly 
observed in Kpnβ1 knock-down cells, and Kpnβ1 over-expression was able to partially reverse these 
effects, suggesting that the anti-cancer effects of INI-43 is mediated through interference of the 
Kpnβ1 function. Toxicology studies and liver microsomal assay showed that INI-43 has an acceptable 
toxicity profile in nude mice and is metabolically stable, allowing its use in in vivo testing. 
Intraperitoneal administration of INI-43 significantly reduced the growth of subcutaneously 
xenografted cervical and oesophageal tumour cells in nude mice, supporting its anti-cancer activity 
in vivo.  
 
xx 
 
To examine the potential of using INI-43 in combination therapy, we examined the effects of the 
combined treatment of INI-43 and Cisplatin (CDDP), a first-line chemotherapeutic agent used in the 
treatment of many cancers. INI-43 treatment at sub-lethal concentrations enhanced cancer cells' 
sensitivity to CDDP, which was similarly observed in Kpnβ1 knock-down cells. Using an ovarian 
cancer model, we demonstrated that CDDP treatment led to elevated expression and nuclear 
localization of Kpnβ1, suggesting that Kpnβ1 is involved in CDDP-induced stress response. INI-43 
treatment impeded the CDDP-induced nuclear accumulation of Kpnβ1 which correlated with 
increased cell death, suggesting that nuclear localization of Kpnβ1 may be important for ovarian 
cancer cell survival when challenged with genotoxins such as CDDP. Using the cervical cancer model, 
we demonstrated that INI-43 enhanced CDDP-induced cell death synergistically, and that the 
enhanced cell death is mediated through stabilizing p53 protein. This associated with decreased 
levels of Myeloid Cell Leukemia 1 (Mcl-1), an anti-apoptotic factor negatively regulated by p53. 
Furthermore, INI-43 treatment reduced the nuclear import of NFκB, a stress-regulated response 
known to promote cancer cell survival. Decreased levels of various downstream pro-survival and 
DNA-repair targets of NFκB were observed, including cyclinD1, c-Myc and X-Linked Inhibitor of 
Apoptosis Protein (XIAP), which correlated with increased DNA damage and apoptosis. Taken 
together, we show that nuclear import inhibition using small molecules could have therapeutic 
benefits in the treatment of cancer, and that INI-43 is a promising candidate for further 
development to be used in anti-cancer monotherapy or combination chemotherapy.  
1 
 
CHAPTER 1 
LITERATURE REVIEW 
1.1. Global trend of cancer and cancer related deaths 
The growing burden of cancer worldwide necessitates the continued and collaborative efforts in 
clinical and basic research, to understand this disease, and to set the grounds for improved 
preventative methods, early and accurate detection, as well as better and more accessible 
treatments. In a report issued by the International Agency for Research on Cancer, it has been 
estimated that approximately 14 million new cancer cases and 8.2 million cancer deaths were 
reported in 2012 worldwide, which is expected to rise to 22 million before reaching 2032, and cancer 
related death is expected to rise from 8.2 million to 13 million in the same timeframe (Globocan, 
2012). In addition to this, developing countries such as Africa, parts of Asia, Central and South 
America accounts for over 60% of total cancer cases worldwide, and over 70% of cancer-related 
deaths worldwide. The alarming rate at which cancer cases and cancer related deaths are escalating 
worldwide, especially in developing countries present a global health concern. 
 
In less developed countries such as Africa, cancer has received low priority in the health care system 
due mainly to the overwhelming load of other communicable diseases such as Human 
Immunodeficiency Virus infection/acquired immune deficiency syndrome (HIV/AIDS) and 
tuberculosis. The limited facilities for providing diagnosis and treatment coupled to the insufficient 
governmental health care budgets are contributing factors to the high rates of cancer-related 
mortality, which accounted for 65% of the global cancer-related deaths (Globocan, 2012). This 
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highlights the urgent need to identify novel strategies for cancer control with increased accessibility 
and decreased economical burden. 
 
1.2. Improving the rate of survival for cancer patients 
Whilst chances of developing cancer in an individual can be reduced by taking preventative 
measures, such as abstaining from smoking tobacco, living a healthy lifestyle, and getting vaccinated 
against certain cancer-causing infections, the risk cannot be completely eliminated due to 
involuntary risk factors such as genetic inheritance. Early detection and efficient treatments thus 
play key roles in the improvement of cancer survival. As an example, the introduction and wide use 
of the Papanicolaou test for the early detection of cervical cancer has successfully reduced cervical 
cancer related deaths by over 80% since the 1930s in the United States1. Unfortunately, with a 
limitation in facilities and trained cytologists in the poorer communities of the developing world, 
access to such screening programs is inadequate.  
 
1.2.1. Current diagnostic tools and ongoing research 
The general diagnostic tools for cancer include: (a) biopsies, where the target tissue is surgically 
removed and examined under the microscope for abnormalities; (b) endoscopies, where the 
suspicious tissue is viewed live in situ; (c) diagnostic imaging, where images of the internal organ is 
produced and analyzed for abnormalities; as well as (d) blood tests, in which the presence or 
concentration of cancer-specific biomarkers is investigated. The early detection of cancer relies on 
both the patient's initiative as well as sensitive and accurate diagnostic tools. These tests are used 
more commonly in combination to detect and confirm the presence of cancer, as single tests can 
sometimes be inconclusive. These form part of an intensive cancer research area, aimed at 
improving the accuracy of diagnosis using more cost-effective, rapid and less invasive methods.  
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Numerous reports have recently described preliminary findings of various protein and RNA 
molecules present in the serum, blood, saliva or vaginal fluid, indicating diagnostic usefulness in 
identifying cancer2-9. Correlation between genetic and cellular abnormalities (such as chromosome 
translocation and multinucleation) with disease state led to the proposal for the incorporation of 
these characteristic traits into routine assessment for certain cancers10, 11; and some research groups 
have recommended using a combination of markers to increase the accuracy of diagnosis12-15. The 
recent identification of exosomes and their implications in cancer have been widely recognized for 
diagnostic significance16-20. In addition to these, the continued testing and development of novel 
methods and technologies to detect possible signs correlating to cancer development is ongoing. 
Some of these include the detection of cancer-related gene mutations by using high resolution 
melting (HRM)21 and amplicon-based next generation sequencing22; development of 
chemiluminescent immunoassays to identify presence of diagnostic biomarkers23; and nanoparticle-
based sensors to detect cancer-related volatile organic compounds from exhaled breath24. Improving 
the current diagnostic tools, coupled to better means of result interpretation are also areas of 
intense research at present25-30.  
 
1.2.2. Contemporary anti-cancer therapies and shortfalls 
A major determinant of cancer survival is treatment. Although treatment outcome depends heavily 
on factors such as the patient's age, health condition, the type and stage of cancer; adequate and 
efficient treatment is still nonetheless impactful on survival. The current treatments for cancer 
comprises various strategies, and the most commonly used are (A) surgery, (B) radiation therapy and 
(C) chemotherapy. 
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1.2.2.1. Current treatment options 
(A) Surgery is the oldest type of cancer therapy and involves the operational removal of the tumour 
and surrounding tissues. Whilst this treatment method is direct and fast, its use is limited for 
disseminated and haematological tumours. Surgery is frequently combined with radiotherapy 
and/or chemotherapy, where the complete tumour removal is not possible due to metastasis or 
damage to the body. 
 
(B) Radiation therapy makes use of photons or charged particles to induce DNA damage in tumour 
cells, thereby causing apoptosis31. Like surgery, radiation therapy is only effective at targeting 
tumour cells localized in one area, and is also used in combination with other therapies. 
 
(C) Chemotherapy involves the use of chemical entities with cytotoxic properties administered orally 
or intravenously, and these can be categorized into the 'conventional' chemotherapeutic agents, 
which display systemic cytoxicity (C-i); targeted therapy (C-ii); and hormonal therapy (C-iii), which 
have narrower spectrum and more specific activities. 
 
(C-i) Conventional chemotherapy acts by disturbing important mitotic functions, such as 
interference with DNA synthesis and replication. This is achieved by various first-line drugs, and 
different classes employ different mechanisms. 
 
Platinum based agents are coordination complexes of platinum, and those frequently used in anti-
cancer treatment include Cisplatin, Carboplatin and Oxaliplatin. Cisplatin (cis-
diamminedichloridoplatinum(II), or CDDP) was the first platinum based drug to be identified in the 
1840's by Italian chemist Michele Peyrone32. Its chemical structure was elucidated in 1893 by the 
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Swiss chemist Alfred Werner (Fig. 1.1)33, and its inhibitory effects on cell division was first 
demonstrated in 1965 in E.coli34. CDDP subsequently gained scientific interest after its anti-tumour 
effects were shown in mice35, and became the first FDA-approved platinum-based compound for 
treatment of cancer in 197836. Since then, it has been used to treat a wide range of cancers including 
sarcomas, carcinoma and germ cell cancers. CDDP is composed of a charged platinum ion 
surrounded by two amine ligands and two chloride ligands37. Upon entry into the cell, CDDP is 
activated where the chloride atoms are displaced by water molecules, a process known as aquation 
which then permits the platinum to interact with DNA bases. This induces DNA damage in cells by 
causing intrastranded adducts and interstranded crosslinks, thereby inhibiting cell division which 
results in apoptotic cell death38. As such, the cytotoxic activities of CDDP is believed to be mediated 
mainly through DNA damage, although CDDP has also been shown to cause other effects such as 
inducing oxidative stress and disturbing the normal intracellular calcium homeostasis; as well as 
causing alterations in various important mediators of cell proliferation, apoptosis and signal 
transduction38. The success of CDDP in anti-cancer therapy has led to interest in other metal-
containing compounds as potential anti-cancer drugs, and various platinum analogues have also 
been studied39.  
 
 
 
 
Figure 1.1. The chemical structure of the platinum-based agent Cisplatin (cis-diamminedichloridoplatinum(II), 
or CDDP).  
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There are other conventional chemotherapeutic agents targeting different processes important to 
cell division. Antimetabolites such as Methotrexate, Fluorouracil and Gemcitabine interferes with 
DNA replication by competing with nucleotides during DNA synthesis, or inhibiting crucial enzymes 
involved in this process40, 41. The anthracycline drugs such as Doxorubicin acts via DNA intercalation 
as well as damaging intracellular molecules by generating free radicals42. Inhibiting the DNA 
structure regulating enzyme topoisomerase is another class of agents including Irinotecan and 
Topotecan, and these drugs generate DNA breakage by preventing the religation step after 
replication and transcription43. Microtubule targeting agents (MTAs) are also effective cytotoxic 
agents. Microtubules are highly dynamic structures especially in mitotic cells where they are 
constantly undergoing polymerization and depolymerization44. MTAs comprises vinca alkaloids such 
as Vincristine and Vinblastine, which prevent polymerization of the tubulin subunits, and taxanes 
such as Paclitaxel and Docetaxel which prevents their depolymerization. These abnormalities in 
microtubule function render the cells incapable of dividing and induces cell cycle arrest, eventually 
leading to apoptosis45. 
 
(C-ii) Targeted therapy, as suggested by its name, is the use of chemical entities which interferes 
with specific molecules involved in tumourigenesis, rather than killing all rapidly dividing cells like 
conventional chemotherapeutic agents46, 47. A well-known example is the tyrosine kinase inhibitor 
Imatinib, which targets tyrosine kinase enzymes, including the fusion protein BCR-ABL148. The BCR-
ABL1 fusion is caused by the Philadelphia chromosome commonly observed in leukemic cancer cells, 
where a translocation from chromosome 9 to chromosome 22 results in the hybrid tyrosine kinase 
protein BCR-ABL1, which is constitutively active and causes uncontrolled cell proliferation49. Its 
exclusive presence in leukemic cancer cells allows the increased selectivity of Imatinib at targeting 
malignant cells only. Other well-known examples are Gefitinib and Erlotinib which are used in the 
treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer50-52. Both compounds target 
the Epidermal Growth Factor Receptor (EGFR), a protein frequently over-active or mutated in 
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cancer53. An advantage of using targeted therapy over conventional chemotherapy is the reduced 
occurrence of adverse side effects51, 52, as these agents are less toxic to non-cancer cells. 
 
(C-iii) Hormonal therapy is commonly used for cancers that are derived from hormonally responsive 
tissues, such as breast and prostate, as these cancers present the opportunity for hormonal 
intervention54, 55. Success has been demonstrated using Aromatase inhibitors in treating breast 
cancer, which acts by decreasing the level of oestrogen56, a hormone known to promote breast 
tumourigenesis through stimulating cell proliferation54. 
 
There are various other therapies currently in practice, such as immunotherapy, hyperthermia 
therapy, virotherapy and gene therapy. These different therapeutic approaches are frequently 
combined to optimize treatment outcome. Whilst early stage, localized tumours can be treated with 
radiation and surgery, disseminated cancer cells resulting from metastatic tumours presents 
difficulty as they may be present at multiple sites, some of which are not physically accessible. In 
these cases, chemotherapeutic agents that can be delivered via the circulatory system to otherwise 
unreachable sites may be beneficial. 
 
1.2.2.2. Adverse side effects associated with chemotherapy 
The use of chemotherapy, as outlined above, targets cellular functions important to cancer cells as 
well as rapidly-dividing normal cells, leading to their insufficient selectivity. Several side effects 
associated with their use directly reflect their toxic effects on non-cancer cells. This is a major 
concern in anti-cancer therapy, as the quality of life for patients undergoing chemotherapy is 
severely compromised57. Discomforts experienced as a result of chemotherapy encompass a wide 
range of symptoms, and some commonly reported ones include pain sensation in the lower back, 
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joint and stomach; swelling of body parts such as the extremities and face; abnormalities of the 
digestive and excretion systems such as nausea, vomiting, constipation, diarrhoea, pain and difficulty 
in urination which often accompanied with blood. Some organs of the body such as skin, heart and 
hair follicles; as well as visual, auditory and respiratory functions are also commonly affected areas. 
Unpleasant experiences such as fevers and chills, unusual bleeding, bruising and sores around the 
mouth are also frequently experienced by patients undergoing chemotherapy58-62.  
 
1.2.2.3. Resistance to chemotherapy 
In addition to all the undesired side effects that accompanies chemotherapy, treatment outcome is 
frequently compromised as a result of resistance to anti-cancer drugs (chemoresistance). The 
mechanisms underlying such resistance have been extensively characterized and various causatives 
have been identified. These can be broadly categorized into two classes; the host factors, and the 
genetic/epigenetic alterations within the cancer cells63. Host factors include alterations which occur 
in the tumour-bearing patient, such as drug absorption, metabolism and excretion. In this class, 
resistance can arise as a result of decreased drug absorption, inappropriate metabolism leading to 
inactive derivative of the parent drug, such as the conversion of Irinotecan by CYP45064, 65, rapid 
excretion63 and failure to deliver drug to the target sites66. 
 
The more extensively researched mechanisms of chemoresistance is the genetic and epigenetic 
alterations, which occur in the actual cancer cells. These include alterations in cellular uptake, 
activation/sequestration, detoxification, suppression of apoptotic pathways, and drug-target 
mutations. The cellular entry of the drugs is dependent on their chemical structures, and various 
anti-cancer agents are known to enter the cells in receptor or transporter mediated ways. In these 
cases, decreased expression or mutation in the receptors or transporters can result in impaired drug 
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uptake, as demonstrated by the receptor Smoothened67-69, nucleoside transporters70, 71 and folate 
transporters72, leading to impaired drug uptake which ultimately manifest a decreased response.  
 
Upon cellular entry, the fate of the anti-cancer drugs is still vulnerable to numerous cellular actions 
leading to their sequestration or inactivation, rendering them ineffective. For example, Cytarabine 
which has been used to treat acute myeloid leukemia and non-Hodgkin Lymphoma requires 
activation through serial phosphorylation to form Cytarabine triphosphate by the enzyme 
Deoxycytidine Kinase. Its toxicity, however, can be evaded via decreased levels or expression of the 
mutant Deoxycytidine Kinase, thereby preventing the formation of the active form of the drug73-76. 
Whilst some drugs present cancer cells with the opportunity to prevent their activation, cancer cells 
have also formulated measures to inactivate active drugs, such as the conjugation of glutathione and 
metallothionine to platinum based agents and anthracyclines77-83. The consequences, whether 
through preventing drug activation or initiating drug inactivation, is decreased responsiveness to 
treatment with these agents. 
 
Moreover, in the use of targeted therapies, resistance can arise as a result of disrupted binding of 
drugs to the target proteins against which they were designed for. This has been demonstrated for 
Imatinib84, Erlotinib and Gefitinib85-87. In these settings, mutations occurring in the target proteins 
prevents drug-target associations, attributing to the drug-resistant phenotypes88-96. On the other 
hand, targeting the HER-2 protein in breast carcinoma using a monoclonal antibody, Trastuzumab 
has yielded resistant cancer cells via various mechanisms. Alterations in binding of Trastuzumab to 
HER-2 is attributed to two mechanisms; firstly, the expression of a truncated HER-2 which lacks the 
Trastuzumab binding epitope97; and secondly, the increased expression of the membrane associated 
Glycoprotein Mucin-4 (MUC4), which masks the Trastuzumab binding epitopes on HER-2, leading to 
decreased binding capacity98, 99. Other mechanisms have also been reported to confer Trastuzumab 
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resistance, including the elevated activation of HER-2 downstream PI3K/AKT pathway100, 101, as well 
as the compensatory activation of parallel pathways such as Insulin-like Growth Factor-1 Receptor 
(IGFR1)102, 103 and HER-3104, 105. 
 
Membrane transporter mediated drug elimination from cancer cells is accountable for resistance to 
a wide range of structurally and mechanistically diverse compounds, and has been reported in many 
types of cancers. This is caused by the increased expression or activity of the ATP-binding cassette 
(ABC) membrane transporters. Of the 49 transporters known in human, 3 have been shown to 
confer drug resistance, including P-glycoprotein (P-gp), Multidrug Resistance-associate Protein 1 
(MRP1) and Mitoxantrone Resistance Protein (MXP). Together, these transporters actively pump out 
a wide range of clinically important chemotherapeutic agents from the cells, including Taxol, 
Vincristine, Vinblastine, Etoposide, Doxorubicin, Paclitaxel, Irinotecan, Methotrexate, topoisomerase 
inhibitors, anthracyclines, Fluorouracil and others63, 106-108. The modification of drugs by conjugation 
to glutathione leads to their recognition by these transporters and subsequent elimination from 
cancer cells107. The challenge posed by drug resistance of this nature presents even more clinical 
difficulty, as the resistance developed as a result of using one agent will result in resistance to a 
broad range of structurally and mechanistically unrelated agents limiting the subsequent treatment 
options107. 
 
Resistance to anti-cancer drugs can be inherent, where cancer cells are innately resistant prior to 
chemotherapeutic treatment; or acquired, where the resistant phenotype is a result of 
chemotherapy107. The acquired drug-resistance can arise with a small subpopulation of the tumour 
cells bearing intrinsic resistance or, alternatively developed resistance by random genetic/epigenetic 
alteration. By the Darwinian law of evolution, these resistant subpopulations become enriched 
under the selective pressure of chemotherapy. It is well-known that tumour development is tightly 
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linked to accumulation of genetic and epigenetic abnormalities, leading to high levels of 
intratumoural hetergeneity109-112. The diversity found within tumour subpopulations may account for 
cancer progression and malignant phenotypes such as invasiveness and metastatic potential. More 
importantly, it has been suggested to be the founding factor for drug resistance, which provides 
increased adaptability for the tumour population as a whole109, 113. Indeed, the heterogeneic nature 
of tumour cells have been demonstrated for many different types of cancers114-119, which is 
associated with drug resistance. For this reason, the inclusion of heterogeneity assessment into 
prognostic evaluations had been proposed117, 119. The heterogeneous nature of tumour cells, coupled 
to the Darwinian evolution almost predicts the resistant fate of cancer cells subjected to 
chemotherapy.  
 
1.2.3. Combination chemotherapy 
Understanding the underlying mechanisms responsible for anti-cancer drug resistance is important, 
as this may provide guidance for future treatments. Successful attempts have been made in various 
cases to reverse chemoresistance. These include the co-administration of efflux pump inhibitors; and 
the use of second-generation drugs which are able to bind to the mutated target proteins in case of 
targeted therapy, where the causal mutation for resistance has been identified120, 121. 
 
The use of combination chemotherapy, in particular, is a powerful strategy with wider application in 
combating chemoresistance in general. The rationale of this approach is to use mechanistically 
different agents each targeting their respective susceptible cells to aim for maximum cell death in 
the heterogeneic tumour population. This is simplified in Fig. 1.2, where drug-A and drug-B is each 
active against a subset of a heterogeneous tumour population. The independent use of either drugs 
will result in enrichment of the resistant subpopulations, which can be avoided by the combined 
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treatment of drug-A and drug-B. True clinical cases are, however, more complicated with higher 
levels of heterogeneity, and combination regimens frequently involve the use of multiple agents. 
The direct correlation between the number of agents used and cure rate has been reported for 
acute lymphoid leukemia, where the use of up to 8 agents showed a cure rate of 80%, supporting 
the efficacy of using combination chemotherapy over monotherapy†. 
 
'Sequential' combination chemotherapy has also been proposed, where the use of each drug in the 
combination is separated temporally, rather than simultaneously. Whilst this may sound feasible, it 
must be taken into consideration that tumours cells are genomically unstable, where genetic and 
epigenetic changes are not static. Accumulation of mutations in these cells thus occur at a much 
faster rate than normal cells. Prolonged survival could therefore afford time for the development of 
an even more heterogeneic population with increased chance of resistance occurring, and 
potentially via mechanisms not targeted by neither drug-A nor drug-B as shown in Fig. 1.2. 
Sequential treatment could thus promote the sequential development of multidrug resistant cells. 
The ideal situation is therefore to target maximal cancer cell death in the shortest period possible. 
Though practically, this is often limited by adverse side effects tolerability, as intensive combination 
chemotherapy regimens can sometimes lead to severe side effects. For this reason, sequential 
treatment is sometimes favoured over simultaneous treatment122. Combination chemotherapy, 
whether through sequential or concurrent administration has nonetheless demonstrated success in 
several cases over single agent treatment, such as the combined use of Docetaxel and Capecitabine, 
compared to Docetaxel alone123, 124; and the combined use of Paclitaxel and Gemcitabine, compared 
to Paclitaxel alone125, for breast cancer patients insensitive to anthracycline treatments. A 
combination of Erlotinib and Gemcitabine has also generated more favourable treatment outcome 
compared to Gemcitabine alone in advanced pancreatic cancer patients126. While increased efficacy  
                                                          
†
Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., Bast, R.C., Gansler, T.S.,Holland, J.F., Frei, E. (Eds). (2003) Holland-Frei Cancer Medicine, 6th 
Edition. Shelton, Connecticut: People's Medical Publishing House-USA.  
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Figure 1.2. Single-agent chemotherapy versus combination chemotherapy. Drug-A and drug-B each targets a 
subset of the heterogeneous tumour population. Monotherapies using drug-A or drug-B alone promotes the growth 
of the resistant subpopulations. This can be avoided by a combined therapy of using drug-A and drug-B together. 
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is observed with various combinations, the toxic effects should also be taken into consideration. A 
phase III clinical trial reported that the addition of Gemcitabine to the Carboplatin-Paclitaxel pair in 
treating ovarian cancer was associated with more frequent grades 3-4 toxicity and decreased the 
quality of life, leading to no survival advantage compared to Carboplatin-Paclitaxel treatment127. 
 
In the battle against chemoresistance, the identification of novel, previously unexploited 'druggable' 
targets holds great potential, and may be a powerful strategy when used in combination with 
clinically relevant cytotoxic agents to improve treatment outcome. The designing of such treatment 
protocols require careful investigative planning and various factors need to be taken into 
consideration. These include the mechanism of action for each drug to be used in combination, 
nature of drug interaction (additive, synergistic or antagonistic), scheduling of administration and 
maintenance, as well as the severity of adverse effects to aim for a balance between benefits of 
treatment and harmful side effects. As this can vary from case to case, each combination should be 
investigated empirically. 
 
1.3. Nuclear transport and cancer 
The development of novel and more specific anti-cancer agents with reduced side effects has 
become a focus of various research organizations and pharmaceutical companies. The identification 
of cancer biomarkers for diagnostic and prognostic purposes, as well as elucidating molecular events 
on which cancer cells are reliant is of particular interest. Our laboratory has previously carried out a 
microarray study to investigate mRNA levels in patient-derived cervical cancer tissues and normal 
cervical specimens. Comparison of the expression profiles elucidated the differential expression of 
various genes between cancer and non-cancer128. Of those, three genes known to be involved in the 
nucleo-cytoplasmic trafficking system showed elevated levels in the cancer, namely crm1, kpnβ1, 
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kpnα2 and Ran. The nucleo-cytoplasmic trafficking system has gained increasing attention in recent 
years for their close correlation to cancer, as malfunction and dysregulation of this cellular process 
have been reported across a broad spectrum of cancers. 
 
In eukaryotic cells, the genetic contents and processes associated with it, such as DNA replication 
and mRNA transcription are separated from the cytoplasm by the double membraned nuclear 
envelope. This compartmentalization of cellular contents is important, providing spatial control for 
important cellular processes which enables the cells to execute different activities simultaneously 
and efficiently. As such, the appropriate shuttling of macromolecules between the cytoplasm and 
nucleus play an important role in maintaining homeostasis and normal cellular functions. For 
example, transcription factors which are synthesized in the cytoplasm needs to enter the nucleus to 
induce gene expression, and mRNAs transcribed in the nucleus needs to exit the nucleus to be 
translated in the cytoplasm. Aberrantly regulated nucleo-cytoplasmic trafficking will lead to 
inappropriate accumulation of proteins and RNAs in these compartments at the incorrect time, and 
this is profoundly linked to pathogenesis129-131. 
 
The important participants in the nucleo-cytoplasmic trafficking system include the Nuclear Pore 
Complex (NPC), the Ras-related Nuclear protein (Ran) and the Karyopherin transporters. The nuclear 
pore complex is a large cylindrical and flexible structure embedded in the nuclear envelope, which 
provides passage for selective and bidirectional transport between the cytoplasm and the nucleus. 
Each NPC comprises a central channel lined with proteins, and peripheral filaments attached to the 
central core, extending into the cytoplasm and nucleoplasm. The majority of the proteins making up 
the components of the NPC are called nucleoporins (Nups), and those lining the central region are 
FG-Nups, as they contain phenylalanine-glycine (FG) motifs in tandem repeats132, 133. There are two 
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important functions provided by the NPC; to form a physical barrier with defined permeability for 
selected molecules, and to assist the traversing of larger macromolecules through its central channel. 
 
The Ran protein on the other hand, is a small Ras-related nuclear guanine nucleotide binding protein 
responsible for supplying energy to facilitate nuclear transport. Inside the nucleus, Ran is present at 
high concentrations in the guanosine triphosphate bound state, RanGTP. This is due to the action of 
the Regulator of Chromosome Condensation 1 (RCC1, also known as Ran Guanosine Nucleotide 
Exchange Factor RanGEF), which exist in close proximity to the chromosomes. Outside of the nucleus, 
RanGTP becomes substrate for RanGTP-Activating Protein 1 (RanGAP1) and Ran-Binding Protein1 
(RanBP1), which together causes GTP hydrolysis, leaving Ran in its guanine diphosphate bound state, 
RanGDP. RanGDP is imported into the nucleus by the Nuclear Transport Factor-2 (NTF2)134, where 
nucleotide exchange by RCC1 returns Ran to its GTP bound state. This regulated system establishes a 
spatial gradient of RanGTP with the highest concentration around the chromosomes in the nucleus 
emanating outwards, eventually reaching the cytoplasm where concentration is the lowest. Such 
distribution of RanGTP is an important regulator for both nuclear transport and spindle assembly 
during mitosis135, 136. Ran is also known to regulate other cellular processes including nucleation and 
polymerization of microtubule during cell division137, 138, nuclear envelope formation and cell-cycle 
checkpoint control139, 140. 
 
Both the NPC and Ran proteins play important roles in the nucleo-cytoplasmic trafficking system, 
and abnormalities in their presentation or function have been linked to tumourigenesis141-144. The 
oncogenic potentials of NPC is represented by its component Nups, where their mutations or altered 
expression have led to their mislocalization and ultimately impacted on signalling pathways and 
transcription profiles either through altered or diminished functionalities141, 145. Ran is frequently 
elevated in cancer and has been shown to be transcriptionally regulated by oncoprotein Myc146. Its 
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oncogenic role is mediated through altering various signalling pathways including the cyclins, CDKs, 
Retinoblastoma protein (Rb), Survivin, Bax and JNK147, 148. In fact, Ran over-activation alone has been 
shown to confer malignant phenotypes in fibroblast cells, indicative of its ability in cellular 
transformation149, 150. Furthermore, Ran directly mediates the nuclear entry of the E7 oncoprotein of 
Human Papillomavirus type 16 (HPV16), a high-risk cervical-cancer causing agent, thereby 
contributing to infection and possibly carcinogenesis known to be associated with HPV16151. 
 
Whilst the abnormal function of both Ran and NPC has been associated with cancer and cellular 
transformation, whether this is directly linked to their nuclear trafficking function has not yet been 
explicitly demonstrated.  This likelihood, however, has been hypothesized by many. For example, the 
loss of function for one of the Nups making up the cytoplasmic filament, Nup88, leads to cytoplasmic 
accumulation of NFκB due to increased nuclear export152. It has been proposed that over-expression 
of Nup88, which is frequently observed in tumour cells153, could reciprocally result in nuclear 
accumulation of NFκB and thereby promote oncogenesis145, although experimental validation 
remain to be elucidated. 
 
1.3.1. Cellular functions of the nuclear transporters: the Karyopherins 
The transporters, the group of proteins that actively facilitate movement of cargoes across the NPC 
make up the Karyopherin superfamily. Although best known for their involvement in nucleo-
cytoplasmic trafficking, they also participate in other vital cellular processes such as NPC and nuclear 
membrane assembly, cell cycle regulation, as well as replication and mitosis154, 155. Members of this 
family can be categorized into Importins (IPOs, Karyopherinβs), which functions to import cargoes 
into the nucleus; Exportins (XPOs, also Karyopherinβs and CAS) which shuttles the cargoes out of the 
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nucleus; Transportins known to engage in bidirectional transport; as well as the Karyopherinα 
adaptor proteins, which mediates the recognition between the Karyopherinβ and their cargoes. 
 
In the classical import process, the Karyopherinα subunit recognizes and binds to the nuclear 
localization signal- (NLS-) bearing cargo156, and Karyopherinβ facilitates the docking of the 
Karyopherinβ/α -cargo complex to the NPC. Karyopherinβ interacts with the FG-Nups present in the 
NPC, allowing the complex to transit through the channel157. Arrival at the nuclear side of the NPC 
allows RanGTP, which is present at high concentrations in the nucleus to bind to the trimeric 
complex, leading to its dissociation158, 159. The cargo is freed to perform its nuclear function, while 
Karyopherinβ and Karyopherinα is recycled back into the cytoplasm coupled to RanGTP, and 
CAS/RanGTP, respectively160. Back in the cytoplasm, RanGTP is hydrolysed by RanGAP and RanBP1 to 
form RanGDP, releasing Karyopherinβ and Karyopherinα from their respective receptors161. 
Karyopherinβ and Karyopherinα remain in the cytoplasm to initiate the next round of import while 
CAS and RanGDP re-enters the nucleus, where RanGDP is converted to RanGTP via the action of 
RCC1 (Fig.1.3). Import of cargo proteins can also occur in a non-classical manner, where direct 
association with cargo protein is made with Karyopherinβ itself independent of Karyopherinα162, 163. 
 
The exporting pathway involves the association of an Exportin and nuclear export signal- (NES-) 
bearing cargoes in the nucleus RanGTP-dependently, and transit through the NPC is made by the 
interaction between Exportin and the Nups. In the cytoplasm, hydrolysis of RanGTP to RanGDP 
allows the dissociation of the cargo protein from the Exportin, which then re-enters the nucleus. The 
action of RCC1 in the nucleus then converts RanGDP to RanGTP (Fig. 1.4)164, 165. 
 
The directional transportation for both import into and export out of the nucleus is conferred by two 
factors. Firstly, the asymmetrical distribution of both RCC1 and RanGAP/RanBP1 in the nucleus and 
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Figure 1.3 Schematic showing the Karyopherinβ/α mediated nuclear import cycle. Karyopherinβ (β), Karyopherinα 
(α) and import cargo (NLS) form a trimeric complex in the cytoplasm (1), and transit through the NPC (2). On the 
nuclear side, binding of RanGTP dissociates the complex (3), releasing the cargo while Karyopherinβ-RanGTP and 
Karyopherinα-CAS-RanGTP exits the nucleus (4). In the cytoplasm, hydrolysis of RanGTP to RanGDP via RanGAP and 
RanBP1 (5) releases Karyopherinβ, Karyopherinα/CAS (6). RanGDP, coupled to NTF2 together with CAS re-enters the 
nucleus (7), and via the action of RCC1 in the nucleus, RanGDP is converted to RanGTP (8).  
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Figure 1.4. Schematic showing the Exportin-mediated nuclear export cycle. Exportin receptor (XPO) binds its export 
cargo (NES) in the presence of RanGTP (1), and the trimeric complex exit the nucleus through the NPC (2). The 
combined actions of RanGAP/RanBP1 hydrolyzes RanGTP to form RanGDP (3), releasing NES-cargo and XPO (4). 
RanGDP coupled to NTF2 and XPO re-enters the nucleus(5), and RCC1 in the nucleus converts RanGDP to RanGTP 
(6).  
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cytoplasm, respectively. This leads to high levels of nuclear RanGTP, which in turn is responsible for 
releasing the cargoes from Karyopherinβ/α in the nucleus. The cytoplasmic RanGAP and RanBP1 
catalyzes RanGTP hydrolysis, allowing Karyopherinβ to be released from Ran and Karyopherinα from 
CAS/Ran in the cytoplasm166. The export pathway is essentially the reciprocal process. Secondly, the 
transit of the import complex through the NPC is made possible by the gradual increase in affinity 
between the Nups and Karyopherinβ from the cytoplasmic end to the nuclear end within the NPC, 
promoting a directional movement towards the nucleus167. 
 
Whilst smaller proteins and molecules can passively diffuse between the nucleus and cytoplasm, the 
majority of macromolecules (typically larger than 40 kDa) require facilitated nuclear entry and exit 
via the Karyopherin family. Although each Karyopherin protein possesses their own substrate 
specificity, some proteins are known to be transferred by multiple transporters, such as ribosomal 
proteins, core histone proteins and NFκB-p65168-171. 
 
As the correct cellular localization of various proteins at the correct time is a prerequisite for proper 
cell functioning, the Karyopherin proteins and their normal function have a key role in ensuring 
normal cellular processes. For example, the Exportin Chromosomal Region Maintenance 1 (CRM1) is 
known to transport various cell-cycle regulators such as p27, E2F and cyclinB. The appropriate transit 
through cell cycle therefore depends on the well-orchestrated regulation of CRM1 function172-174, 
and indeed, dysregulation of CRM1 is correlated with abnormal cell cycle progression175, 176. It is 
therefore not surprising that the dysregulation or abnormal function of the Karyopherins is linked to 
pathogenesis, such as the development and progression of cancer164.  
 
Several studies have detailed the observation of protein mislocalization in association to a wide 
range of malignancies, including breast, stomach, colon, cervical, brain, skin, leukemia and others177-
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183. Although the inappropriate localization of these proteins may be due to fault in the cargo 
proteins themselves, for example, mutation or aberrant post translational modifications, but the 
aberrant functioning of the transport machinery is likely to cause global mislocalization of proteins, 
thereby promoting carcinogenesis.  
 
Research done in our laboratory have previously shown that the levels of Karyopherin Beta 1 
(Kpnβ1), Karyopherinα2 (Kpnα2) and CRM1 were elevated in cervical cancer cells compared to non-
cancer cells, as well as in transformed lung fibroblast compared to their non-transformed 
counterparts128, suggesting increased nuclear import and export in cancer and transformed cells184. 
The accelerated nuclear trafficking is thought to manage the increased metabolic and proliferative 
demands. Indeed, Kuusisto et al. have reported increased expression of the Importin Karyopherinβ1 
(Kpnβ1) in correlation with increased rate of nuclear import activities in transformed breast 
epithelial compared to the non-transformed counterparts185. These suggest that increased 
expression, and thus function of the transporters is associated with cellular transformation. 
Supporting this, alterations in the expression and/or function of the Karyopherin proteins have been 
reported across a broad spectrum of cancers including oesophageal, breast, colon, pancreatic, 
prostate, ovarian, and hepatocellular carcinoma128, 186-192. 
 
 1.3.2. Impaired nuclear transport regulation and cancer 
Dysregulation of the nuclear trafficking system, mainly members of the Karyopherins has been 
reported in a many cancers, which can arise from various molecular alterations. Here we discuss a 
few mechanism known to induce abnormal nuclear trafficking associated with the transporters, 
including altered expression, aberrant post translational modification, mutation and disruption of 
the endogenous transporters (for more details, see review by Stelma et al.193). 
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Using the cervical cancer model, van der Watt et al. reported that over-expression of both Kpnα2 
and Kpnβ1 results from the impaired E2F/Rb regulation, where the constitutively active E2F 
associated with increased expression of its downstream targets, including both Kpnα2 and Kpnβ1194. 
The E2F/Rb regulation is known to be disrupted in many human cancers195, accounting for the 
increased expression of both proteins observed in multiple cancers. As the viral oncoprotein E7 is 
known to amplify E2F activity both Rb-dependently and independently196, 197, it is likely that the 
increased Kpnα2 and Kpnβ1 expression is due to HPV infection in some cervical cancer cells194. In 
addition to the increased transcriptional activity, down-regulation of negative regulator micro-RNAs 
has also been reported to attribute to increased expression of both Kpnα2 and Kpnβ1 in other 
cancers198, 199. 
 
Another mechanism reported to impair regulation of Karyopherin family members is the genomic 
rearrangement of the 20q13 chromosome, which is known to accommodate amplifications linked to 
aggressive breast cancer200. In 1996, Brinkmann et al. mapped the CAS encoding gene, cse1, to 
chromosome 20q13, and amplification of cse1 was detected in leukemia, colon cancer and breast 
cancer201. CAS and Kpnα2 have both been reported to be negatively regulated by p53 through 
induction of p21202. The loss of p53 function frequently observed in cancer could therefore account 
for increased CAS and Kpnα2 expression203. Indeed, increased CAS expression has been reported in 
colon cancer, lung cancer, leukemia, lymphoma, breast cancer and ovarian cancer201, 204-206. 
Brinkmann et al. investigated the expression of CAS in normal human tissues, and found that cells 
with increased proliferative activities manifested higher CAS expression204, supporting the idea that 
increased expression of these transporter may be associated with increased proliferative demands 
of cancer cells. 
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Aberrant regulation of CRM1 expression in cervical cancer and transformed cell lines has been 
suggested to result from increased levels of NF-Y and Sp1 transcription factors176. Interestingly, all 
three subunits of NF-Y, namely NF-Ya, NF-Yb and NF-Yc are transported into the nucleus by Kpnβ1 
and IPO13207, suggesting a possible explanation as to why elevated expression of both Kpnβ1 and 
CRM1 is often observed in the same cancer128, 208, 209. Similar to CAS and Kpnα2, transcription of crm1 
has also been reported to be negatively regulated by p53 under DNA damaging conditions176, the 
frequent loss of p53 function in cancer cells may therefore also attribute to elevated CRM1 
expression. Interestingly, nuclear export of p53 is mediated by CRM1 under DNA damaging 
conditions128, indicating a possible feed-back loop regulatory mechanism. In normal cells, increased 
p53 induced by DNA damage represses CRM1 expression, however, in cancer cells harbouring non-
functional or suppressed p53, the repression on crm1 transcription is alleviated, resulting in 
increased CRM1 expression, which then enhances nuclear exclusion of p53 thereby preventing p53-
mediated suppression on CRM1 expression. 
 
Various other causatives have also been identified to directly or indirectly interfere with the nuclear 
transport machinery. These include the inappropriate post-translational modification, such as that 
observed with the CAS protein where phosphorylation by both AKT and MEK-1 determines its 
localization210, 211. As nuclear CAS exhibited increased oncogenic properties compared to cytoplasmic 
CAS210, the altered activities of the upstream kinases could therefore lead to inappropriate 
localization of CAS, resulting in pathogenesis. Mutations leading to impaired transport activities of 
the Karyopherins is another known factor to be linked to malignancy, and this has been reported for 
Karyopherinα and Exportin5, where the mutant versions of these proteins were unable to execute 
their respective functions leading to inappropriate p53 import and micro-RNA export, respectively212, 
213. Endogenous negative regulators of the nuclear transporters, namely Aplasia Ras Homolog 
Member 1 (ARH1/DIRAS3/NOEY2), Complement Component 3 (CC3/TIP30) and Etoposide Induced 
Protein 2.4 (Ei24/PIG8) have been reported to show reduced levels or activity in many cancers214-216, 
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which consequently led to elevated activities of the transporters and associated with 
carcinogenesis217-220.  
 
Together, these demonstrate the association between aberrant nuclear transport functions and 
cellular malignancy, and highlights the need of a well-organized, intricately regulated nuclear 
transport system. Mechanisms are devised through every step of the protein synthesis and 
regulatory pathway, including transcriptional and translational, as well as at the post-translational 
level. In healthy cells, they guard the smooth execution through each transporting cycle, ensuring 
the correct localization at the correct time for various cargoes. This does not only impact on protein 
localization, but virtually all cellular processes are reliant on a proper transport system for the 
correct execution of downstream pathways. The malfunction of this system strongly correlates with 
cancer progression, but at the same time provides opportunities for intervention, which will be 
discussed in the next section. 
 
1.3.3. Therapeutic potential of the Karyopherins 
Association of the Karyopherin proteins and cellular malignancy is a good indicator for their 
potentials as biomarkers. Indeed, various members have already been studied for their values in 
diagnosis, prognosis and therapy. The prognostic value of both the expression and localization of 
Kpnα2 has been well demonstrated in a variety of cancers188, 190, 191, 221, 222. However, its functional 
importance appears to be variable, as its inhibition does not always affect cancer cell proliferation 
and survival128. This is possibly due to the overlapping substrate specificities between the 
Karyopherinα members170, and Kpnα2 has therefore been focussed on more as a prognostic tool. 
Although therapeutic potentials have been suggested for Kpnα2 in some cancers188, 223, further 
experimental validation is required.  
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The Exportin protein CRM1, on the other hand, is the most extensively studied Karyopherin member 
as an anti-cancer target to date193, 224-227. Its increased expression has been reported in a multitude 
of cancers, including leukemia, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical 
cancer, glioma, pancreatic cancer, osteosarcoma and myeloma128, 228-236. CRM1 inhibition via genetic 
or chemical intervention resulted in growth inhibition and apoptosis in cancer cells, suggesting 
increased reliance of cancer cells on CRM1 function as opposed to non-cancer cells128, 228, 230, 232, 237, 238. 
Leptomycin B (LMB) was the first identified natural compound with anti-CRM1 activity239, and acts by 
alkylating the cysteine-529 residue on CRM1, thereby inhibiting its function240. Although preliminary 
and preclinical studies were promising241, LMB was eventually discontinued due to high toxicity in 
the phase I clinical trials242. Following that, various other CRM1 inhibitors were identified or 
developed, including LMB analogues243 and CBS9106244, both of which showed anti-tumour efficacies 
in vitro and in vivo. In addition, CRM1 has been shown to be the target of two natural-derived 
compounds Plumbagin and Piperlongumine, which were previously reported to show anti-cancer 
effects in vitro and in vivo 245, 246. The clinical relevance of these compounds, however, remain to be 
defined. 
 
More recently, a series of compounds termed the Selective Inhibitors of Nuclear Export (SINE) was 
generated by Karyopharm Therapeutic (Karyopharm Therapeutics, Inc., Boston, MA, USA) via in silico 
screening. These showed capacity to irreversibly modify the NES-binding groove of the CRM1 protein, 
thereby preventing its nuclear exporting function228. These bioavailable compounds showed great 
success in preclinical studies in various cancers including myeloid leukemia, kidney cancer, 
lymphoma, breast cancer, non-small cell lung cancer, melanoma and prostate cancer229, 237, 247-252. 
The clinical trials for selected SINE compounds, Selinexor (KPT-330) and KPT-335, which exhibited 
favourable pharmacokinetic and pharmacodynamic properties are ongoing, and have generated 
promising outcome so far in liposarcoma, multiple myeloma, glioblastoma and gynaecological 
cancers224, 253.  
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The CRM1-inhibition phenotype has been proposed to result from a few mechanisms, such as the 
cytoplasmic retention of tumour suppressor proteins, and the reversal of EMT, an important process 
closely linked to malignant phenotypes226, 254, 255. CRM1 activity has also been associated with 
resistance to current chemotherapeutic interventions by preventing nuclear localization (thus 
activation) of tumour suppressors and chemotherapeutic responsive proteins228, 256-258, suggesting a 
link between nuclear transport and drug resistance. In line with this, the combined therapy using 
conventional chemotherapeutic agents coupled to CRM1 inhibition via LMB, the SINE compounds or 
Piperlongumine have yielded promising results in reversing the chemoresistant phenotype259-263. In 
addition to its therapeutic values, ongoing research has also revealed prognostic potentials for CRM1, 
where its increased expression in tumour samples correlated with various malignant phenotypes 
and is generally associated with poor patient outcome232-235, 264. 
 
1.4. The Importin Karyopherinβ1 
The nuclear transport system certainly present therapeutic opportunities in the current search for 
previously undescribed 'druggable' targets. The potential of Kpnβ1, one of the well-characterized 
Importin members is however, under-exploited. Kpnβ1 was first discovered in 1994 as a soluble 
factor that bridged the cargo recognition step in the cytoplasm to the translocation step at the NPC 
in the import pathway265. It was subsequently cloned independently by Gorlich et al. and Chi et al266, 
267. Fluorescent in situ hybridization located the Kpnβ1 encoding gene, kpnβ1 to chromosome 
17q21268, translating to a 97 kDa protein comprising 876 amino acids. Kpnβ1 is a superhelical 
structure composed of approximately 20 parallel HEAT repeat domains stacked together with a 
slight clock-wise twist. The N-terminal is responsible for interactions with RanGTP, while the inner 
concave and the C-terminal binds its Karyopherinα-independent cargoes and Karyopherinα, 
respectively269. 
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Increased expression and activity of the protein itself is frequently observed in malignant tumour 
cells. Its contribution to carcinogenic activities has been proposed, most notably through the 
elevated nuclear import of other oncoproteins; such as NFκB in myeloma and hepatocellular 
carcinoma, Gli1 in glioma, and Stat1 in gastric cancer192, 209, 270, 271. Various proteins known to 
correlate with the cancer progression, such as those involved in EMT and inflammation have also 
been identified as Kpnβ1 cargoes, including EZH2, ING1, EGFR, STAT3, ETO, Smad3 and Nrf2, 
although the oncogenic contribution of their increased nuclear import by Kpnβ1 remain to be 
defined199, 272-277. In addition, the viral proteins L2 and E6 of HPV16, a high-risk cervical-cancer 
causing agent also relies on nuclear import by Kpnβ1, suggesting an aiding role of Kpnβ1 in the 
successful infection and reproduction of HPV16278, 279. 
 
Beyond its nuclear trafficking functions, Kpnβ1 is also important in the regulation of mitotic 
progressions, including spindle assembly and microtubule regulation, mitotic exit and nuclear 
membrane reformation after mitosis. Mitotic regulation is achieved by Kpnβ1 binding to and 
sequestering the activities of the spindle assembly factors (SAFs), and RanGTP promotes the release 
of SAFs from Kpnβ1, allowing them to participate in spindle assembly and microtubule regulation280-
283. As RanGTP accumulates near the chromosomes, Kpnβ1, together with RanGTP provides a spatial 
control in SAF activity ensuring that they function at the appropriate cellular locations. Subsequently, 
Kpnβ1 engages in cellular exit from mitosis as well as regulating the reformation of interphase cell 
nuclear membrane284, 285. Whilst the elevated expression of Kpnβ1 in interphase cells may support 
the increased demands of cancer cells by increasing the rate of cargo import, some studies have 
reported a negative impact of Kpnβ1 over-expression in mitotic cells. These mitotic catastrophes 
were however, avoided by the co-over-expression of Kpnβ1 interacting partners, such as TPX2, Ran, 
RanBP2 and CRM1282, 285, 286, suggesting that elevated expression of Kpnβ1 in cancer cells is coupled 
to increased expression of these proteins, allowing the uninterrupted progression through mitosis. 
Indeed, both TPX2 and Ran are known to be elevated in cancer cells compared to non-transformed 
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counterparts287, 288. Moreover, Kpnβ1 has also been shown to regulate other cellular properties and 
functions, such as the NPC permeability; the degradation of misfolded proteins in the endoplasmic 
reticulum; as well as preventing histone H1 cytoplasmic aggregation289-291.  
 
The function of Kpnβ1 can impact on a multitude of cellular functions from nuclear transport in 
interphase cells to division in mitotic cells, advocating the criticality of a well-orchestrated regulation 
for Kpnβ1. In line with this, intricate regulatory strategies have been reported to modulate the 
efficiency of Kpnβ1 and nuclear import, and some mechanisms where aberrancy have been 
associated to cancer were discussed above. In a report published by Yasuhara et al., the 
Karyopherinβ/α mediated nuclear import efficiency is cell-cycle sensitive, exhibiting highest 
importing efficiency at late G1 and late S-phase292. Binding of both micro-RNA-9 and micro-RNA-30d 
has been demonstrated to negatively regulate Kpnβ1 expression by targeting its 3'-UTR in the mRNA, 
preventing its translation199, 293. The high intracellular level of calcium is another mechanism through 
which Kpnβ1 activity is modulated294. Recently, the newly characterized member of the Poly (ADP-
Ribose) Polymerase (PARP/ARTD) family, ARTD15, a endoplasmic reticulum residing protein has 
been reported to directly bind to and ADP-ribosylate Kpnβ1, although the significance of this 
modification remains to be elucidated295. The impact of deregulated Kpnβ1 activity highlights the 
importance of its function in maintaining normal cellular functions, and abnormalities in its 
presentation or function may serve to indicate abnormalities in the cellular status. 
 
1.4.1. Karyopherinβ1: a potential biomarker and therapeutic target for cancer 
There is growing evidence in support of Kpnβ1 as a cancer biomarker, mainly as a prognostic marker 
and therapeutic target. This area of study, however, is still in its developing stage. The elevated 
Kpnβ1 levels has been reported in a many cancers, including cervical carcinoma, breast carcinoma, 
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myeloma, hepatocellular carcinoma, malignant peripheral nerve sheath tumour, gastric cancer and 
ovarian cancer when compared to their normal counterparts128, 192, 199, 209, 270, 296, 297. In a recent report 
by Kuusisto et al., the extent of Kpnβ1 over-expression was found to directly reflect the disease state 
in the MCF10 breast tumour progression series, where increased malignancy was correlated to 
increased Kpnβ1 expression296. This finding illustrated the possible prognostic use of Kpnβ1, and 
indeed, elevated Kpnβ1 levels has been shown to significantly correlate to histological grade, 
metastasis, vein invasion and tumour size in hepatocellular cancer192; and tumour grade, Ki-67 
staining and infiltration depth in gastric cancer209. 
 
As a therapeutic target, the inhibition of Kpnβ1 function through genetic or pharmacological 
interventions have yielded promising outcomes in various in vitro cancer models. To date, anti-
cancer effects stemming from Kpnβ1 inhibition have been demonstrated for cervical carcinoma, 
myeloma, malignant peripheral nerve sheath tumours, hepatocellular carcinoma, breast carcinoma, 
head and neck carcinoma, lung carcinoma and gastric cancer128, 192, 199, 209, 270, 296, 298, 299, suggesting 
that targeting Kpnβ1 may have broad-spectrum anti-cancer effects. Using the cervical cancer model, 
research in our laboratory demonstrated that Kpnβ1 inhibition led to a G2/M cell cycle arrest 
coupled to various mitotic defects, which ultimately triggered an apoptotic response via the intrinsic 
mitochondrial pathway300. The mechanism by which Kpnβ1 inhibition induces apoptosis in other 
cancer model, however, remains to be elucidated. 
 
Targeting Kpnβ1 for cancer treatment has raised a few concerns. Firstly, various tumour suppressors 
are known to rely on Kpnβ1 for nuclear import, such as p53, BRCA1 and pRB301-303. The consequent 
prevention of their nuclear accumulation as a result of Kpnβ1 inhibition may thus not provide 
therapeutic benefits. These tumour suppressors, however, are frequently inactivated or non-
functional in cancer cells to begin with. As such, Kpnβ1 inhibition is likely to reduce the actions of 
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oncoproteins which are highly active in cancer; more so than repressing tumour suppressors. 
Secondly, as the function of Kpnβ1 is utilized by both cancer and normal cells, targeting it for cancer 
therapy may induce undesired side effects as a result of cytotoxic effects to non-cancer cells. As 
cancer cells are derived from normal cells, most cellular machineries are used by both. Whilst some 
cancer-specific mutations can be targeted (like the BCR-ABL1 in leukemia), such mutations are not 
always present since most cancers arise from accumulative alterations in a multitude of different 
pathways rather than in a single protein. It is however, important to note that there exist an 
'additional reliance' of cancer cells on certain cellular functions compared to normal cells, Kpnβ1-
mediated nuclear import being one of them. This is supported by several experimental findings 
where cancer and transformed cells exhibited significantly higher sensitivity to Kpnβ1 inhibition 
compared to their normal counterparts128, 270, 296, 300. In addition, some proteins with important 
cellular functions have also proven to be effective targets in anti-cancer treatment, such as the 20S 
proteosome targeted by Bortezomib and Carfilzomib304, 305. van der Watt et al. and Kuusisto et al. 
both reported that siRNA mediated inhibition of other Karyopherin members, including Kpnα1, 
Kpnα2 and Kpnα3 has shown either no anti-cancer activity or no selectivity between malignant and 
benign cells, suggesting that the selective anti-cancer effects of Kpnβ1 inhibition was a result unique 
to Kpnβ1 inhibition128, 296. The results from these studies propose that targeting Kpnβ1 may have 
value as an anti-cancer strategy and requires further investigation. 
 
In addition to its potential as a direct anti-cancer target, there is evidence suggesting that Kpnβ1 
could mediate sensitivity to other chemotherapeutic agents. This was first described by Drinyaev et 
al., where Avermectin (the parent compound of Ivermectin, a Karyopherinβ/α mediated nuclear 
import inhibitor) was found to enhance Vincristine-induced tumour growth suppression306, although 
the underlying mechanism has not yet been defined. Moreover, Kpnβ1 has also been proposed to 
confer Docetaxel resistance, and its inhibition via siRNA enhanced the effect of Docetaxel treatment 
in cancer cells209. As CRM1 inhibition sensitized cancer cells to chemotherapeutic agents via 
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increasing nuclear retention of tumour suppressors165, 257, there could exist a reciprocated role for 
Kpnβ1. Amongst the cargoes imported by Kpnβ1, many have been implicated to confer drug 
resistance such as STAT-1, Myc and NFκB307-309. As targeting Kpnβ1 will impair their nuclear entry, 
this could potentially interfere with survival mechanisms thereby enhancing drug sensitivity. 
Supporting this idea, there are evidence showing that suppression of NFκB enhanced 
chemosensitivity310, and sensitization of cervical cancer cells to CDDP has been demonstrated in 
combination with Genistein, which acts by suppressing the NFκB response311. Furthermore, the 
inhibition of RelB:p52 nuclear import sensitized cancer cells to ionizing radiation312; and as radiation 
therapy acts mainly by causing DNA damage, this suggests a potential for nuclear import inhibition 
coupled to DNA-damaging agent as a combination chemotherapeutic regimen. Since none of the 
current chemotherapeutic agents target the nuclear import pathway, the combination of Kpnβ1 
inhibition to a clinically relevant DNA-damaging agent thus fit the criteria where two agents are 
mechanistically different. 
 
1.4.2. Intervening with Karyopherinβ1-mediated nuclear import 
Attempts to alter the nuclear import system began in the 1990's, where a cell-permeable peptide 
mimicking the NFκB-p50 NLS, the SN50, was shown to inhibit nuclear translocation of NFκB-p50, AP1, 
NFAT, STAT1 and Nrf2277, 313, 314. SN50 was initially believed to inhibit import via targeting 
Karyopherinα, however, later works demonstrated its inhibitory effect on nuclear import of SREBP315, 
a cargo imported into the nucleus Karyopherinα-independently316. This indicated that SN50 can also 
directly target Kpnβ1. By a similar approach, the inhibition of nuclear import of RelB:p52 was 
achieved using the SN52 peptide, which was shown to sensitize prostate cancer cells to 
radiotherapy312. With the intention of developing specific inhibitors for Kpnβ1/Karyopherinα 
mediated nuclear import, Kosugi et al. employed the peptide inhibitor design and developed Bimax1 
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and Bimax2, both of which targeted nuclear import via Karyopherinα, but were ineffective at 
inhibiting Kpnβ1-only mediated nuclear import317.  
 
There are three small molecules with nuclear import inhibitory effects described to date, namely 
Ivermectin, Karyostatin 1A and Importazole. Ivermectin, the oldest of the three was first discovered 
in the 1970's and came into clinical use in the 1980's for treating parasitic infections. Several years 
later, its anti-cancer effects were recognized against ascites and solid experimental tumours, 
although no correlation to nuclear import inhibition were made306. A few studies have since 
reported Ivermectin as an anti-cancer agent through alternative mechanisms318, 319. Only recently 
was its effect on nuclear import recognized, however, like the Bimax peptides, Ivermectin interfered 
with nuclear import only when Karyopherinα is involved320, 321. The first report linking Ivermectin, 
nuclear import inhibition and cancer was published earlier this year, wherein Ivermectin was shown 
to decrease tumour formation in vitro and in vivo for hepatocellular carcinoma. This study showed 
that Ivermectin was capable of inhibiting YAP1, an important mediator in the Hippo pathway, and 
proposed that this may result from decreased nuclear import of YAP1322. Whilst there are growing 
evidence to support the anti-cancer effects of Ivermectin, it has also been shown to induce the 
expression of P-gp, the membrane bound efflux pump closely associated with drug resistance, 
raising some concerns in its use for anti-cancer treatment323. 
 
Both Karyostatin 1A and Importazole are small molecules recently identified to specifically target for 
Kpnβ1/Karyopherinα mediated nuclear import, and both exerts its effect via disrupting the Kpnβ1-
RanGTP interaction324, 325. Moreover, both small molecules specifically target the Kpnβ1 mediated 
nuclear import without affecting Transportin or CRM1 activity. Whilst effective at inhibiting nuclear 
import, their use mostly involves investigating cellular functions such as mitosis, and little work has 
been done in the cancer setting. Importazole has recently been shown to exhibit anti-tumour activity 
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in multiple myeloma and breast cancer in vitro296, 298, although the underlying mechanisms still 
remain unclear.  
 
Another potential Kpnβ1 inhibitor, 58H5-6, was identified from peptidomimetic libraries using 
permeabilized cell nuclear import assays, and is thought to act via disrupting the Kpnβ1-nucleoporin 
interactions. It also specifically targeted Kpnβ1/Karyopherinα mediated nuclear import, without 
affecting Transportin activity. This compound however, lacks in vivo efficacy, possibly due to low 
permeability or in vivo enzymatic activities, and further modifications are required before it can be 
used for biological assays326.  
 
These preliminary data are encouraging, yet the appropriate preclinical and clinical examinations are 
still lacking to demonstrate the feasibility and chemotherapeutic practicality of targeting nuclear 
import for anti-cancer therapy, and more extensive investigations should be executed. 
 
1.4.3. The identification of a potential Karyopherinβ1 inhibitor: INI-43 
In a search for novel small molecules with potential to bind to Kpnβ1 and inhibit its activity, a 
structure-based in silico screen was carried-out in our laboratory in collaboration with researchers at 
the Brown Cancer Centre (University of Louisville, Kentucky, USA). Based on the known crystal 
structure of Kpnβ1, a library of 12,662,570 small molecules were screened for their predicted ability 
to bind to the overlapping Karyopherinα and RanGTP binding sites within Kpnβ1, corresponding to 
amino acids 331-363. This region has previously been identified as essential for Kpnβ1 function, 
whereby its deletion rendered Kpnβ1 unable to import cargoes into the nucleus158. The search 
yielded 74 hits, and were numbered according to their predicted affinity for binding Kpnβ1. The 43rd 
compound in this series, 3-(1H-1,3-benzimidazol-2-yl)-1-[3-(dimethylamino)propyl]-1H-pyrrolol[2,3-
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b]quinoxalin-2-amine, which we named Inhibition of Nuclear Import-43 (INI-43), was a candidate 
chosen for further analysis, as it showed nuclear import inhibitory effects as well as half maximal 
inhibitory concentration (IC50) values within the current chemotherapeutic range (less than 50 µM) 
as tested in cervical cancer cell lines. 
 
 
 
 
 
INI-43 is an autofluorescent compound (emission peak around 519nm) possessing both quinoxaline 
and benzimidazole groups (Fig. 1.5). Quinoxaline is a heterocyclic compound made of a benzene ring 
and a pyrazine ring, and the benzimidazole side chain is a bicyclic compound consisting of a benzene 
and imidazole fused together. Interestingly, both quinoxaline and benzimidazole have been reported 
to show anti-cancer activities independently327-332. Pioneering work in our laboratory demonstrated 
that INI-43 impeded nuclear import of Kpnα2 in CaSki cells stably expressing the Kpnα2-GFP fusion 
Figure 1.5. Structure of the small molecule Inhibitor of Nuclear Import-43 (INI-43). INI-43 is a quinoxaline 
derivative containing a benzimidazole side chain, with a molecular mass of 385g/mole. 
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protein‡, as well as Kpnβ1 in HeLa cells333, indicating that INI-43 is able to impact on Kpnβ1/Kpnα2 
mediated nuclear import. Supporting this, it was subsequently found that INI-43 treatment resulted 
in decreased transcriptional activity of a Kpnβ1 cargo protein NFAT as measured by a NFAT-
luciferase reporter system. The inhibitory activity of INI-43 on nuclear import pathways was further 
shown for various known Kpnβ1/Karyoherinα cargoes, including AP1 and NFY. Excitingly, Kpnβ1 
over-expression was found to rescue the repressed nuclear import of NFκB-p65 as a result of INI-43 
treatment, suggesting that nuclear import inhibitory effect of INI-43 is exerted through Kpnβ1333. 
 
1.5. Significance 
There are evidence to support that Kpnβ1-mediated nuclear import may have potential as a target 
for anti-cancer treatment, yet extensive research and appropriate preclinical modelling of the 
current nuclear import inhibitors are still lacking. This study verifies a newly identified small 
molecule INI-43 as a potential lead 'parent' compound in the nuclear import inhibitor class, by 
investigating its in vitro and in vivo efficacy. If successful, INI-43 can be further developed for future 
clinical use both as a single agent or in combination with other clinically relevant drugs in combating 
cancer. 
 
  
                                                          
‡
Stowell, C. "Identification of Nuclear Import Inhibitors That Display Anti-cancer activity." University of Cape Town, 2011 
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1.6. Project aims 
This project aims to: 
(i) Investigate the anti-cancer potential of INI-43 as a lead compound, by examining the effects of 
INI-43 on cancer and non-cancer cell proliferation and viability using both cell culture system and an 
in vivo mouse xenograft model. In the in vivo model we aim to investigate its toxicity and anti-
tumour activity.  
 
(ii) Investigate the effects of INI-43 in combination with a clinically relevant cytotoxic agent Cisplatin 
(CDDP) on cancer cells. This will be done using two gynaecological cancer models; ovarian and 
cervical cancers. The molecular mechanisms associated with cell death as a result of the 
combination treatment was further explored. 
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CHAPTER 2 
INVESTIGATING THE ANTI-CANCER EFFECTS AND DRUG PROPERTIES 
OF INI-43, A SMALL MOLECULE WITH POTENTIAL NUCLEAR IMPORT 
INHIBITORY ACTIVITY 
2.1. Introduction 
The identification of the altered Kpnβ1 expression in cancer versus normal, and its necessity in 
cancer growth and survival suggested that it has potential as a target for anti-cancer therapy. The 
subsequent in silico and biological screenings for potential inhibitors of Kpnβ1 identified various 
'hits', one of which, the Inhibitor of Nuclear Import-43 (INI-43) was further examined. We have 
previously shown that INI-43 inhibited nuclear localization of both Kpnβ1333 and GFP-tagged Kpnα2§. 
The nuclear import of various Kpnβ1-cargoes were prevented by INI-43 treatment, including AP1, 
NFY and NFκB. NFAT-luciferase reporter assays revealed that INI-43 treatment significantly reduced 
the transcriptional activity of the NFAT transcription factor, suggesting that the decreased nuclear 
import translated into functional relevance. Importantly, exogenously over-expressed Kpnβ1 
alleviated the inhibitory effect of INI-43 on nuclear localization of NFκB. These data show that firstly, 
INI-43 had inhibitory effects on nuclear import activity, and secondly, these effects were likely 
mediated through interfering with Kpnβ1 function, making it an attractive compound for further 
investigation as an anti-cancer agent.  
 
                                                          
§
Stowell, C. "Identification of Nuclear Import Inhibitors That Display Anti-cancer activity." University of Cape Town, 2011 
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Beyond its inhibitory effect on Kpnβ1-mediated nuclear import, preliminary findings in our 
laboratory have demonstrated the anti-cancer effect of INI-43 using the cervical cancer model. INI-
43 showed a half maximal inhibitory concentration (IC50) of 10 µM in cervical cancer cell lines HeLa 
and CaSki, which is within the range of chemotherapeutic agents in current practice. In addition, INI-
43 treatment reiterated many phenotypes observed in Kpnβ1 knock-down cells. These included its 
anti-cancer effects, while causing less harm to non-cancer fibroblast cells; as well as cell cycle arrest 
at the G2/M checkpoint300, 333. The similar phenotypes observed between INI-43 treated and Kpnβ1 
knock-down cells further support the idea that INI-43 is exerting its effect through perturbation of 
Kpnβ1 function. 
 
Whilst the anti-cancer properties of INI-43 has been demonstrated using cervical cancer cells grown 
in culture333, little is known about its mechanisms of action and in vivo effects. The aim of this 
chapter is therefore to investigate the phenotypic outcomes of INI-43 treatment both in vitro and in 
vivo. These included investigating cell viability and cell proliferation under various growth conditions; 
the apoptosis related release of mitochondrial cytochrome C and PARP-cleavage; the drug-
properties of INI-43 including stability and toxicity in nude mice. Our data provides evidence that 
intraperitoneally administered INI-43 reduced tumour growth in an ectopic xenograft mouse model.  
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2.2. Results 
2.2.1. Confirming the purity of commercially bought INI-43 
The subject of this study, the small molecule INI-43 was purchased from Chembridge (San Diego, CA, 
USA) and MolPort (Riga, Latvia). Before using it in our investigation, we independently examined its 
purity by using high pressure liquid chromatography-diode array detection-mass spectrometry 
(HPLC-DAD-MS). Solutions of three different batches were prepared to a concentration of 100 µM in 
DMSO separately and together, and subjected HPLC-DAD-MS. The DAD chromatogram result 
showed two peaks at retention time (Rt) 1.05 and 5.95 which is representative of DMSO and INI-43 
from the mix of all three batches (Fig. 2.1.A). The mass spectrum of the Rt 5.95 peak on the total ion 
chromatogram of the MS confirmed the mass of INI-43 to be 385Da from the[M+H]+ ion at m/z ratio 
of 386 (Fig. 2.1.B). These results confirmed that all batches of INI-43 used in our laboratory were > 
99% pure.  
 
2.2.2. INI-43 reduced cancer cell viability and proliferation 
To determine the effect of INI-43 on cell viability and proliferation in a panel of cancers and non-
cancer cell lines, the half maximal inhibitory concentration (IC50) was investigated for a treatment 
period of 48 hours. IC50 is a measure of the minimum concentration that is required to inhibit 50% of 
a specific biological or biochemical function, and in this case, cell viability was investigated using the 
MTT assay. Cells were treated with ranging concentrations of INI-43 for 48 hours and viable cells 
were determined for each INI-43 concentration. Cell viability was then converted to a numerical 
value, the 'fraction affected' (Fa), where Fa of 0 depicts 100% viable cells (i.e. no effect), and Fa of 1 
is equivalent to complete cell death. The Log[Fa/(1-Fa)] is then plotted against Log INI-43 
concentration, and the IC50 value was calculated using the formula IC50 = 10
x-intercept. When 50% of cell 
growth was inhibited, Fa and 1-Fa both equal to 0.5, equating to a y-value (Log[Fa/(1-Fa)]) of zero, 
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Figure 2.1. Purity and mass confirmation of INI-43. A DAD chromatogram showing the mixture of three different 
batches of INI-43, with peaks at Rt 1.05 and 5.95 representing DMSO and INI-43, confirming its purity (A). The 
mass spectrum of Rt 5.95 peak, confirming mass of INI-43 at [M+H]+ ion at m/z of 386 (B). 
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which is where the x-axis is crossed. As the x-axis represents the drug concentration in log scale, the 
actual drug concentration is calculated using 10x-intercept. Using this method, the INI-43 IC50 values 
were determined for ovarian cancer, oesphageal cancer and non-cancer cell lines. A representative 
for each cancer is shown (Fig. 2.2.A, for other cell lines refer to Appendix Fig. A.1), and the cervical 
cancer cell lines HeLa was included as a control and generated IC50 values similar to that previously 
observed333. The INI-43 IC50 values for each cell line are summarized in Fig. 2.2.B and Table 2.1. INI-
43 exhibited IC50 values of between 5 µM and 10 µM in ovarian cancer cells, oesophageal cancer 
cells and transformed cells. The non-cancer fibroblast cell lines CCD-1068SK, FG0 and DMB exhibited 
reduced sensitivity to INI-43 treatment, with IC50 values 2-3 fold higher than cancer cells (22 µM, 33 
µM and 35 µM respectively). 
 
In addition, cell viability after 5 µM, 10 µM and 15 µM INI-43 treatment were analyzed for each cell 
line, and in all cancer cell lines examined, 10 µM INI-43 treatment led to varying degrees of growth 
inhibitory effects, and 15 µM treatment caused complete cell death (Fig. 2.3). However, in the non-
cancer cell lines CCD-1068SK, FG0 and DMB, 10 µM INI-43 treatment had little effects, and more than 
50% of the cells were still viable after 15 µM INI-43 treatment. These results illustrated increased 
sensitivity to INI-43 treatment in cancer cells compared to non-cancer cells. 
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  Figure 2.2. INI-43 IC50 determination in selected cancers and non-cancer fibroblast cells. Five-thousand cells 
were seeded per well in 96-well plates and allowed to adhere overnight, followed by INI-43 treatment at various 
concentrations. Viable cells were examined using the MTT reagent 48 hours later, and standardized to the 
untreated. The result are plotted as log [Fa/(1-Fa)] against the INI-43 concentration in log scale, where Fa = 
fraction of cells affected. IC50 values were calculated as 10
x-intercept
. One representative cell line is shown for each 
of the ovarian cancer, oesophageal cancer and non-cancer fibroblast (A, see the rest in Appendix Fig. A.1). For 
control, the cervical cancer cell line HeLa was included, and generated acceptable INI-43 IC50 value as previously 
established in our laboratory. Results shown are the mean ± SEM of experiments performed in 5 replicates, and 
repeated at least two times in each cell line (A), and IC50 values for each cell line shown are representatives of 
experiments performed in 5 replicates and repeated at least two independent times. 
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Table 2.1. INI-43 IC50 in cancer cell lines of different tissue origin and non-cancer cell lines 
 
Origin Cell line INI-43 IC50 (µM) 
Cervical cancer HeLa 9.2 
Cervical cancer CaSki 10.2 
Oesophageal cancer KYSE30 8.9 
Oesophageal cancer WHCO5 9.9 
Oesophageal cancer WHCO6 10.1 
Ovarian cancer A2780 5.0 
Ovarian cancer OVCAR3 10.4 
Ovarian cancer OVCAR4 10.2 
Ovarian cancer OVCAR5 8.8 
Ovarian cancer OVCAR8 11.6 
Ovarian cancer SKOV3 10.9 
fibroblast CCD-1068SK 22.4 
fibroblast FG0 33.0 
fibroblast DMB 34.6 
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2.2.3. Anti-cancer properties of INI-43 
Having shown that INI-43 selectively reduced cancer cell viability, we next investigated the effect of 
INI-43 on cell proliferation in a time-dependent manner, and under various growth conditions in 
selected cancer cell lines. 
Figure 2.3. The effect of INI-43 on viability of cancer, transformed and non-cancer fibroblast cells. Cells were 
plated at 5000 per well in a 96-well dish and allowed to settle overnight, followed by incubation with 0 µM, 10 
µM or 15 µM INI-43 for 48 hours. Viable cells were determined using the MTT reagent, and standardized to the 
untreated cells. Results shown are mean ± SEM of experiments performed in 6 replicates and repeated at least 
twice, *p < 0.05. 
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2.2.3.1. The effect of INI-43 on anchorage-dependent cell proliferation  
To confirm the inhibitory effect of INI-43 on cell growth, representative cells of cervical cancer (HeLa 
and CaSki), oesophageal cancer (KYSE30 and WHCO6) and non-cancer (FG0 and DMB) were grown 
under anchorage-dependent conditions in the presence of 1 µM, 5 µM and 10 µM INI-43, and 
proliferation was measured using the MTT assay over a period of four days. These assays showed 
that 10 µM INI-43 treatment significantly inhibited the proliferation of all cancer cell lines (Fig. 2.4). 
The inhibitory effect of INI-43 on cancer cell growth was maintained over the entire duration of the 
experiment, with no recovery observed. However, proliferation of both non-cancer fibroblast cell 
lines FG0 and DMB were unaffected at 10 µM INI-43 (Fig. 2.4). These results support earlier findings 
that cancer cells appear more sensitive to INI-43 treatment compared to non-cancer cells. It should 
be noted that while 10 µM INI-43 led to complete inhibition of cell growth in this experiment, the 
same treatment rendered fractions of cancer cells viable shown in the viability assay (Fig. 2.3). This is 
likely due to the experimental set-up, as different cell numbers were seeded for these two 
experiments. In this experiment, we were interested in cell proliferation, and thus five-times less 
cells were plated to provide room for proliferation. The decreased confluency increased the drug to 
cell number ratio, possibly accounting for the different outcomes between the two experiments 
observed at the same INI-43 concentration. The net effect of INI-43 treatment, however, remains 
that it significantly inhibits cancer cell proliferation.  
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Figure 2.4. Proliferation of selected cancer and non-cancer cell lines treated with INI-43 over 4 days. Cells were 
seeded at 1000 per well in 96-well plates and treated with 0 µM, 1 µM, 5 µM and 10 µM INI-43 the following day. 
Proliferation was examined every 24 hours using the MTT reagent for 4 days after treatment, and normalized to 
the viable cells on day 0. Results shown are mean ± SEM of 6 replicates, and each experiment is repeated at least 
twice, *p < 0.05. 
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2.2.3.2. The effect of INI-43 on anchorage-dependent colony formation 
We next examined the colony forming ability of cancer cells after INI-43 treatment by performing 
clonogenic assays as previously described334. Differing from the proliferation assay, which examined 
the proliferative activity of cells in the presence of a damaging agent, the colony formation assay 
assesses sensitivity by evaluating the reproductive viability of cells after the source of damage is 
removed. In order to form a colony, a single cell must survive and maintain its proliferative 
potentials to form a macroscopic colony. In this assay, cells were seeded sparsely allowing each cell 
to settle in isolation, thereby eliminating complexities caused by interactions between members of 
large cell population. Cells were then treated with INI-43 at various concentrations for 24 hours, 
after which the drug was removed from the growth media. The cells were then incubated over a 
period of 12 days, after which cells were stained with crystal violet and macroscopic colonies were 
visually examined335. Each macroscopic colony consists of more than 50 cells, and the number of 
macroscopic colonies is an indication of drug sensitivity. The clonogenic assays showed that in both 
HeLa and KYSE30 cells, 1 µM and 5 µM treatment did not cause significant differences in colony 
formation compared to the untreated cells (Fig. 2.5). However, 10 µM INI-43 completely inhibited 
colony formation, and no cells survived to produce colonies in both cancer cell lines. Coupled to the 
proliferation assay, this result confirmed that 10 µM INI-43 robustly prevented cancer cell survival 
and proliferation.  
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Figure 2.5. Survivability of HeLa and KYSE30 cells after INI-43 exposure. Cells were plated sparsely at 1000 per 35 
mm dish followed by INI-43 treatment at 1 µM, 5 µM and 10 µM. After 24 hours, INI-43 was removed and media 
was replenished every second day for 12 days. Viable colonies were fixed and stained with crystal violet, and 
images were captured. Results shown are representatives experiments performed in triplicates and repeated two 
independent times. 
 
 
50 
 
2.2.3.3. The effect of INI-43 on anchorage-independent cell growth 
One character of tumourigenic phenotype is the ability of cells to proliferate under substrate-free 
conditions (i.e. anchorage independently) by forming colonies336. We were therefore interested to 
examine whether INI-43 could affect the anchorage-independent cell growth of selected cancer cells 
by performing cell proliferation assays under non-adherent growth conditions. To do this, cells were 
resuspended in 1% methylcellulose in the absence or presence of INI-43 on poly-HEMA coated 
surfaces. While the methylcellulose prevented cells from migrating towards each other, the poly-
HEMA prevented cells from adhering to the dish surface. Cells were left to proliferate and form 
colonies over a period of nine days, and subsequently treated with MTT reagent to identify viable 
colonies. In the untreated and 5 µM INI-43 treated cells, several MTT stained colonies were 
observed in both HeLa and WHCO6 cells, while 10 µM and 15 µM treatment resulted in smaller, non-
viable colonies, shown by the lack of MTT staining (Fig. 2.6). This result indicated that 10 µM or 
higher concentrations of INI-43 prevented cancer cell proliferation in substrate-free media. In the 5 
µM INI-43 treated cells, a slight reduction in colony size was observed, suggesting that at this 
concentration, INI-43 was able to exert inhibitory effects on cancer cell proliferation under 
substrate-free conditions. Taken together, these results showed INI-43 exhibited increased 
cytotoxicity in cancer cells compared to normal fibroblast cells, and that 10 µM INI-43 treatment 
reduced cell viability and inhibited cell proliferation in cancer cells grown both anchorage-
dependently and independently.  
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2.2.4. The effect of Kpnβ1 knock-down on cell proliferation 
We next independently examined the effect of Kpnβ1 knock-down on cell proliferation using small 
(or short)-hairpin RNA (shRNA). The shRNA is an artificial RNA molecule resembling the structure of a 
hairpin, which potently inhibits the expression of its target gene via the RNA-induced silencing 
complex (RISC). The shRNA encoding plasmid is delivered into the host cells by viral-mediated 
infection or liposomal transfection. Upon entry into the cell, it uses the host cell's transcription 
machinery to produce shRNA molecules, which then becomes cleaved by Dicer, producing the sense 
and anti-sense strands. The anti-sense strand couples with the RISC complex, guiding it to the target 
Figure 2.6. Effects of INI-43 on anchorage-independent proliferation in HeLa and WHCO6 cells. Cells were 
resuspended in 1% methylcellulose containing media and plated in poly-(HEMA) coated 96-well plates in the 
presence or absence of INI-43 for 9 days. Viable colonies were stained with MTT reagent and photographed under 
brightfield microscopy. Images shown are representative experiments performed in triplicates and repeated three 
times. 
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mRNA by complementary base-pairing. This ultimately results in the target mRNA degradation, 
preventing protein synthesis337. 
 
2.2.4.1. The doxycycline (dox) inducible pTIG-shKpnβ1 construct effectively reduced endogenous 
Kpnβ1 expression 
In this study, we used the pHIV7-TetR-IRES-GFP plasmid (pTIG, a kind gift from Prof. S. Prince, 
University of Cape Town; and Prof M. Weinberg, University of Witwatersrand), which expresses the 
shRNA under the control of a doxycycline-inducible U6 promoter (see Appendix Fig. A.2)338. Kpnβ1-
targeting shRNA (shKpnβ1) was designed and cloned into the pTIG vector, forming pTIG-shKpnβ1-1 
as described in Materials and Methods. As the pTIG vector constitutively expresses GFP, GFP 
fluorescence was used as a read-out of the transfection efficiency. To determine the best 
transfection conditions, HeLa cells were transfected with pTIG-shKpnβ1-1 ranging from 0 ng/mL to 
500 ng/mL, and shRNA expression were induced with 1 ng/µL doxycycline treatment. pTIG-shKpnβ1-
1 uptake was examined using fluorescent microscopy, which showed concentration-dependent 
increase in transfection (Fig. 2.7.A). The results showed good transfection efficiency at 250 ng/mL 
and 500 ng/mL pTIG-shKpnβ1-1, and at 500 ng/mL the efficiency was close to 100%. To examine 
whether pTIG-shKpnβ1-1 caused efficient inhibition of Kpnβ1 expression, proteins were harvested 
and Kpnβ1 levels were analyzed by western blot. Corresponding to the transfection efficiency, 
Kpnβ1 knock-down occurred concentration-dependently, and were most visible in cells transfected 
with 250 ng/mL and 500 ng/mL plasmids (Fig. 2.7.B).  
 
Having confirmed that pTIG vector effectively expressed the shRNA, two additional Kpnβ1 targeting 
shRNAs were designed, shKpnβ1-2 and shKpnβ1-3, and separately cloned into the pTIG vector, 
forming pTIG-shKpnβ1-2 and pTIG-shKpnβ1-3. All three pTIG-shRNA constructs, together with the 
control, the pTIG-scrambled (pTIG-scr) were transfected into HeLa cells and subsequently induced 
53 
 
 
 
  
A 
54 
 
 
 
 
 
 
 
 
 
 
with doxycycline. Western blot analysis revealed that all three shKpnβ1s effectively down-regulated 
endogenous Kpnβ1 expression (Fig. 2.7.C). The inducible U6 promoter from which the shRNAs were 
expressed, however, appeared to be poorly regulated in HeLa cells, as Kpnβ1 levels were also 
reduced in the absence of doxycycline induction suggesting leakiness (Fig. 2.7.C). Various attempts 
Figure 2.7. Transfection of HeLa cells with pTIG-shKpnβ1-1. HeLa cells were transfected with ranging 
concentrations of the pTIG-shKpnβ1-1 plasmid for 24 hours, followed by doxycycline (dox) induction at 1 ng/mL 
for 24 hours. The expression of GFP was examined using fluorescent microscopy as an indication of transfection 
efficiency (A). Kpnβ1 expression in pTIG-shKpnβ1-1 transfected cells (B), and Kpnβ1 expression in pTIG-scrambled, 
pTIG-shKpnβ1-1, pTIG-shKpnβ1-2 and pTIG-shKpnβ1-3 transfected cells with or without doxycycline induction (C). 
Results shown are representatives of experiments performed 3 independent times. 
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were made to reduce the U6 promoter leakiness, but were unsuccessful. For this reason, pTIG-scr 
transfected cells were used as a non-Kpnβ1 knock-down control. 
 
2.2.4.2. shRNA-mediated Kpnβ1 knock-down reduced HeLa cell growth 
Having shown that all the pTIG-shKpnβ1 constructs efficiently reduced Kpnβ1 expression, we next 
examined the effect of shRNA-mediated Kpnβ1 knock-down on cell proliferation in HeLa cells. Cells 
were transfected with pTIG-scr or pTIG-shKpnβ1 constructs for 24 hours, followed by 1 ng/mL 
doxycycline treatment to induce shRNA expression. Phase contrast images of the cells were captured 
72 hours after doxycycline treatment, and results showed that cells transfected with pTIG-shKpnβ1-1, 
pTIG-shKpnβ1-2 and pTIG-shKpnβ1-3 all showed significant reduction in number of viable, adherent 
cells compared to the mock transfected control cells (Fig. 2.8.A). Quantification of the viable cells by 
MTT confirmed this, showing that in all Kpnβ1 knock-down cells, significant reduction in cell 
proliferation was observed in comparison to the control pTIG-scr transfected cells (Fig. 2.8.B). These 
results showed that shRNA-mediated Kpnβ1 inhibition resulted in similar inhibitory effects on cancer 
cell proliferation as observed with INI-43 treatment. 
 
2.2.5. Kpnβ1 over-expressing HeLa cells exhibited increased tolerance to INI-43 treatment 
INI-43 was initially identified as a potential inhibitor of Kpnβ1 based on in silico prediction of the 
known Kpnβ1 crystal structure. Furthermore, INI-43 showed inhibitory effects on both nuclear 
import and cancer cell proliferation333, both of which were observed when Kpnβ1 was inhibited via 
RNAi300. In addition to this, Kpnβ1 over-expression reversed INI-43 induced inhibition on NFκB-p65 
nuclear import, a known Kpnβ1 cargo333, supporting that INI-43 acts via Kpnβ1 associated nuclear 
import. We therefore proposed that Kpnβ1 over-expression could rescue INI-43 induced inhibitory 
effect on HeLa cell viability. To examine this, a stable Kpnβ1 over-expressing cell line, HeLa-pEFIRES-
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Kpnβ1-GFP which expresses Kpnβ1 tagged to GFP, and the control cell line HeLa-pEFIRES-GFP were 
used333. To confirm the expression of the appropriate proteins, western blot analysis was performed 
using both Kpnβ1 and GFP specific antibodies. HeLa-pEFIRES-Kpnβ1-GFP expressed Kpnβ1-GFP at 
similar levels to that of endogenous Kpnβ1 level, suggesting the presence of approximately twice as 
much Kpnβ1 as in the control cells (Fig. 2.9.A).  
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Figure 2.8. Proliferative activities in Kpnβ1 knock-down HeLa cells. HeLa cells were transfected with pTIG-scr, 
pTIG-shKpnβ1-1, pTIG-shKpnβ1-2 or pTIG-shKpnβ1-3, followed by 1 ng/mL doxycycline induction (day 0). Cells 
were photographed 72 hours after doxycycline induction (A), and cell proliferation was quantified every 24 hours 
for five days (B). Results shown are mean ± SEM of five replicates normalized to viable cells on day 0. 
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Figure 2.9. Kpnβ1 over-expressing HeLa cells showed decreased sensitivity to INI-43 treatment. Protein lysate 
from the HeLa-pEFIRES stable cell lines were examined via western blot to confirm the establishment of cells 
stably expressing GFP (HeLa-GFP) and Kpnβ1-GFP (HeLa-Kpnβ1-GFP). GAPDH was included as a loading control 
(A). INI-43 IC50 was examined for the GFP-expressing control and Kpnβ1-GFP over-expressing cells (B). The effect 
of INI-43 treatment on viability of HeLa-GFP and HeLa-Kpnβ1-GFP cells were examined, cells were seeded at 5000 
per well in 96-well dishes followed by INI-43 treatment for 48 hours. Viable cells were determined using the MTT 
reagent, and OD595 readings were normalized to the untreated cells. Results shown are mean ± SEM of three 
independent experiments, with 6 replicates in each experiment, *p < 0.05. 
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Analysis showed that HeLa-pEFIRES-Kpnβ1-GFP exhibited significantly higher INI-43 IC50 value (11.7 
µM) compared to the control cells (8.3 µM, Fig. 2.9.B), and that significantly more viable cells were 
observed in Kpnβ1 over-expressing cells compared to control cells after 5 µM and 10 µM INI-43 
treatment (Fig. 2.9.C). These results showed that Kpnβ1 over-expression had a dampening effect on 
INI-43 induced cytotoxicity, thereby confirming that INI-43, at least in part, exerted its cancer killing 
effects by targeting Kpnβ1.  
 
2.2.6. INI-43 causes cancer cell death via apoptosis  
The mechanism of INI-43 induced cancer cell death was next investigated. We examined the 
cleavage of poly(ADP-ribose) polymerase (PARP), which is executed by caspase-3, a late event 
occurring in the apoptotic pathway. Cleavage of PARP into a 89 kDa product is an irreversible 
commitment to apoptosis, and is thus an accurate reflection of the apoptotic events339. Western blot 
analysis showed that INI-43 treatment caused PARP-cleavage both time and concentration 
dependently (Fig. 2.10.A). At both 1 x and 1.5 x INI-43 IC50 values, i.e. 10 µM and 15 µM, PARP-
cleavage was already visible 3 hours after treatment. In the 10 µM treated cells, there was continual 
increase in cleaved PARP with the maximal cleaved PARP 24 hours after treatment. At 15 µM INI-43, 
GAPDH degradation was observed 12 hours after treatment, which became completely degraded by 
24 hours after treatment, suggestive of global protein degradation which correlated with complete 
cell death observed. Treatment of HeLa cells with 1 x IC50 and 1.5 x IC50 concentrations of nuclear 
import inhibitors Importazole and Ivermectin similarly resulted in increased PARP-cleavage, but were 
only observed 24 hours after treatment for both drugs at their respective IC50 values (Fig. 2.10.B). 
These results showed that INI-43 induced apoptosis in cancer cells more rapidly than other known 
nuclear import inhibitors - where at their respective IC50 values, INI-43 induced PARP-cleavage within 
three hours, but Importazole and Ivermectin treatment only induced PARP cleavage after 24 hours. 
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To determine whether INI-43 induced apoptosis was associated with the intrinsic mitochondrial 
pathway, the mitochondrial content of cytochrome C was examined, as cyctochrome C release from 
the mitochondria is an event preceding PARP cleavage in the intrinsic apoptotic pathway. 
Corresponding to the PARP-cleavage event, decreased mitochondrial cytochrome C was observed in 
HeLa cells after 10 µM INI-43 treatment time-dependently (Fig. 2.11.A). A subtle decrease of 
Figure 2.10. Cleavage of PARP in HeLa cells treated with nuclear import inhibitors. HeLa cells were treated with 
INI-43 at its 1 x and 1.5 x IC50 values and proteins were harvested 3, 6, 12 and 24 hours after treatment. PARP 
status was analyzed by western blot (A). The effect of two additional nuclear import inhibitors, Importazole and 
Ivermectin on PARP cleavage were also examined at 1 x and 1.5 x their respective IC50 6 and 24 hours after 
treatment (B). GAPDH were included for loading control. PARP-cleavage analysis using INI-43 in HeLa cells was 
conducted two independent times. 
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cytochrome C was observed 3 hours after INI-43 treatment, which continued to decrease with 
increasing time of drug incubation, and the lowest mitochondrial cytochrome C was observed 24 
hours after INI-43 treatment (Fig. 2.11.A and B). These results support the idea that INI-43 treatment 
induced apoptotic events in cancer cells via activating the intrinsic mitochondrial pathway, leading to 
mitochondrial release of cytochrome C and the subsequent cleavage of PARP.  
 
 
 
 
  
Figure 2.11. Mitochondrial levels of cytochrome C in HeLa cells treated with INI-43. HeLa cells were treated with 
10 µM INI-43, and mitochondrial cytochrome C was examined 3, 6 and 24 hours after treatment with western 
blot. Peroxiredoxin-3 (Prdx3) was included as the mitochondrial loading control (A). cytochrome C levels were 
densitometrically quantified relative to Prdx3 (B). Results shown are representative of two independent 
experiments. 
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2.2.7. Investigating drug properties of INI-43 for further use in animal studies 
Whilst commercially available nuclear import inhibitors such as Importazole and Ivermectin have 
been widely used in biological assays to investigate the functional relevance of nuclear import, little 
work has been done to investigate their anti-cancer properties, and intensive examination in animal 
models is still lacking. We thus examined the stability of INI-43, and focussed more extensively on 
the drug toxicity in an animal model system.  
 
2.2.7.1. INI-43 exhibited moderate stability in liver microsome assays 
Metabolically unstable drugs are rapidly degraded upon administration into the living system, 
thereby not allowing enough time for candidate drugs to reach the target site. For this reason, we 
first examined the metabolic stability of INI-43 by performing the liver microsome assay. The liver 
microsome assay is an in vitro assay used to predict possible break-down products of the compound 
of interest, as well as examining the stability of the parent compound in the presence of 
metabolizing enzymes from the liver. The concept behind this experiment it to incubate the 
compound of interest with enzymes isolated from the hepatocytes, as the liver is largely responsible 
for drug metabolism in the living system. Liver microsomes are processed liver tissues to remove 
other cellular components, leaving behind the concentrated liver enzymes. It consists mostly of 
vesicle-like artefacts formed from the endoplasmic reticulum where the most active enzymes are 
found, and is prepared by homogenizing liver tissues followed by differential centrifugation thereby 
separating the cell membrane, cytoplasm and organelles. An advantage of removing cell membranes 
is that the active enzymes are readily exposed to the compound of interest upon addition, allowing 
the reaction incubation time to be significantly reduced, as the compound of interest is not required 
to cross the cell membrane. To ensure that INI-43 exhibits sufficient stability for animal testing, liver 
microsome was first carried out to assess its metabolic stability. 
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INI-43 was incubated with liver microsomes under the appropriate physiological conditions, and the 
resulting samples were subjected to HPLC-MS/MS to determine the percentage of un-metabolized, 
intact INI-43 remaining. The percentage remaining was then used to calculate its half-life (T1/2) which 
is tabulated in Table 2.2. Two additional compounds with known stabilities, Midazolam and 
Propranolol were included as the controls, and gave values within their acceptable ranges. As shown 
in Table 2.2, 88% of the parental INI-43 compound remained intact after 30 minutes incubation 
period, projecting to a half-life of 161.2 minutes in human liver microsomes. It exhibited decreased 
stability in mouse microsome, with 59% parental compound remaining after incubation, and the 
half-life was calculated to be 39.4 minutes. In both human and mouse liver microsomes, INI-43 
showed greater stability than Propranolol, which is considered to be a moderately stable compound, 
suggesting that INI-43 is sufficiently stable for use in preclinical studies. 
 
 
Table 2.2. Microsomal turnover of INI-43  
Drug 
% remaining Half-life (minutes) 
Human Mouse Human Mouse 
INI-43 87.90 59.00 161.23 39.41 
Midazolam 0.77 1.53 5.12 4.96 
Propranolol 62.00 5.33 43.80 7.09 
 
  Data presented are the mean of triplicate (for % remaining) and the half-life was calculated based on the average 
% remaining values (see Materials and Methods, section .6.2.12). 
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2.2.7.2. Assessing INI-43 cytotoxicity in athymic nude mice 
In in vitro studies, the efficacy of INI-43 is examined by addition of drug directly to cells, which does 
not take into account the possible interactions between INI-43 and other cells in vivo. These 
interactions may lead to toxic side effects, which can sometimes be fatal. Indeed, toxicity has been 
reported to be one of the major reasons for failure of developing drugs to reach the market, as well 
as withdrawal of drugs already on the market340. For this reason, possible undesired side effects 
should be carefully and extensively scrutinized. Here, we examined the possible side-effects by 
performing toxicology analysis, where mice receiving a dose of INI-43 were compared to the vehicle 
DMSO receiving control mice. Drugs were administered intraperitoneally (i.p.) every second day for 
a period of 28 days (14 treatments in total, Fig. 2.12.A), during which the mice's body mass and 
behaviour was monitored daily as an indication of the animals' wellbeing. The experiment began 
with 1 mg/kg INI-43 treatment (low dose), and the control mice were treated with equivalent 
volumes of DMSO. Throughout the entire experiment, no signs of distress or abnormal behaviour 
were observed with the animals, and body mass fluctuations between the two groups of mice were 
similar (Fig. 2.12.B). No significant difference in body mass gain between control and 1 mg/kg INI-43 
receiving mice were observed (20% versus 15%, Fig. 2.12.E). Similarly, control and 10 mg/kg INI-43 
(intermediate dose) treated mice showed no significant differences in body mass changes, with 
approximately 22% and 24% gain in body mass at the end of the study for the control and treated 
mice, respectively (Fig. 2.12.C and E). Lastly, we also examined adverse effects at 50 mg/kg INI-43 
(high dose). While the INI-43 treated mice showed no signs of discomfort or sickness, a decrease was 
observed in body mass gain compared to the controls (22% in INI-43 treated mice versus 39% in 
control mice, Fig. 2.12.D and E), although the difference was not statistically significant. The treated 
mice in this group, however, gained body mass which was within acceptable range, and the 
difference observed between the control and treated mice was likely attributed to the control mice 
gaining more weight than usual.  
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Post mortem evaluation of the INI-43 treated mice by an animal technician concluded no 
abnormalities in the lung, spleen, ovaries, kidneys, liver and heart. As enlargement of the liver has 
been reported to be a sign of toxicity341, the liver mass were measured from the control and INI-43 
treated mice for all dose groups, and expressed relative to their body mass, which showed no 
significant difference at all three INI-43 doses examined (Fig. 2.13). In addition, histological 
evaluations of liver sections showed no pathology within the parenchyma, no lesions were observed 
and morphological assessment were consistent with normal architecture of the murine liver. These 
results demonstrated that nude mice tolerated INI-43 up to, but not necessarily restricted to 50 
mg/kg. For this reason, 50 mg/kg INI-43 were used in the subsequent tumourigenesis assays.  
Figure 2.12. Toxicology analysis of INI-43. The toxicology study was carried out in three sequential stages, 
starting with 1 mg/kg, followed by 10 mg/kg and 50 mg/kg. All three experiments were executed in identical 
format (A). Body mass were measured on the day treatment started, and everyday thereafter. Body mass was 
calculated as percentage increase from the initial measurement for 1 mg/kg (B), 10 mg/kg (C) and 50 mg/kg (D). 
Results shown are mean ± SEM for six mice in each group. The gain in body mass at the end of the study are 
presented in a Box-and-Whiskers plot showing median, minimum and maximum values, N = 6 (E). 
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2.2.8.The effect of INI-43 treatment on induced tumour growth in nude mice 
In order to determine the effect of INI-43 on tumour development in vivo, we employed the ectopic 
xenograft mouse model, where cancer cells of the human origin were injected subcutaneously into 
nude mice.  
 
2.2.8.1. Pilot study to determine the optimal number of cells to inoculate for tumour induction 
A pilot study was carried out to determine the optimal number of cells to inoculate in order to 
induce tumour formation. As our initial attempt of subcutaneous injection of 1 million HeLa cells 
failed to induce tumour formation, we investigated the injection of 5, 7.5 and 10 million cancer cells. 
Nine mice were used for each cell line (HeLa, CaSki, WHCO6 and KYSE30), which was divided into 
Figure 2.13. Liver size at the end of the toxicology study. The mice's liver mass at the end of each toxicology 
study was measured and normalized to each mouse’s body mass for the 1 mg/kg group, 10 mg/kg group and 50 
mg/kg group. Results are presented in Box-and-Whisker plots showing the median, minimum and maximum 
values in each group of mice, N = 6. 
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three groups of 3 mice each, and each group received the same number of cells at inoculation. To 
minimize the suffering of the animals, they were euthanized upon tumour size reaching 20 mm in 
any dimension, observation of severe necrosis in the tumour tissue, or observation of distress in the 
animals, whichever occurred first. The endpoint of the study was marked by the euthanization of the 
last mouse for each cell line.  
 
Tumour induction using HeLa cells were unsuccessful at all cell numbers tested (data not shown). 
The other cervical cancer cell line, CaSki, started forming visible tumours around 80 days after 
inoculation of 5 million cells (Fig. 2.14.A, top). All three animals formed tumours and grew uniformly, 
and was only euthanized at the study endpoint of the study as the tumours did not exceed 20 mm in 
any dimension, and only one tumour developed necrosis. Mice inoculated with 7.5 million CaSki cells 
exhibited major inconsistency in tumour formation and development. Of the three mice inoculated, 
one mouse did not develop any visible tumour by the study endpoint, which was 110 days after 
inoculation, and the other two mice formed visible tumours approximately 25 days after inoculation 
(Fig. 2.14.A, middle). Of those two that formed tumours, the tumours grew at very different rates - 
while one mouse developed a tumour of 1360mm3 by day 84 and had to be euthanized prematurely, 
the other mouse formed a tumour of only 163.09mm3 by the study endpoint. Interestingly, none of 
the mice inoculated with 10 million CaSki cells formed any visible tumours (Fig. 2.14.A, bottom), 
suggesting that inoculation of more cells does not necessarily result in faster tumour growth. Based 
on these observations, 5 million cells was selected for the actual tumourigenesis assay.  
 
WHCO6 cells developed tumours more uniformly with all inoculations leading to tumour formation 
(Fig. 2.14.B). All tumours were visible within one week after treatment, and tumours grew more 
rapidly in mice inoculated with 7.5 million and 10 million cells. In both groups, all animals were 
euthanized on or before day 35 (Fig. 2.14.B, middle and bottom). Mice inoculated with 5 million cells 
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showed slower tumour growth, and were euthanized 46, 49 and 76 days after inoculation (Fig. 
2.14.B, top).  
 
Inoculation of KYSE30 cells led to tumour formation in all but one mouse (Fig. 2.14.C). Of the three 
mice inoculated with 5 million KYSE30 cells, two successfully formed tumours and were euthanized 
on days 39 and 46 due to necrosis, and one mouse never developed a visible tumour by the end of 
the study, which was 79 days after inoculation (Fig. 2.14.C, top). Inoculation of 7.5 million and 10 
million KYSE30 cells developed visible tumours within one week, and were all euthanized 
prematurely due to either large tumour size or necrotic development (Fig. 2.14.C, middle and 
bottom). As mice inoculated with 7.5 million and 10 million cells showed extremely aggressive 
growth with high necrotic occurrence (4 out of 6), 5 million cells were selected for inoculation of the 
tumourigenesis assay. 
 
Interestingly, the tumours formed from the three different cell lines showed different characteristics. 
CaSki cells developed tumours that were softer, and two out of the five tumours showed signs of 
necrosis (Fig. 2.15, (i, arrow). WHCO6 cells induced tumours were firm, but instead of forming one 
round tumour like CaSki, WHCO6 cells tend to form irregularly shaped, fractured tumours with no 
necrotic signs (Fig. 2.15, (ii)). KYSE30 tumours were larger, firmer, showed a blister-like appearance, 
and four of eight tumours developed necrosis (Fig. 2.15, (iii) and (iv, arrow)). The necrotic occurrence 
in tumour tissues is an indication of aggressiveness and often associated with metastatic 
potentials342. The use of these three cell lines in tumourigenesis assays provided an opportunity for 
the effect of INI-43 to be tested against tumours of different aggressiveness. 
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Figure 2.14. Tumour growth rates in nude mice inoculated with cancer cells. Nine mice were randomized into 
three groups of three each, and subcutaneously inoculated with 5 million (top), 7.5 million (middle) and 10 million 
(bottom) CaSki (A), WHCO6 (B) and KYSE30 (C) cells on day 0. The length (L) and width (W) of tumours were 
measured twice a week, and converted to tumour volume by the formula V = (LxW
2
)/2. Results shown are mean ± 
SEM of N, where N = the number of animals alive at each time point. 
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2.2.8.2. Tumourigenesis assay in nude mice: Effect of INI-43 on tumour development 
Having established the cell numbers required for xenograft tumour formation in nude mice, we next 
examined the effect of intraperitoneally administered INI-43 on tumour development, using CaSki, 
KYSE30 and WHCO6 cells. Mice were inoculated with 5 million cancer cells, and treated with DMSO 
or INI-43 upon palpable tumour formation. As the different cell lines formed tumours at different 
rates, the day which treatment began was marked as day 0 in each experiment. Mice were treated 
three times a week (CaSki and KYSE30, Fig. 2.16.A and 2.16.C) or every second or third day (WHCO6, 
Fig. 2.16.B), and tumour sizes were measured twice a week for 4 weeks in CaSki-tumour bearing 
mice, 3 weeks for WHCO6-tumour bearing mice and 2.5 weeks for KYSE30-tumour bearing mice. 
Figure 2.15. Tumours formed from the different cancer cell lines. Tumour growth induced with CaSki, WHCO6 
and KYSE30 were photographed after euthanization. (i) CaSki tumour formed 110 days after inoculation with 5 
million cells, (ii) WHCO6 tumour formed 16 days after inoculation with 10 million cells, (iii) KYSE30 tumour formed 
28 days after inoculation with 7.5 million cells, and (iv) KYSE30 tumour formed 23 days after inoculation with 10 
million cells. Arrows indicates observation of visible signs of necrosis in the tumour.   
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Figure 2.16. Timelines showing treatment protocols for the tumourigenesis assays. Five million cancer cells were 
subcutaneously inoculated in nude mice for CaSki (A), WHCO6 (B) and KYSE30 (C). Upon palpable tumour 
formation, mice were randomized into the DMSO control group and INI-43 test group (N = 6), followed by 
treatment as indicated from day 0. Treatments were administered via intraperitoneal (i.p.) injections, and the 
animals were euthanized at the study endpoint. 
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Continual observation and measurements of the tumour sizes revealed that INI-43 treated mice 
showed a decreasing trend in tumour growth rate when compared to the DMSO-treated control 
group for all three cell lines (Fig. 2.17). Moreover, the difference reached significance for CaSki and 
WHCO6 tumours (Fig. 2.17.A and B). A decrease in KYSE30 tumours was observed (Fig. 2.17.C), the 
difference was however, not significant. The fold change in tumour volume between day 0 and the 
last day showed a significant difference for both CaSki and WHCO6 tumours (Fig. 2.18.A). In mice 
bearing CaSki tumours, the control mice showed a 4.9-fold increase in tumour volume while INI-43 
treatment group showed only 2.3-fold increase. Similarly for the WHCO6 tumours, 5.7-fold increase 
and 1.9-fold increase in tumour volumes were observed for control and INI-43 treated mice, 
respectively. In addition, comparison of tumour mass at the end point also showed decreased 
tumour mass in all INI-43 treated mice compared to DMSO treated mice in all three cell lines (Fig. 
2.18.B). In the course of the experiment performed with WHCO6 cells, one mouse was euthanized 
prematurely due to unexpected illness before day 21 excluding it from the last day's measurements. 
For this reason, measurements on day 21 were excluded from the data, making day 18 the endpoint 
for this experiment. Taken together, these results suggest that INI-43 significantly reduced CaSki and 
WHCO6 cancer cell growth in vivo, but had less effects on tumour size of highly aggressive KYSE30 
cancer cells.  
 
In addition to reducing tumour growth, INI-43 treated mice also showed less frequent necrotic 
development in tumour tissues compared to the control mice (Fig. 2.19). Necrotic tissues can vary in 
appearance depending on its severity. Mild necrosis manifests a doughnut-shaped tumour, where a 
collapse in the tumour centre is observed. More severe necrosis is characterized by darkened and 
liquefied tissue at the tumour centre, and in some extreme cases, destruction of tumour tissues is 
visible. As previously shown, both CaSki and KYSE30 tumours showed necrotic potentials (Fig. 2.19, A 
and C). In CaSki cells, the onset of necrosis was observed as early as 10 days into treatment for the 
control mice, while the first necrotic signs in INI-43 treated mice were only observed on day 19. At  
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Figure 2.17. The effect of INI-43 treatment on xenografted tumour growth in nude mice. Tumour development 
for control (DMSO) and INI-43 treated mice bearing CaSki (A), WHCO6 (B) and KYSE30 (C) tumours. Results shown 
are mean ± SEM for 6 mice in each group, *p < 0.05.  
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the experimental endpoint, necrotic tumours were observed in four out of six control mice, including 
one severe, two moderate and one mild necrosis. On the other hand, INI-43 treated mice showed 
only two out of six necrotic tumours, and one was only observed on the last day of the study (Fig. 
2.19.A, asterisk marks). Paralleling this, KYSE30 tumours had four out of six necrotic tumours in the 
control group, and two out of six in the INI-43 treated group (Fig. 2.19.C, asterisk marks). WHCO6 
tumours did not show any obvious signs of necrosis in both control and INI-43 treated groups (Fig. 
2.19.B). 
 
 
 
  
Figure 2.18. Analysis of tumour size at the end of the treatment schedule. The fold increase in tumour size at the 
end of the study relative to the starting tumour size (A), and the tumour mass at the end of the study for all 
groups of mice (B). Results shown are mean ± SEM for 6 mice in each group, *p < 0.05.  
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Figure 2.19. Tumours at the end of the tumourigenesis assay. At the endpoint of the tumourigenesis assay the 
mice were euthanized and tumours were dissected out. Tumours from both DMSO and INI-43 treated groups 
were photographed for CaSki (A), WHCO6 (B) and KYSE30 (C) tumours. Asterisk marks indicates observation of 
necrosis in the tumour mass. 
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The change in mice body mass and behaviour were monitored daily alongside to ensure that 
minimal distress was experienced by the animals (Fig. 2.20). No abnormalities were observed in 
behaviour of mice in both DMSO control and INI-43 treated groups, and similar fluctuation of body 
mass which is likely a result of intraperitoneal injections were observed in both groups of mice, 
confirming that INI-43 treatment at 50 mg/kg does not appear to compromise the animals' wellbeing 
(Fig. 2.20, A-C). Furthermore, the total gain in body mass between DMSO and INI-43 treatment 
groups were similar for all three experiments conducted with CaSki, KYSE30 and WHCO6 cells (Fig. 
2.20, D-F), supporting that INI-43 is tolerated in the nude mice model. Taken together, these results 
showed that INI-43 demonstrated inhibitory effect on cancer cell growth both in vitro and in vivo 
without causing intolerable toxicity in nude mice.  
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Figure 2.20. Body mass change in mice. During the tumourigenesis assay, the animals’ body mass were 
monitored daily for both DMSO and INI-43 treatment groups for CaSki (A), WHCO6 (B) and KYSE30 (C) tumour 
bearing mice. Body mass was expressed as percentage change to the body mass measured on day 0 of each 
experiment, and shown as mean ± SEM, with 6 mice in each group. The percentage gain in body mass for control 
and treated mice are shown for each cell line (D-F). Results are presented in Box-and-Whisker plots showing 
median, minimum and maximum values generated by Graphpad Prism. 
 
 
 
 
 
 
C 
B 
A 
F 
E 
D 
80 
 
2.3. Discussion 
Conventional chemotherapy has been employed for decades in anti-cancer therapies, and may be 
used for curative or palliative purposes. In general, chemotherapy involves the use of chemical 
substances and is often combined with radiotherapy or surgery. Various classes of 
chemotherapeutic agents exist, such as alkylating agents, taxanes, anthracycline, antimetabolites 
and others. Whilst each class of agents achieve cytotoxicity via different mechanisms, the 
commonality (and shortfall) of all chemotherapeutic agents is that they target all rapidly dividing 
cells, thereby killing cells such as those in the gut lining and hair follicles, resulting in severe 
undesired side effects such as hair loss and vomiting. The insufficient selectivity of current 
chemotherapeutics is a major drawback in cancer treatment, and the identification of novel anti-
cancer agents with increased specificity for cancer cells is anticipated to provide better and more 
efficient therapeutic means.  
 
In recent years, interference of the nuclear transport system has gained increasing attention as an 
anti-cancer approach, with the focus mainly on the inhibition of CRM1-mediated nuclear export128, 
229, 230, 237, 245, 343-347. Here, we have identified and examined a novel inhibitor of nuclear import 
designated INI-43, potentially through inhibition of Kpnβ1, and showed that it is effective at inducing 
cancer cell death both in vitro and in vivo. Supporting its role as an inhibitor of the Kpnβ1 protein, 
RNAi mediated Kpnβ1 inhibition displayed similar selective cancer killing effects via cell cycle arrest 
and apoptotic induction as observed with INI-43 treatment300, 333. Moreover, INI-43 displayed 
inhibitory effects on the nuclear import of various Kpnβ1 cargoes, including AP1, NFAT and NFY, and 
exogenous Kpnβ1 over-expression was able to partially reverse the inhibitory effect of INI-43 on 
NFκB-p65 nuclear import as well as cell viability333. These results suggest that INI-43 causes selective 
cancer killing effects via inhibiting Kpnβ1 function. Other Kpnβ1 inhibitors such as Ivermectin and 
Importazole have been reported to exhibit anti-cancer effects in ovarian cancer and multiple 
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myeloma298, 318. The mechanisms and selectivity of these agents, however, remain to be investigated. 
It has been reported that CRM1 inhibition via small molecules specifically induced apoptosis in 
cancer cells with minimal effects in non-cancer cells238, 243, 348, suggesting that interfering with the 
nuclear transport system, i.e. members of the Karyopherin family, may be an effective strategy to 
intervene with cancer growth and development. In this study we showed that INI-43 was 
significantly more toxic to cancer cells compared to non-cancer fibroblast cells, supporting that INI-
43 could be selective in its cytotoxic activities. However, the possibility that the difference observed 
is due to other reasons should not be ruled out - as the control cells used in this study were 
isogenically different to the cancer cells (fibroblast versus epithelial). Our laboratory has, however, 
previously shown that siRNA mediated Kpnβ1 inhibition showed higher killing effects in cancer cells 
compared to normal epithelial cells EPC2128, suggesting that targeting Kpnβ1 is selective. The 
specificity of nuclear transport inhibition against cancer cells may be attributed to the increased 
reliance on nuclear trafficking which has been associated with cellular transformation and cancerous 
phenotypes128, 185, 231, 347. 
 
In this study, the effect of INI-43 on cancer cell growth and viability was assayed under various 
conditions, and this showed inhibitory effects on both cell proliferation and survival when grown 
anchorage-dependently and independently. Examination of the mitochondrial content of 
cytochrome C and the apoptotic related cleavage of PARP demonstrated that INI-43 induced 
apoptosis via the intrinsic mitochondrial pathway. Similarly, the intrinsic apoptotic pathway was also 
found to be activated in cervical cancer cells when Kpnβ1 was inhibited via RNAi300, confirming that 
INI-43 treatment and Kpnβ1 inhibition resulted in similar cell death mechanisms. Whilst sufficient 
evidence exist to show that inhibition of nuclear import activates apoptotic pathways, this does not 
rule out the possibility that other cell death pathways may also be involved, such as autophagy. 
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The discovery and development of novel drugs, at some stage, involves pharmacokinetic and 
pharmacodynamic evaluations, including properties such as absorption, distribution, metabolism 
excretion and toxicity (ADMET). More often than not, promising candidates fail at this stage due to 
adverse findings, halting the process when a great deal of efforts and money have already been 
dedicated. In a study authored by van de Waterbeemd and Gifford, 39% of total drug discovery 
failure is attributed to suboptimal pharmacokinetic properties and 11% were a result of animal 
toxicity, suggesting that these two areas should be evaluated as early as possible in the drug 
discovery process340. While the in vivo pharmacokinetic and pharmacodynamic is currently under 
investigation in our laboratory, in this study we assessed the metabolic stability and animal toxicity. 
The examination of microsomal stability of the drug was particularly important prior to animal 
testing, as various candidates which showed promising results in vitro quite often fail to produce 
significant effects in vivo. In some cases, this is not due to lack of drug efficacy, but rather lack of 
metabolic stability. Since the majority of drug metabolism takes place in the liver, we evaluated the 
stability of INI-43 using both human and mouse liver microsomes. We showed that INI-43 exhibited 
good stability, with half-lives in both human and mouse liver microsomes longer than that of 
propranolol, a moderately stable compound. Next, possible adverse effects of INI-43 were studied at 
three different doses sequentially, and the result suggested that nude mice could tolerate INI-43 at 
least up to 50 mg/kg, at which dose the mice showed no obvious signs of discomfort or stress, and 
body mass gain were within acceptable range. The moderate stability and lack of toxicity of INI-43 at 
the concentrations tested, coupled to the promising in vitro anti-cancer activities set the premise for 
preclinical testing. 
 
Subsequent tumourigenesis assays using an ectopic xenograft mouse model revealed that INI-43 
displayed anti-tumour effect in vivo. Reduced growth rate as well as reduced necrotic tumour 
occurrence were observed in mice treated with INI-43 compared to the control mice treated with 
DMSO. The necrotic occurrence is likely a result of tumour growth beyond its vasculature supply, 
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and is generally associated with aggressive phenotypes such as invasion and metastasis342, 349. 
Although necrotic tumours represents death in the tumour tissue, it often induces powerful 
inflammation responses, resulting in increased growth in the surrounding tumour tissues due to the 
stimulatory effects of inflammation350. Indeed, it has been suggested that necrotic cell death and 
inflammation promote tumour growth in adult-related cancers351. Moreover, the association 
between poor prognosis and necrotic tumours have been demonstrated in urothelial carcinoma352-
354, renal cell carcinoma349, 355, colorectal cancer356,non-small cell lung cancer357 and pancreatic 
cancer358. The ability of INI-43 to reduce necrotic events may be an indication of its inhibitory effects 
on the aggressiveness of certain types of tumours. 
 
Taken together, these findings demonstrated that interference of nuclear import activities via the 
use of INI-43, potentially through inhibiting Kpnβ1 function induced apoptosis in cancer cells in vitro 
and decreased tumour growth rate in vivo. These anti-tumour effects of INI-43 makes it an attractive 
candidate to further pursue and develop for chemotherapeutic purposes, and in the next sections 
we explore the possibility of combining INI-43 with an established chemotherapeutic drug Cisplatin 
(CDDP) in treating gynaecological cancers. 
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CHAPTER 3 
INVESTIGATING THE COMBINATION TREATMENT OF INI-43 AND 
CDDP IN OVARIAN CANCER 
3.1. Introduction 
Ovarian carcinoma, although not the most frequently diagnosed, exhibits the highest mortality rate 
of gynaecological cancers359. This is attributed to two main reasons; firstly, the lack of symptoms 
which often lead to late diagnosis when the cancer has advanced already and treatment is difficult360. 
Secondly, the emergence of drug resistance is frequently observed in women receiving 
chemotherapy360, compromising treatment outcome and most patients relapse within two years of 
initial treatment361. The latter has remained one of the main challenges in treating ovarian cancer 
today.  
 
Platinum-based agents such as CDDP and Carboplatin form the important backbone in treating 
ovarian cancer36, and in the last two decades, research and clinical trials have demonstrated 
favourable outcome in their combined use with taxanes, compared to their monotherapy or 
combination with non-taxanes362-364. The combined use of CDDP or Carboplatin with Paclitaxel have 
become the standard approach for treatment and is generally effective365. While both combinations 
have similar treatment outcome in terms of survival366, Paclitaxel paired with Caboplatin is favoured 
over CDDP due to better toxicity profiles in clinical studies367. The combined use of CDDP and 
Etoposide has also been studied in relapsed patients, which was shown to be effective368, 369, 
although some concerns have been raised regarding its high rate of toxicity370. The incorporation of 
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molecularly targeted therapies into the standard platinum-taxane treatment is also a subject of 
study, and in particular, addition of Bevacizumab, an angiogenic inhibitor into the treatment 
regimen have shown improved progression-free survival in two clinical studies371, 372. 
 
While Kpnβ1 has not been extensively studied in ovarian cancer, there is literature describing 
increased Kpnβ1 expression at both mRNA and protein levels, suggesting increased reliance of 
ovarian cancer on the nuclear import function297. We were able to show that ovarian cancer cells 
exhibited sensitivity to INI-43 at IC50 values similar to that of cervical and oesophageal cancer, 
indicating a similar dependence of ovarian cancer on Kpnβ1 associated function. In addition, there is 
evidence showing elevated expression of other members of the Karyopherin family, including 
CRM1232 and Kpnα2191, 373, suggesting a link between nuclear transport and ovarian cancer. Various 
studies have addressed the therapeutic role of CRM1 in ovarian cancer175, 344, 346 and examined 
Kpnα2 as a prognostic marker374, while Kpnβ1 is beginning to be explored.  
 
More recently, CRM1 inhibition via the KPT compounds or Piperlongumine has been examined in 
combination with various cytotoxic agents263, 375, which showed additive or synergistic effects when 
partnered to CDDP, Topotecan, Doxorubicin, Paclitaxel and Bevacizumab in vitro, and combined use 
with Topotecan, Paclitaxel and Bevacizumab demonstrated effectiveness in preclinical mouse 
models376, 377, indicating a role for nuclear transport in chemoresistance. These suggest that co-
targeting the nuclear transport system with other cytotoxic agents may yield better treatment 
outcome compared to monotherapy. 
 
In this study, we investigated whether INI-43 can cooperate with the platinum based drug CDDP to 
achieve better therapeutic outcome. This is, to the best of our knowledge, a first study aimed at 
investigating a novel approach of combining a potential nuclear import inhibitor and CDDP.   
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3.2. Results 
3.2.1. The effect of INI-43 on nuclear import in ovarian cancer 
We have previously shown in cervical cancer cells that INI-43 exhibited inhibitory effects on nuclear 
import of various Kpnβ1 cargoes as well as Kpnβ1 itself333. These data showed that INI-43 negatively 
impacted nuclear import activities, and this is likely mediated through interfering with Kpnβ1 
function. To determine whether INI-43 could similarly interfere with Kpnβ1 in the ovarian cancer 
model, we investigated the effect of INI-43 on Kpnβ1 localization, as well as a pseudo-cargo protein, 
the nuclear localization signal (NLS) bearing mCherry protein (NLS-mCherry).  
 
3.2.1.1. INI-43 decreased nuclear localization of Kpnβ1 in ovarian cancer cell lines OVCAR4 and 
OVCAR8 
To examine Kpnβ1 localization in the presence and absence of INI-43, cells were treated accordingly 
for 1 hour, followed by immunofluorescence staining for Kpnβ1 and analyzed by confocal 
microscopy. Kpnβ1 staining in the DMSO-only treated control cells showed mostly an equal 
distribution between the cytoplasm and nucleus, with stronger signal in the peri-nuclear region (Fig. 
3.1.A, arrows indicate position of the nuclei). In cells treated with 5 µM INI-43, the cytoplasmic 
fluorescence became distinctively stronger compared to the nucleus (Fig. 3.1.A). This result suggests 
that 5 µM INI-43 treatment for 1 hour is sufficient to decrease the nuclear translocation of Kpnβ1. 
Cells were scored as either showing cytoplasmic or equal distribution of Kpnβ1, and plotted as a 
percentage, which revealed that INI-43 treatment led to an increase in percentage of cells showing 
cytoplasmic Kpnβ1 compared to the control cells (19% versus 67%, Fig. 3.1.B). To confirm the visual 
interpretation of the data, Kpnβ1 fluorescence intensity was quantified along the linear axis for two 
selected cells from each treatment (Fig. 3.1.C, line indicates position along which fluorescence 
intensity was quantified, and quantification path was drawn to avoid the nucleolus). Quantification  
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Figure 3.1. INI-43 treatment decreased nuclear Kpnβ1. OVCAR4 cells were treated with DMSO or 5 µM INI-43 for 
1 hour, followed by fixation and immunofluorescence staining and confocal microscopy (A). For both untreated 
and INI-43 treatment, at least 100 cells were scored as showing either cytoplasmic distribution or equal 
distribution (equal intensity in the nucleus and cytoplasm), and plotted as a percentage (B). Kpnβ1 fluorescence 
intensity along the cell linear axis (indicated by yellow line) was quantified and plotted. Positions of the nucleus 
and cytoplasm was shown with red solid line and green dotted line, respectively (C). Data shown are 
representative of three independent experiments. 
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of Kpnβ1 fluorescence showed two distinct profiles; in the DMSO treated cells, there were smaller 
fluctuations in fluorescence intensity along the length of the cell which did not correlate to 
cytoplasmic or nuclear positions, suggesting a more uniform distribution of Kpnβ1 throughout the 
entire cell. In the INI-43 treated cells, there was a clear biconcave distribution, with the two nuclear 
regions showing a marked decrease in Kpnβ1 concentration (green dotted line) compared to the 
cytoplasmic region (red solid line), confirming the visual interpretation that INI-43 treatment led to 
decreased nuclear Kpnβ1 localization. 
 
To independently confirm these results, cytoplasmic and nuclear proteins were harvested separately 
after treatment with or without INI-43 from OVCAR4 and OVCAR8 cells, and Kpnβ1 content analyzed 
via western blotting. In both cell lines, a decrease in nuclear Kpnβ1 after one hour treatment with 5 
µM INI-43 was observed (Fig. 3.2). Histone H3, a marker for nuclear proteins remained unchanged. 
No change in nuclear Kpnβ1 was noticeable after 1 µM INI-43 treatment, suggesting a minimal 
concentration of INI-43 is required for inhibitory effects to occur. To confirm that the nuclear 
fraction was not contaminated with cytoplasmic proteins, β-tubulin was probed and compared 
against a cytoplasmic fraction 'C'. 
 
3.2.1.2. INI-43 increased the cytoplasmic accumulation of NLS-mCherry in OVCAR4 
Having shown that INI-43 treatment interfered with the nuclear localization of Kpnβ1, we next 
examined whether INI-43 affected the localization of a classical NLS-tagged mCherry fluorescent 
reporter protein (NLS-mCherry), as this type of NLS containing cargoes are known substrates for 
Kpnβ1378. OVCAR4 cells were transfected with the pQC-NLS-mCherry-IX plasmid (Addgene plasmid 
37354, see Appendix Fig. A.3), which constitutively expresses NLS-mCherry under the control of CMV 
promoter. Cells were then treated with 5 µM and 10 µM INI-43 48 hours after transfection for 1 
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hour, followed by fixation and fluorescent microscopy was used to examine mCherry localization. In 
the 
 
 
 
 
 
 
untreated cells, mCherry was predominantly localized inside the nucleus, and INI-43 treatment 
resulted in increased cytoplasmic retention of NLS-mCherry (Fig. 3.3.A). Interestingly, INI-43 did not 
block nuclear localization of NLS-mCherry completely, this could be due to the experimental setup, 
as cells were treated with INI-43 48 hours after transfection. It is likely that by then mCherry was 
already expressed and imported into the nucleus, and the INI-43 treatment affected mainly the 
newly synthesized mCherry, preventing it from entering the nucleus leading to increased 
cytoplasmic retention. The mCherry fluorescence intensity was quantified and expressed as 
cytoplasmic mCherry fluorescence relative to nuclear mCherry fluorescence (Fc(Cy/Nu)). This 
Figure 3.2. INI-43 lead to decreased nuclear Kpnβ1. Nuclear and cytoplasmic proteins were independently 
harvested from OVCAR4 and OVCAR8 cells after treatment with 0 µM, 1 µM or 5 µM INI-43 for one hour, and 
Kpnβ1 levels in the nuclear fraction (Nu) was analyzed by western blot. Histone H3 and β-tubulin serve as loading 
control for nucleus and cytoplasm, respectively. A cytoplasmic sample 'C' was included to confirm proper 
separation of nuclear and cytoplasmic fractions. Results shown are representative of two independent 
experiments. 
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showed a significant increase in cytoplasmic mCherry after 5 µM and 10 µM INI-43 treatment 
compared to the untreated cells (Fig. 3.3.B). 
 
 
 
  
Figure 3.3. INI-43 treatment leads to increased cytoplasmic retention of NLS-mCherry. OVCAR4 cells were 
transfected with the constitutive NLS-mCherry expressing construct, pQC-NLS-mCherry-IX for 48 hours followed 
by 5 µM or 10 µM INI-43 treatment for 1 hour. Cells were fixed and stained with DAPI, and fluorescent 
microscopy were performed to examine localization of NLS-mCherry (A). NLS-mCherry fluorescence intensity was 
quantified using ImageJ and expressed as cytoplasmic fluorescence relative to nuclear fluorescence (Fc(Cy/Nu)), 
and normalized to the untreated cells (B, *p < 0.05). Results shown are mean ± SEM of 6 cells, the experiment was 
repeated two independent times. 
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Taken together, these results showed that INI-43 increased the cytoplasmic retention of a NLS-
bearing protein as well as Kpnβ1 itself, supporting the idea that INI-43 has an inhibitory effect on 
nuclear import, and that this is possibly mediated through interfering with Kpnβ1.  
 
3.2.2. INI-43 pre-treatment sensitized ovarian cancer cells to CDDP 
3.2.2.1. INI-43 pre-treatment led to decreased CDDP IC50 in OVCAR4 and OVCAR5 
Having shown that INI-43 caused an inhibitory effect on nuclear import similar to that observed in 
cervical cancer, we next assessed whether interference of the nuclear import system can affect 
cancer cells' response to DNA damage stress by examining CDDP sensitivity. To test this, three 
ovarian carcinoma cell lines OVCAR4, OVCAR5 and OVCAR8 were pre-treated with vehicle control 
DMSO or 5 µM INI-43 for 2 hours, a concentration which is sufficient to decrease nuclear import as 
shown in section 3.2.1, but does not cause significant cell death. After INI-43 pre-treatment, CDDP 
IC50 was determined for both control (single treatment) and INI-43 pre-treated (combination 
treatment) cells without removing INI-43 from the growth media. In all three cell lines, there was a 
significant reduction in CDDP IC50 (8.8 µM to 6.1 µM, 9.4 µM to 6.2 µM, and 14.8 µM to 10.2 µM for 
OVCAR4, OVCAR5 and OVCAR8 cells, respectively, Fig.3.4.A). This effectively represented 30%, 34% 
and 31% reduction in CDDP concentration which is needed to inhibit cell viability by 50% for OVCAR4, 
OVCAR5, and OVCAR8 respectively. A representing IC50 determination plot is shown for each cell line, 
and the IC50 values were calculated using the formula IC50 = 10
x-intercept as previously described (Fig. 
3.4.B). 
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3.2.2.2. INI-43 pre-treatment augmented CDDP-induced cytotoxic effects in OVCAR4 and OVCAR5 
To assess whether the difference in CDDP IC50 between single and combination treatment translated 
into a relevant difference in CDDP sensitivity, cell viability was examined in OVCAR4, OVCAR5 and 
OVCAR8 cells. Cells were pre-treated with DMSO or 5 µM INI-43 for 2 hours, followed by addition of 
CDDP to the growth media without removing INI-43. Viable cells were quantified using the MTT 
assay 48 hours later. The results demonstrated that while 5 µM INI-43 on its own caused negligible 
cell death, when coupled to CDDP it enhanced the inhibitory effect of CDDP on cell viability (Fig. 3.5).  
  
Figure 3.4. INI-43 pre-treatment decreased CDDP IC50 in ovarian cancer cell line OVCAR4, OVCAR5 and OVCAR8. 
Cells were pre-treated with DMSO (single treatment) or 5 µM INI-43 (combination treatment) before CDDP IC50 
determination. (A) Average CDDP IC50 for single and combination treatments (*p < 0.05). (B) One representing 
experiment for CDDP IC50 determination for single and combination treatment is shown for each cell line. Results 
shown are mean ± SEM of experiments performed in 6 replicates and repeated at least three times. 
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Figure 3.5. INI-43 pre-treatment sensitized OVCAR4 and OVCAR5 cells to CDDP. OVCAR4, OVCAR5 and OVCAR8 
cells were pre-treated with DMSO (light grey bars) or 5 µM INI-43 (black bars) before CDDP treatment at various 
concentrations. Cell viability was determined by MTT 48 hours after CDDP treatment (*p < 0.05). Results shown 
are representative experiments of three repeats for each cell line, mean ± SEM of 6 replicates. 
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3.2.2.3. INI-43 pre-treatment enhanced CDDP-induced cell death via increased apoptosis in 
OVCAR4 and OVCAR5 
Next, we investigated whether the reduced cell viability observed in the combination treatment was 
due to increased apoptosis. To examine apoptotic events in single and combination treated cells, 
PARP-cleavage was analyzed. Cells were pre-treated with DMSO or INI-43 for 2 hours followed by 
48-hour CDDP incubation, and the PARP status was determined by western blot. Results showed 
that INI-43 pre-treatment led to enhanced PARP cleavage at both 5 µM and 10 µM CDDP, compared 
to cells receiving CDDP only for both cell lines (Fig. 3.6). In addition, 5 µM INI-43 pre-treatment alone 
caused no PARP cleavage, confirming previous findings that this concentration of INI-43 does not 
significantly affect cell viability. These results indicated that INI-43 pre-treatment increases CDDP-
induced cell death via increasing apoptosis. 
 
Together, our data shows that INI-43 pre-treatment sensitized ovarian cancer cells to CDDP, 
implicating the importance of the nuclear import function in response to DNA damage stress. We 
speculate that when this function is perturbed, the cells became less tolerant to CDDP treatment. 
 
3.2.3. Kpnβ1 inhibition via siRNA sensitized OVCAR4 and OVAR5 cells to CDDP 
As described in Chapter 1, INI-43 was identified in an in silico screening as a potential inhibitor of 
Kpnβ1, and we have shown that INI-43 treatment decreased nuclear import as well as induced 
cancer cell death similar to that observed in Kpnβ1 knock-down cells128, 300, 333. Furthermore, we 
showed that INI-43 treatment decreased nuclear Kpnβ1333, suggesting that its inhibitory effect on 
nuclear import is possibly mediated through Kpnβ1. So we next verified whether the enhancing 
effect of INI-43 on CDDP cytotoxicity is mediated directly through Kpnβ1 inhibition, and not possible  
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off-target effects of INI-43. To address this, we inhibited Kpnβ1 expression by siRNA transfection and 
examined CDDP sensitivity. 
 
 
 
  
Figure 3.6. INI-43 pre-treatment enhanced CDDP-induced PARP cleavage. OVCAR4 and OVCAR5 cells were 
subjected to single or combination treatment at 5 µM and 10 µM CDDP for 48 hours. Proteins from both live and 
dead cells were collected and analyzed by western blot for PARP cleavage. For OVCAR4 cells, cleaved PARP was 
probed using an antibody specific for cleaved PARP, and for OVCAR5 cells, an antibody which recognized total 
PARP was used. GAPDH was used as loading control. Results shown are representative experiments performed at 
least two independent times.  
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3.2.3.1. Kpnβ1 knock-down with siRNA leads to decreased CDDP IC50 in OVCAR4 and OVCAR5 
CDDP IC50 was evaluated in cells transfected with 20 nM control siRNA (si-ctrl) and Kpnβ1 siRNA (si-
Kpnβ1), and knock-down was confirmed by western blot in OVCAR4 and OVCAR5 cells (Fig. 3.7.A). 
CDDP IC50 was determined using the standard MTT assay, and results showed a decrease in CDDP 
IC50, from 10.3 µM to 5.7 µM for OVCAR4 cells and from 12.6 µM to 4.7 µM for OVCAR5 cells (Fig. 
3.7.B). These represented 44% and 63% reduction in CDDP concentration that is required to kill 50% 
of the cells in OVCAR4 and OVCAR5, respectively. 
 
 
 
 
 
Figure 3.7. Kpnβ1 knock-down decreased CDDP IC50 in OVCAR4 and OVCAR5 cells. Cells were transfected with 20 
nM control siRNA (si-ctrl) or Kpnβ1 targeting siRNA (si-Kpnβ1) for 48 hours, and Kpnβ1 knock-down was 
confirmed via western blot (A). Representing CDDP IC50 determination plots for control and Kpnβ1 knock-down 
cells are shown for both cell lines. Results shown are mean ± SEM of 6 replicates, the experiment was repeated 
two independent times.  
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3.2.3.2. Kpnβ1 knock-down enhanced CDDP cytotoxicity in ovarian cancer 
Next we examined the effect of CDDP on cell viability in Kpnβ1 knock-down cells and control cells. 
The knock-down conditions were carried out as previously described in section 3.2.3.1, and cell 
viability was examined after CDDP treatment at various concentrations using the standard MTT 
assay. In OVCAR4 cells, Kpnβ1 knock-down led to decreased cell viability compared to the control 
cells, including those that were not treated with CDDP (Fig. 3.8.A, compare viability at 0 µM CDDP 
treatment). These cell death were likely due to potent inhibition of Kpnβ1 achieved by siRNA128, 300, 
and to eliminate the cell death that was caused by Kpnβ1 inhibition only, cell viability was 
normalized to the CDDP-untreated cells in each transfection group. The corrected results showed a 
significant decrease in cell viability in the Kpnβ1 knock-down cells compared to the control cells at all 
CDDP concentrations tested (Fig. 3.8.B). This was similarly observed in OVCAR5 cells (Fig. 3.8.C and 
D). 
 
Having shown that siRNA mediated Kpnβ1 knock-down enhanced the cytotoxicity of CDDP, we next 
examined whether transient Kpnβ1 inhibition affected cell growth at a lower CDDP concentration. 
Control and Kpnβ1 knock-down OVCAR5 cells were seeded sparsely (2000 cells/35 mm dish) and 
incubated with 1 µM CDDP for 24 hours, before CDDP-containing media was replaced with fresh 
growth media and cell growth was examined nine days later. Whilst the conventional MTT assay 
examines cell viability in the presence of the damaging source for a short period of time, this 
experiment inspects the cell's ability to survive a damaging agent after the source is withdrawn. The 
result showed that cell growth was able to recover nine days after transient Kpnβ1 knock-down (Fig. 
3.8.E, compare (i) and (ii)), however, low concentration CDDP treated cells with transient Kpnβ1 
knock-down showed a substantial decrease in cell number after nine days of culture, compared to 
the control cells (Fig. 3.8, compare (iii) and (iv)). These results demonstrated that cells with transient  
  
98 
 
 
  
A 
B 
C 
D 
E 
Figure 3.8. Kpnβ1 knock-down enhanced CDDP cytotoxicity in OVCAR4 and OVCAR5 cells. Cells were first 
transfected with 20 nM si-ctrl or si-Kpnβ1, followed by CDDP treatment at various concentrations. Cell viability 
was examined using MTT assay after 48 hours of CDDP treatment (A and C). Cell viability was corrected to the 
untreated cells for each transfection group to eliminate the effect that were specific to Kpnβ1 knock-down (B and 
D, *p < 0.05). Phase contrast images showing si-ctrl and si-Kpnβ1 transfected cells 9 days after 24 hours exposure 
to 1 µM CDDP (E). Results shown are mean ± SEM of 6 replicates (A-D), and each experiment was repeated two 
independent times.  
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Kpnβ1 knock-down showed decreased survival compared to the control cells with an intact nuclear 
import system. As the Kpnβ1 knock-down effect would be long lost by day 9, it is likely that the low 
CDDP concentration was able to kill more of the initial population in the Kpnβ1 knock-down cells 
compared to the control cells, thereby leaving less cells to proliferate and thus less cells were 
observed after nine days.  
 
3.2.3.3. Kpnβ1 knock-down enhanced PARP cleavage in CDDP treated OVCAR5 cells 
Next we investigated whether the enhanced cell death observed after CDDP treatment in Kpnβ1 
knock-down cells resulted from an increase in apoptosis as observed with INI-43 pre-treatment. si-
ctrl and si-Kpnβ1 transfected OVCAR5 cells were treated with CDDP for 48 hours and the amount of 
cleaved PARP present in each cell population was analyzed by western blot. Of the cells which 
received the same CDDP concentration, those with Kpnβ1 knock-down showed higher levels of 
PARP-cleavage compared to the control cells (Fig. 3.9.A). Densitometry analysis was used to quantify 
cleaved PARP to total PARP, and this confirmed that elevated cleaved PARP was present in Kpnβ1 
knock-down cells compared to control cells at the same CDDP concentration (Fig. 3.9.B). 
 
Taken together, these results showed that Kpnβ1 knock-down cells resulted in sensitization of 
ovarian cancer cells to CDDP similar to that observed in INI-43 treated cells, supporting the 
hypothesis that INI-43 augmented CDDP-induced apoptosis via interfering with Kpnβ1 function. 
 
3.2.4. CDDP treatment increased Kpnβ1 expression in ovarian cancer cells, but not non-
cancer cells 
As shown in the previous sections, INI-43 pre-treatment followed by CDDP treatment resulted in a 
increase in sensitivity and cell death in ovarian cancer cells. This suggests that when cancer cells are 
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challenged with genotoxic stress such as that caused by CDDP treatment, they rely on Kpnβ1 
function more so than the unchallenged cells. Based on this, we hypothesized that Kpnβ1 may be 
responsive to genotoxic stress caused by CDDP treatment. To test this, OVCAR4 and OVCAR5 cells 
were treated with CDDP at different concentrations for 24 hours, followed by protein extraction 
which was then subjected to western blot analysis. To confirm DNA damage, the phosphorylated 
form of histone H2A.X (γH2AX) was detected alongside Kpnβ1. Histone H2A.X is known to be 
B 
A 
Figure 3.9. Kpnβ1 knock-down enhanced CDDP-induced apoptosis. Kpnβ1 knock-down OVCAR5 cells were 
treated with CDDP for 48 hours, followed by protein collection from both live and dead cells. PARP and cleaved 
PARP (C-PARP) were examined using western blot, GAPDH served as loading control (A). Densitometric 
quantification of protein bands in (A), expressed as C-PARP relative to total PARP, and corrected to GAPDH levels 
(B). Result shown is representative of 2 independent experiments. 
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phosphorylated at serine-139 by kinases such as Ataxia Telangiectasia Mutated (ATM), and it is a 
well-established marker for DNA damage379. Analysis revealed that Kpnβ1 expression increased with 
CDDP treatment in a concentration dependent manner for both cell lines, which correlated with the 
amount of DNA damage, as indicated by increased γH2AX (Fig. 3.10). 
 
 
  
Figure 3.10. CDDP treatment increased Kpnβ1 expression in OVCAR4 and OVCAR5 cells. OVCAR4 and OVCAR5 
cells were treated with CDDP at various concentrations for 24 hours, and Kpnβ1 expression was analyzed using 
western blot. Levels of γHA2X were examined alongside to confirm CDDP-induced DNA damage, and GAPDH 
served as loading control. Results shown are representatives of two independent experiments from each cell line. 
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We further investigated whether Kpnβ1 elevation in response to CDDP treatment occurs in other 
ovarian cancer cell lines; including A2780, OVCAR8 and CP70; as well as the immortalized 
nontumourigenic human ovarian surface epithelial cell line T29380. The cells were either untreated or 
treated with a concentration of CDDP similar to their own CDDP IC50 (Fig. 3.11.A, 0.9 µM, 13.3 µM, 
11.6 µM and 4.9 µM for A2780, OVCAR8, CP70 and T29 respectively). Our results showed a clear 
induction of Kpnβ1 expression in both A2780 and OVCAR8 cells, and a weaker induction in CP70 cells 
when treated with CDDP at their own IC50 (Fig. 3.11.B), which was confirmed by densitometrical 
quantification (Fig. 3.11.C). Interestingly, the nontumourigenic cell line T29 did not show increased 
Kpnβ1 levels after CDDP treatment, suggesting that it is possibly less reliant on the nuclear import 
system under DNA-damaging conditions. Indeed, INI-43 pre-treatment of T29 cells did not 
significantly improve the outcome of CDDP treatment in T29 cells, shifting the CDDP IC50 values from 
5.4 µM to 5.3 µM (Fig. 3.11.D).  
 
3.2.5. CDDP treatment induced Kpnβ1 nuclear localization in OVCAR4 and OVCAR5 cells  
Having shown that Kpnβ1 expression was responsive to CDDP treatment, we next examined its 
localization in the presence and absence of CDDP. OVCAR4 and OVCAR5 cells were treated with 
CDDP at 0.5 x and 1 x its IC50 values for 24 hours, followed by fixation and Kpnβ1 was stained using a 
FITC conjugated secondary antibody. Fluorescent microscopy analysis showed that without 
treatment, most cells showed an even distribution of Kpnβ1 in both the cytoplasm and nucleus with 
stronger signal in the peri-nuclear region (Fig. 3.12.A). In cells treated with 5 µM or 10 µM of CDDP, 
localization of Kpnβ1 became more nuclear for the majority of cells (Fig. 3.12.A). The Kpnβ1 
fluorescence intensity (FC-Kpnβ1, FITC) was correlated to the nucleus (FC-nucleus, DAPI) for a 
random cell from each treatment, as previously described. This demonstrated an overlap of Kpnβ1 
fluorescence and DAPI fluorescence in the presence of 5 µM and 10 µM CDDP compared to the 
control cell, where Kpnβ1 intensity fluctuated around a baseline value (Fig. 3.12.B). Furthermore, 
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Figure 3.11. CDDP treatment increased Kpnβ1 expression in ovarian cancer cells but not the non-cancer cell line 
T29. CDDP IC50 values were determined in ovarian cancer cell lines A2780, OVCAR8, CP70 and non-cancer cell line 
T29 (A), and Kpnβ1 expression were then examined for each cell line at their respective CDDP IC50 values (B), with 
GAPDH as the loading control. Kpnβ1 expression was densitometrically quantified and expressed relative to 
GAPDH for each cell line (C). A representative of CDDP IC50 determination plot for T29 cells pre-treated with and 
without INI-43, the experiment was repeated twice (D). Data shown here are representatives of experiments 
performed at least two independent times (A, B and D), and values plotted are mean ± SEM of 6 replicates from 
the representative experiment (A and D).  
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cells treated with 5 µM and 10 µM showed significant correlation between the nucleus (DAPI) and 
Kpnβ1 (FITC) fluorescence intensities, with R2 values of 0.91 and 0.91, compared to 0.17 in the 
untreated cells. Similar observations were made in OVCAR5 cells, where untreated cells exhibited 
poor correlation between Kpnβ1 and DAPI fluorescence (Fig. 3.12.C). When cells were treated with 
CDDP, there was a noticeable increase of Kpnβ1 in the nucleus (Fig. 3.12.C), and fluorescence 
intensity quantification confirmed co-localization of FITC and DAPI, indicating nuclear accumulation 
of Kpnβ1 in the CDDP treated cells (Fig. 3.12.D). Correlation analysis of the DAPI and FITC intensity 
was only significant in the 5 µM and 10 µM treated cells, and R2 values were 0.026, 0.79 and 0.84 for 
untreated, 5 µM CDDP treated and 10 µM CDDP treated cells, respectively.  
 
To independently validate the results obtained from the immunofluorescence experiments, nuclear 
proteins were harvested separately from the cytoplasmic proteins for both OVCAR4 and OVCAR5 
cells after treatment with CDDP. The amount of Kpnβ1 present in the nuclear fraction was examined 
using western blot, and results confirmed an increase in nuclear Kpnβ1 after CDDP treatment in both 
cell lines (Fig. 3.13).  
 
Taken together, these results show that in ovarian cancer cells, the uniform distribution of Kpnβ1 
between the cytoplasmic and nuclear compartments is disrupted by CDDP treatment, as increased 
nuclear accumulation of Kpnβ1 is observed after CDDP treatment. 
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Figure 3.12. CDDP treatment induced nuclear accumulation of Kpnβ1 in OVCAR4 and OVCAR5 cells. Cells were 
treated with CDDP for 24 hours, followed by fixation and staining with FITC (Kpnβ1) and DAPI (nucleus). Images 
were captured using a fluorescent microscope and a representing image for each treatment was shown for 
OVCAR4 (A) and OVCAR5 (C) cells. Correlation between FITC (Kpnβ1) and DAPI (nucleus) fluorescence intensity 
were performed using ImageJ for OVCAR4 (B) and OVCAR5 (D) cells. The experiment was repeated two 
independent time, and representative images from one experiment is shown. 
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3.2.6. INI-43 pre-treatment reduced CDDP-induced nuclear import of Kpnβ1 
We have shown so far that OVCAR4 and OVCAR5 cells responded to CDDP treatment by elevating 
Kpnβ1 expression as well as nuclear accumulation. We have also presented evidence showing that 
nuclear import inhibition by INI-43, whose action is likely mediated through Kpnβ1, sensitized 
ovarian cancer cells to CDDP. Based on these, we next investigated whether, and how, INI-43 
affected CDDP-induced alternations in Kpnβ1. 
 
To do this, we used immunofluorescence to examine Kpnβ1 distribution via an Alexa-Fluor 647 
labelled antibody. Cells were pre-treated with DMSO or INI-43 for 2 hours, followed by 24 hours of 
CDDP treatment (with the DMSO or INI-43 kept in the media). Cells were then fixed and stained with 
the Kpnβ1 primary antibody and fluorescently labelled secondary antibody. Control (untreated) cells 
and cells treated only with INI-43 were included for comparison. Images were then captured using a 
Figure 3.13. CDDP treatment led to increased nuclear Kpnβ1. Western blot analysis of nuclear proteins (Nu) 
treated with CDDP for 24 hours in OVCAR4 and OVCAR5 cells. GAPDH and Histone H3 serve as cytoplasmic and 
nuclear loading controls, respectively, and a cytoplasmic fraction 'C' was included to confirm non-cross 
contamination of the two cellular compartments. Results were densitometrically quantified and shown as 
Kpnβ1/Histone H3, relative to the untreated in each cell line (B). Results shown are representative of experiments 
repeated three independent times. 
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fluorescent microscope and analyzed by a scoring system where cells were categorized into three 
different populations: (i) where Kpnβ1 fluorescence intensity was higher in the cytoplasm 
(cytoplasmic), (ii) where Kpnβ1 fluorescence was higher in the nucleus (nuclear), or (iii) where Kpnβ1 
was equally distributed between the two compartments, including those with strong peri-nuclear 
signal (equal distribution). One-hundred cells were scored for each treatment (Fig. 3.14), and 
numbers are tabulated in Table 3.1. 
 
Table 3.1. Cellular distribution of Kpnβ1 after treatment with INI-43, CDDP or a combination of 
both 
Treatment Kpnβ1 distribution (%) 
INI-43 (µM) CDDP (µM) Cytoplasmic Nuclear 
Equal 
distribution 
0 0 31 5 64 
5 0 81 8 11 
10 0 90 2 8 
0 5 18 42 40 
5 5 57 11 32 
10 5 68 4 28 
0 10 7 85 8 
5 10 29 35 36 
10 10 60 8 32 
 
 
 
 
 
Data shown are quantification of 100 cells from multiple field of views photographed using a fluorescent 
microscope for each treatment. 
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Without any treatment, Kpnβ1 was present in both cellular compartments with roughly equal 
intensity for the majority of the cells (64%, Fig. 3.14.A), suggesting an equal distribution. Kpnβ1 
became predominantly cytoplasmic with INI-43 treatment (81% and 90% for 5 µM and 10 µM, 
respectively, Fig. 3.14.A). Without INI-43 pre-treatment, 5 µM CDDP markedly increased the 
percentage of cells showing nuclear Kpnβ1, from 5% to 42%. On the other hand, pre-treatment with 
INI-43 decreased CDDP-induced Kpnβ1 nuclear localization in a concentration dependent manner - 
from 42% in the single treatment to 11% and 4% for 5 µM and 10 µM INI-43 pre-treatment, 
respectively. The same was observed when cells were treated with 10 µM CDDP - whilst single 
treatment led to 85% of the cells showing nuclear Kpnβ1, INI-43 pre-treatment reduced it to 35% 
and 8% for 5 µM and 10 µM INI-43 pre-treatment, respectively. A representative image for each 
treatment is shown, and the fluorescence intensities for Alexa-647 (representing Kpnβ1 
concentration) and DAPI were quantified as previously described (Fig. 3.14.B and C). Fluorescence 
quantification showed that in the untreated cells, Kpnβ1 fluorescence intensity was poorly 
associated to DAPI intensity, suggesting that Kpnβ1 was not particularly localized to either 
compartment (Fig. 3.14.C). INI-43 treated cell showed a clear decrease in Kpnβ1 intensity where 
DAPI intensities were maximal, suggesting decreased Kpnβ1 localization in the nucleus. In the CDDP-
only treated cell, Kpnβ1 and DAPI fluorescence signal exhibited similar trends, suggesting higher 
Kpnβ1 in the nucleus. Lastly, in the combination treated cell, a profile similar to the INI-43 only 
treated cell was observed, whereby the nuclear concentration of Kpnβ1 was lowest in the nuclear 
region (Fig. 3.14.C). These plots supports the accuracy of the scoring system which was carried out 
visually. Taken together, these results showed that INI-43 pre-treatment suppressed the CDDP-
induced nuclear accumulation of Kpnβ1. 
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Figure 3.14. INI-43 pre-treatment suppressed CDDP-induced nuclear accumulation of Kpnβ1. OVCAR5 cells were 
subjected to INI-43 only, CDDP or a combination of INI-43 and CDDP as previously described. Cells were then fixed 
and Kpnβ1 was stained with Alexa-647, and Kpnβ1 localization was analyzed using fluorescent microscopy. For 
each treatment, 100 cells were scored either as showing nuclear Kpnβ1, cytoplasmic Kpnβ1 or even distribution 
of Kpnβ1 (A). A representative image for each type of treatment is shown (B), and the fluorescence intensity for 
Kpnβ1 (Alexa fluor-647) and the nucleus (DAPI) are plotted as previously described (C). Results showed that INI-43 
pre-treatment decreased CDDP-induced nuclear import of Kpnβ1.  
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3.3. Discussion 
An effective combination therapy is one where using both drugs together provides an outcome that 
is greater than the combined effect of both drugs when used alone. In this chapter, we presented 
evidence showing that a combination treatment where cancer cells are first exposed to INI-43 at a 
sub-lethal concentration sufficient to reduce nuclear import, followed by CDDP treatment resulted in 
greater killing effect compared to the combined effect of both drugs when used alone. Furthermore, 
the enhanced cell death occurred via the apoptotic pathway, a desired mechanism for cell death in 
anti-cancer therapy. 
 
As previously discussed, INI-43 is a small molecule identified based on its predicted ability to bind to 
functional sites of Kpnβ1, thereby acting as an inhibitor of Kpnβ1. Data generated from our 
laboratory have shown that INI-43 manifested inhibitory effects on the nuclear import of various 
transcription factors, including AP1, NFκB and NFAT in cervical cancer cells333. These results suggest 
that INI-43 decreases nuclear import via interfering with Kpnβ1 function, as those are all known 
cargoes of Kpnβ1. The role of INI-43 on nuclear transport in ovarian cancer, however, has not been 
explored to date. Here, we report novel findings showing that it affected the cellular distribution of 
mCherry protein tagged with the classical NLS, which under normal circumstances accumulates in 
the nucleus via Kpnβ1/Karyopherinα dependent importing activity. In INI-43 treated cells, we 
observed increased cytoplasmic retention of NLS-mCherry, confirming that INI-43 is interfering with 
the nuclear import system in ovarian cancer. Furthermore, the localization of Kpnβ1 itself was 
altered by INI-43 treatment, suggesting that INI-43 interferes with nuclear import via Kpnβ1 in 
ovarian cancer cells. 
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INI-43 treatment, as well as Kpnβ1 knock-down both enhanced CDDP sensitivity in ovarian cancer 
cells, which was evident through the decreased viability and increased apoptosis. The degree of this 
enhancement is more prominent in Kpnβ1 knock-down cells compared to INI-43 pre-treated cells, 
which is likely due to the greater inhibitory effect achieved with 20 nM siRNA compared to the dose 
of INI-43 used in the experiments. 
 
We also report elevated Kpnβ1 levels and increased nuclear accumulation in response to CDDP 
treatment, and this could be interpreted in different ways. Firstly, the increased expression could 
suggest increased reliance on Kpnβ1 function under DNA damage conditions. However, the general 
consensus is that nuclear trafficking is repressed in stressed cells381-383. Whilst this may seem 
contradictory to our findings, there could be alteration in transport substrate specificity under DNA 
damage conditions, so that although the overall nuclear trafficking activities are reduced, trafficking 
of selected proteins could still be elevated. This is supported by two factors; firstly, Kodiha et al. 
showed that although nuclear import was repressed in response to oxidative stress, it was not 
completely abolished and some facilitated nuclear import is still supported by the cell381. Secondly, 
nuclear trafficking of various proteins have been reported to be induced by stress signals384-387. The 
alteration in substrate specificity may derive from modifications of the substrate themselves rather 
than the nuclear transporters, but importantly, they still rely on the transporters for appropriate 
localization. These findings suggest that under stressed conditions, even though nuclear transport 
machinery may be repressed but they still play important roles in regulating stress response. 
 
Interestingly, Kodiha et al. demonstrated that Kpnβ1 was more prone to proteosme-dependent 
degradation under oxidative stress conditions leading to decreased levels; however, their results 
were obtained after one hour exposure to oxidative stress. Our observation of elevated Kpnβ1 24 
hours after CDDP treatment could be a result of later events occurring in the stress response 
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pathway. Alternatively, it could be a result specific to stress induced by CDDP-treatment, as CDDP 
specifically induces DNA damage whereas the oxidants have damaging effects on a broader 
spectrum. 
 
We also demonstrated increased nuclear accumulation of Kpnβ1 after CDDP treatment. In the cargo 
import process, whether executed with or without Karyopherinα, Kpnβ1 itself needs to enter the 
nucleus, and may then stay in the nucleus or exit the nucleus coupled with RanGTP. Kpnβ1 is thus 
constantly shuttled between the two cellular compartments, which is supported by our observation 
that under normal conditions, it is present in both the cytoplasm and the nucleus, with some 
accumulation at the peri-nuclear region, possibly associated with the Nups during transit. The 
increased nuclear accumulation of Kpnβ1 observed after CDDP treatment could result from 
increased nuclear import rate or decreased nuclear export by RanGTP. As the global nuclear 
trafficking is reported to be repressed in stressed cells, it is more likely that the increased Kpnβ1 
nuclear accumulation is due to its decreased export rather than increased nuclear import. Indeed, 
similar findings have been reported in oxidative stressed cells, which was attributed to a dissipation 
of RanGTP gradient381. However, whether this is true in our CDDP-treated ovarian cancer system 
remain to be elucidated. Our findings showed that INI-43 interfered with Kpnβ1 translocation into 
the nucleus after CDDP treatment, and that this associated with greater cell death as observed in the 
combination treatment. We speculate that this relocalization may be a 'rescue mechanism' 
associated with cell survival, and may be related to altered importing activities of Kpnβ1. There exist, 
however, a possibility that these two observations were two independent events. If Kpnβ1 
accumulation inside the nucleus in CDDP treated cells was a result of loss of RanGTP gradient, this 
would prevent nuclear exit of most Kpnβ1 (possibly contributing to the decreased global importing 
activity), and INI-43 treatment would simply diminish the importing activity of the residual Kpnβ1 
that is still able to exit the nucleus. So even though an antagonistic effect on Kpnβ1 localization was 
observed with INI-43 and CDDP treatments, INI-43 in essence just suppressed nuclear import 
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irrespective of CDDP-induced nuclear accumulation of Kpnβ1. Furthermore, the increased Kpnβ1 
levels after CDDP treatment could be a response to ensure that sufficient importing activity can still 
occur even when the majority of the Kpnβ1 is trapped in the nucleus. 
 
A question that arises, is how the perturbation of Kpnβ1 function affects the cellular response to 
CDDP, resulting in enhanced killing. Recent studies have suggested targeting DNA repair pathways in 
combination with DNA-damaging agents to achieve synergism388, 389, which highlights the potential 
role of the DNA-repair function in anti-cancer therapy. Indispensible to this process is the nuclear 
transport function, which plays an integral part in DNA-repair, as re-organization of protein 
distribution is known to be a response of cells under replication stress, such as DNA damage caused 
by CDDP390. Indeed, various proteins involved in DNA repair pathways have been reported to 
undergo nucleo-cytoplasmic translocations when exposed to DNA-damaging agents. For example, 
the p38 Mitogen-Activated Protein Kinase (MAPK)391, both Rad51 and its interacting protein 
Rad51C392, p21393, the damage-specific DNA Binding Protein (DDB)394, and the MDM2 homolog 
protein MDMX395 are all DNA damage response proteins known to localize to the nucleus after DNA 
damage. On the other hand, the cell cycle regulator Cdc25396 and precursor microRNAs397 have been 
reported to show accelerated export out of the nucleus upon DNA damage. All of these findings 
highlight the importance of the nuclear transport function in response to stressful conditions.  
 
Whilst Kpnβ1 is not responsible for the entire transport network within the cell, it is a key mediator 
of nuclear import for macro-molecules, which can occur with or without the Karyopherinα adaptors. 
This could explain why stressed cells become more reliant on the nuclear import (and export) system, 
as this allows them to redistribute proteins to the right locations where they can react to the stress 
appropriately. Supporting this, various DNA damage response proteins possess NLS, amongst which 
many even contain multiple NLSs, including ERCC6, XPC and Rep-3/Duc-1398. More recently it has 
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been reported that a non-classical bipartite NLS, which was previously thought to be absent, has 
been identified in XCRR1, another DNA-repair protein399. As the NLS is a sequence used for cargo 
recognition by Kpnβ1/Karyopherinα, these findings suggest that those proteins are imported in a 
Kpnβ1-dependent manner. This may provide an explanation as to why Kpnβ1 inhibition via siRNA or 
INI-43 resulted in greater killing at the same dosage of CDDP, and may result from an impaired 
response mechanism of cancer cells with its Kpnβ1 function is deprived.  
 
In addition to its nuclear importing function in interphase cells, Kpnβ1 is also an important regulator 
of many aspects of mitosis, and manipulation of its expression, whether elevated or repressed 
causes mitotic defects282, 286, 300. Kpnβ1 inhibition via siRNA or INI-43 could therefore sensitize cancer 
cells to CDDP through inducing genomic instability, which could render cancer cells more sensitive to 
DNA damage.  
 
In this chapter, we presented novel findings to suggest that combining nuclear import inhibition with 
a DNA-damaging agent could have enhanced therapeutic benefits. Whilst CDDP alone has been used 
widely to treat a variety of cancers, its off-target effects are a long-standing challenge in cancer 
therapy400, 401. Lowering the dose of CDDP and combining it with a nuclear import inhibitor could 
provide viable alternatives to treatment and could be useful in minimizing the off-target effects of 
CDDP, warranting further studies. 
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CHAPTER 4 
INVESTIGATING THE COMBINATION TREATMENT OF INI-43 AND 
CDDP IN CERVICAL CANCER  
4.1. Introduction 
Cervical cancer is the third most common cancer in women worldwide, and according to the 
International Agency for Research on Cancer (World Health Organization), it has been estimated that 
in the year 2020, over 120 000 diagnosis and over 75 000 deaths will occur in Africa alone. The 
current treatment options for cervical cancer include surgery, radiation therapy, chemoradiation 
(combination of chemotherapy and radiation) and chemotherapy. Early stage tumours are 
frequently treated with surgery and radiation therapy, and locally advanced cancers are treated with 
chemoradiation. Metastatic, late stage cervical cancer appearing at distant sites cannot be surgically 
removed, in which case the use of chemotherapeutic agents becomes necessary402. In addition, 
recurrent disease with increased chemoresistance and decreased response rate in cervical cancer 
patients present further clinical difficulty as treatment options become limited403. 
 
Chemotherapeutic options include several platinum-based, anthracycline and microtubule targeting 
agents404. While CDDP is considered the most effective and form part of the standard care404, its use 
is often compromised due to its toxicity profile and resistance in previously irradiated patients405, 406. 
Combination chemotherapy is an effective approach to increase treatment response, and survival 
advantage has been demonstrated for platinum-based combinations incorporating Topotecan, 
Irinotecan, Gemcitabine and Docetaxel compared to the use of single agents407-410. Recently, 
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sensitization of cervical cancer cells to CDDP has been demonstrated using natural-derived 
compounds such as Melatonin, Epigallocatechin Gallate and Genistein, as well as the autophagy 
inhibitor 3MA in vitro311, 411-413. These findings demonstrated potentials for exploring novel CDDP-
based combination chemotherapy which could increase the effectiveness of CDDP treatment in 
cervical cancers, or alternatively, enable lower doses of CDDP to minimize associated toxicity. 
 
We have recently reported data supporting the role of INI-43 as an inhibitor of nuclear import 
potentially mediated through Kpnβ1333. Furthermore, INI-43 treatment sensitized ovarian cancer 
cells to CDDP-induced death signals. This proposed a novel approach of combining nuclear import 
inhibition and CDDP in the treatment of ovarian cancer. In this chapter, we investigated the 
combination of INI-43 and CDDP treatment on a panel of cervical cancer cell lines. In addition, the 
molecular pathways underlying cancer cell's response to CDDP in Kpnβ1-inhibited cells was 
investigated. This aspect of the study focussed on the HPV18 positive HeLa cells and HPV16 positive 
SiHa cells, the latter having been reported as CDDP-resistant414. We used the same treatment 
protocol as previously described, where combination treatment refers to pre-exposing cells to a 
dose of INI-43 sufficient to reduce nuclear transport, but insufficient to induce cell death on its own, 
followed by CDDP treatment.  
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4.2. Results  
4.2.1. INI-43 treatment sensitized cervical cancer cells to CDDP 
To investigate whether nuclear import inhibition via INI-43 sensitized cervical cancer cells to CDDP, 
we investigated the effect of single and combination treatments. Briefly, cells were pre-treated with 
vehicle control DMSO (single treatment) or sub-lethal dose of INI-43 (combination treatment) for 2 
hours before CDDP treatment, followed by various different experiments to determine CDDP 
sensitivity. The pre-treatment was performed for two hours as we have recently shown that INI-43 
repressed nuclear import of Kpnβ1 cargoes within 1.5 hours in cervical cancer cells333. 
 
4.2.1.1. INI-43 pre-treatment decreased CDDP IC50 in HeLa and SiHa cells 
To examine whether nuclear import inhibition sensitized cervical cancer cells to CDDP, CDDP IC50 
values were determined for control DMSO or INI-43 pre-treated cells. Of the four cell lines tested, 
both HeLa and SiHa cells showed significant decreased in CDDP IC50 values when pre-treated with 
INI-43 in a concentration dependent manner. (Fig. 4.1.A). CaSki cells showed a smaller reduction of 
CDDP IC50 when pre-treated with 5 µM INI-43, although the difference was not significant. The C33A 
cells did not show significant changes in CDDP sensitivity when pre-treated with INI-43 at both 
concentrations tested (Fig. 4.1.A). In HeLa cells, the average CDDP IC50 was approximately 18.0 µM, 
which was decreased to 11.8 µM and 10.1 µM after 2.5 µM and 5 µM INI-43 pre-treatment, 
respectively. Similarly for SiHa cells, CDDP IC50 reduced from 30.8 µM for single treatment to 23.0 
µM and 16.9 µM for 2.5 µM and 5 µM INI-43 pre-treated cells, respectively. This effectively 
represented 44% and 46% decrease in CDDP IC50 when pre-treated with 5 µM INI-43 for HeLa cells 
and SiHa cells. A representing CDDP IC50 determination plot for single and combination treatment is 
shown for each cell line (Fig. 4.1.B).  
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Figure 4.1. CDDP IC50 in cervical cancer cells with or without INI-43 pre-treatment. CDDP IC50 values were 
determined for cervical cancer cell lines HeLa, Caski, SiHa and C33A in single and combination treatments as 
previously described (A). Results shown are mean ± SEM of three independent experiments, each performed with 
6 replicates, and the mean ± SEM for one representing experiment is shown for each cell line (B), *p < 0.05.  
 
B 
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Interestingly, SiHa cells which has been reported as a CDDP-resistant cervical carcinoma showed a 
CDDP IC50 that is approximately 1.5-2 fold higher compared to HeLa, CaSki and C33A
414, 415. As SiHa 
cells showed significantly increased sensitivity to CDDP after INI-43 pre-treatment, this suggests that 
the combined use of these two agents could be an effective approach in treating CDDP-resistant 
cervical cancer cells.  
 
To confirm the IC50 results, cell viability was examined in response to CDDP with or without INI-43 
pre-treatment. Cells were pre-treated with DMSO or 5 µM INI-43 for 2 hours prior to CDDP 
treatment at their respective CDDP IC50 values, and viable cells were quantified using the MTT assay. 
The results showed that in HeLa, CaSki and SiHa cells, 5 µM INI-43 pre-treatment enhanced the cell 
killing effect of CDDP, whereby cell viability was significantly lower in the INI-43 pre-treated cells 
compared to the control cells (Fig. 4.2, A-C). Treatment with 5 µM INI-43 alone had negligible effects 
on cell viability (Fig. 4.2). The most significant effects were observed in HeLa and SiHa cells, with 67% 
and 50% reductions in cell viability in the combination treatment, respectively (Fig. 4.2.A and C). 
CaSki cells showed enhanced CDDP effect, but to a lesser degree, with a 28% decrease in cell viability 
for combination treatment compared to single treatment (Fig. 4.2.B). In line with the IC50 results, 
C33A cells showed no further reduction in cell viability when subjected to combination treatment 
(Fig. 4.2.D).  
 
4.2.1.2. INI-43 pre-treatment enhanced CDDP-induced apoptosis in HeLa and SiHa cells 
To determine whether the decreased cell viability observed in the combination treatment was a 
result of increased apoptosis, caspase-3/7 activity and PARP cleavage were examined. Various 
signals can trigger an apoptotic response, which leads to a series of well-coordinated events 
culminating in caspase-3/7 activation, leading to cleavage of various substrates including PARP416.  
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Caspase-3/7 activation and PARP cleavage thus serve as good indicators of apoptosis. SiHa cells were 
subjected to single or combination treatment as previously described for 48 hours, and the cell 
lysates were harvested for caspase-3/7 assays and western blots. Results showed that CDDP-induced 
caspase-3/7 activity was significantly augmented by INI-43 pre-treatment, with more than two-fold 
increase observed after 30 µM and 60 µM CDDP treatment (Fig. 4.3.A). In line with this, enhanced 
PARP cleavage was observed for cells receiving the INI-43 pre-treatment, compared to those which 
received CDDP only (Fig. 4.3.B). Similar results were observed in HeLa cells, where INI-43 pre-treated 
cells showed enhanced PARP cleavage compared to their single treatment counterparts (Fig. 4.3.B). 
These results were densitometrically quantified and showed elevated PARP cleavage in response to 
INI-43 and CDDP combination treatments (Fig. 4.3.C).  
 
Figure 4.2. The effect of single and combination treatment of cervical cancer cell viability. Cervical cancer cell 
lines HeLa, CaSki, SiHa and C33A were seeded overnight, and cells were sequentially treated with 5 µM INI-43 or 
DMSO followed by CDDP as previously described. Viable cells were determined 48 hours after CDDP treatment, 
and expressed as a normalized value to the viability of untreated cells. Results shown are mean ± SEM of 6 
replicates, and each experiment was repeated at least twice, *p < 0.05.  
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These results showed that a combination treatment where pre-exposure to INI-43 in cervical cancer 
cells resulted in significant enhancement of CDDP-induced cell death. This was observed in CDDP-
Figure 4.3. The effect of single and combination treatment on apoptosis in SiHa and HeLa cells. To determine if 
the enhanced effect of CDDP on cell viability observed in INI-43 pre-treated cells was due to increased apoptosis, 
caspase-3/7 activity and PARP cleavage were examined. The caspase-3/7 activity in SiHa cells subjected to single 
and combination treatment were examined using the Caspase-GloR 3/7 assay, and expressed as a normalized 
value to viable cells as determined by MTT assay performed in parallel (A). SiHa and HeLa cells were subjected to 
single and combination treatment at various CDDP concentrations for 48 hours, and PARP cleavage was analyzed 
by western blot, GAPDH was included for loading control (B). Densitometrical analysis of cleaved PARP relative to 
total PARP, normalized to GAPDH (C). Results shown are mean ± SEM of triplicates (A), and each experiment was 
repeated at least two independent times (A and B), *p < 0.05. 
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sensitive cell lines HeLa and CaSki, as well as the reported CDDP-resistant cell line SiHa. The 
concentration of CDDP needed to achieve a 50% of killing was significantly lowered, as indicated by 
the decrease in CDDP IC50. The increased apoptotic activity shown by increased caspase-3/7 activity 
and PARP cleavage accounted for the decreased cell viability observed in combination treatment 
compared to single treatment.  
 
4.2.2. Kpnβ1 inhibition sensitized SiHa cells to CDDP 
To confirm that the enhanced cell death observed in the combination treatment was a result specific 
to Kpnβ1 inhibition, we investigated whether Kpnβ1 knock-down cells could similarly increase CDDP 
sensitivity. Control and Kpnβ1 siRNA transfected SiHa cells were subjected to CDDP IC50 
determination, cell viability assay and PARP cleavage analysis. 
 
Successful Kpnβ1 knock-down was confirmed using western blot 48 hours after transfection, at 
which time point CDDP treatment began (Fig. 4.4.A). The IC50 determination revealed that in Kpnβ1 
knock-down cells, there was a reduction in CDDP IC50 compared to the control cells (19.3 µM versus 
30.5 µM, Fig. 4.4.B), suggesting increased CDDP sensitivity in Kpnβ1 knock-down cells. Investigation 
of cell viability showed that Kpnβ1 knock-down cells were significantly less viable compared to 
control cells even without CDDP treatment (data not shown). To eliminate the cell death that was 
caused by si-Kpnβ1 transfection, viable cells at each CDDP concentration was normalized to the 
untreated cells in each transfection group. The results showed a significant decrease in cell viability 
in the Kpnβ1 knock-down cells at all CDDP concentrations tested compared to the control cells (Fig. 
4.4.C). To investigate whether the decreased cell viability associated with increased apoptosis, PARP 
cleavage was examined via western blot. The result showed enhanced cleaved PARP in Kpnβ1 knock-
down cells treated with CDDP, which is particularly evident at 60 µM CDDP (Fig. 4.4.D). 
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Densitometrical quantification of cleaved PARP relative to total PARP confirmed this result (Fig. 
4.4.E). These results showed that Kpnβ1 knock-down similarly sensitized SiHa cells to CDDP as 
observed with INI-43 pre-treatment, providing supporting evidence that INI-43 enhanced CDDP 
treatment by interfering with Kpnβ1 associated functions. 
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Figure 4.4. The effect of Kpnβ1 knock-down on CDDP sensitivity in SiHa cells. Cells were transfected with 20 nM 
of control or Kpnβ1 targeting siRNA (si-ctrl and si-Kpnβ1), and knock-down was confirmed 48 hours post 
transfection (A). CDDP IC50 was determined in si-ctrl and si-Kpnβ1 transfected cells (B), and cell viability at 1 x, 1.5 
x and 2 x CDDP IC50 treatment were analyzed by MTT assay, and expressed as a normalized value to the viability of 
untreated cells in each transfection group (C). PARP cleavage was examined in si-ctrl and si-Kpnβ1 transfected 
cells treated with CDDP for 48 hours, with GAPDH as the loading control (D), and densitometrical quantification 
are shown for cleaved PARP relative to total PARP, normalized to GAPDH (E). Results shown are mean ± SEM of 6 
replicates (B and C), and each experiment was repeated at least two independent times (B, C and D), *p < 0.05.  
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4.2.3. INI-43 and CDDP synergistically enhanced cell death in SiHa cells 
Combination treatments can lead to various outcomes, which can generally be categorized into 
antagonism, additivity or synergism. Antagonism describes an interaction where two agents cancel 
the effects of each other, producing a combined effect less than the sum of effects produced by each 
individual agent when used individually. An additive effect refers to two agents producing an effect 
which is equivalent to the sum of effects of each when used individually. Synergism depicts a 
combination treatment outcome which is greater than the sum of the effects of each individual 
agent used independently, which is primarily what combination treatment is aiming to achieve. 
 
Various methods have been proposed to model antagonism, additivity and synergism, of which the 
Chou-Talalay method has been the most widely used. This method is based on the median effect 
equation, where the combination index value (CI) defines the interaction of two drugs417. The CI is 
calculated using the equation CI = 
CDx.A
IDx.A
+
CDx.B
IDx.B
, where IDx.A and IDx.B represents the concentration of 
each drug (A and B) needed to achieve a certain effect when used alone, and CDx.A and CDx.B refers 
to the dose of A and B in combination required to produce the same effect. A CI value of less than 
one, equal to one and greater than one suggest synergistic, additive and antagonistic interactions of 
the two drugs, respectively418. 
 
In order to determine the nature of the interaction for INI-43 and CDDP, CI values were calculated 
using dose-response curves, where SiHa cells were treated with INI-43 and CDDP singly and in 
combination, after which cell viability was determined. A range of concentrations for both drugs 
were used, and paired in such a way that the ratio between the two drugs remain fixed in each 
experiment. As the IC50 for INI-43 and CDDP is approximately 10 µM and 30 µM for SiHa cells, 
respectively, we tested INI-43:CDDP ratios of 1:3, 1:4 and 1:5 (for detail of concentrations used, see 
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Appendix Table A.1). Combination treatments were performed in the same way as previously 
described, where cells were exposed to INI-43 for 2 hours prior to CDDP treatment, and cell viability 
was quantified via MTT reagent 48 hours after CDDP treatment. The results showed evident 
enhancement of cell death in INI-43 pre-treated cells at 22.5 µM and higher CDDP concentrations for 
the 1:3 ratio, and 30 µM and higher CDDP concentrations for 1:4 and 1:5 ratios (Fig. 4.5.A, see 
arrow). For both 1:4 and 1:5 ratios, CDDP cytotoxicity was particularly amplified especially at higher 
concentrations of CDDP, as INI-43 alone at those concentration caused no cell death, but in 
combination it was able to augment CDDP-induced cell death.  
 
Based on the viability result, CI values were then calculated for each combination ratio using the 
CompuSyn software (ComboSyn, Inc., Paramus, NJ). The synergistic interaction of the two drugs, 
which is indicated by CI values of less than one, was apparent when the fraction affected (x-axis, 
fraction affected of 1 = complete cell death) was greater than a threshold value indicated by X (Fig. 
4.5.B). These results confirmed that INI-43 synergized with CDDP in SiHa cells at CDDP 
concentrations greater than 22.5 µM.  
 
4.2.4. CDDP treatment does not alter Kpnβ1 expression and nuclear localization in HeLa 
and SiHa cells 
In the ovarian cancer model, we found CDDP treatment led to increased Kpnβ1 expression and 
nuclear accumulation, suggesting that Kpnβ1 is responsive to DNA damage stress in this model. To 
investigate whether this is similar in cervical cancer, we investigated Kpnβ1 expression and 
localization in response to CDDP treatment. 
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Figure 4.5. Combination index (CI) evaluation for the INI-43 and CDDP combination treatment in SiHa cells. Cells 
were subjected to INI-43 only, CDDP only and INI-43 plus CDDP combined treatments at INI-43:CDDP ratios of 1:3, 
1:4 and 1:5 (see Appendix Table A.1 for drug concentrations used). Cell viability was assayed after 48 hours of 
drug treatment, and expressed as a normalized value to the untreated (A, arrows indicate enhanced cell death). 
The calculated CI values were plotted for each INI-43:CDDP ratio examined against the fraction affected, where 
fraction affected of 1 = 100% cell death (B). Results shown are mean ± SEM of 5 replicates of 1 experiment which 
was repeated two independent times. 
 
A 
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HeLa and SiHa cells were treated with CDDP at their respective IC50 values for 24 hours, and proteins 
were harvested for western blot analysis using a Kpnβ1 specific antibody. To confirm that CDDP 
treatment was effective, γH2AX levels were examined alongside as a confirmation for CDDP-induced 
DNA damage. The results showed that while increased γH2AX was observed in both cell lines, Kpnβ1 
expression remained unaltered (Fig. 4.6). We then examined Kpnβ1 localization in CDDP-treated 
HeLa and SiHa cells, using concentrations around their respective IC50 values. Nuclear and 
cytoplasmic proteins were harvested separately, and nuclear Kpnβ1 levels was analyzed by western 
blot. Our results revealed similar Kpnβ1 levels in the nucleus for both HeLa and SiHa cells after CDDP 
treatment (Fig.4.7.A). This result was independently confirmed by immunostaining and fluorescence 
microscopy, which showed similar Kpnβ1 distribution between control and 30 µM CDDP treated SiHa 
cells (Fig. 4.7.B). 
 
 
 
 
 
 
 
  
Figure 4.6. Kpnβ1 expression in response to CDDP-induced DNA damage in cervical cancer cell lines. HeLa and 
SiHa cells were treated with CDDP at their respective CDDP IC50 values for 24 hours. Protein lysate were examined 
for changes in Kpnβ1 level, alongside γH2AX to confirm for DNA damage by western blot. GAPDH was included for 
loading control. Each experiment was repeated at least two independent times. 
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Figure 4.7. The effect of CDDP on Kpnβ1 nuclear localization in HeLa and SiHa cells. HeLa and SiHa cells were 
treated with a range of CDDP concentrations around their own respective CDDP IC50 values for 24 hours, followed 
by nuclear and cytoplasmic protein fractionation. Nuclear fractions were analyzed by western blot for Kpnβ1 
content, TBP and Histone H3 were detected for nuclear loading control, and β-tubulin and GAPDH were included 
to confirm that clean nuclear lysates were obtained in comparison to a cytoplasmic protein sample 'C' from each 
experiment (A). Kpnβ1 was stained with Alexa-647 conjugated secondary antibody in CDDP treated and fixed SiHa 
cells. Localization was analyzed by fluorescent microscopy, and images were captured. At least 6 different field of 
views were captured for each treatment, and one representative is shown (B). Nuclear fractionation experiment 
was repeated three independent times (A) and immunofluorescence analysis was performed two independent 
times (B). 
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Although CDDP has been used in anti-cancer therapy for both cervical and ovarian malignancies, our 
results suggest different Kpnβ1 responses to CDDP treatment in these two cancers. While the effects 
of CDDP on Kpnβ1 expression and localization were apparent in ovarian cancer cells, this was not 
observed in cervical cancer cells. However, we have shown earlier that Kpnβ1 knock-down in cervical 
cancer cells exhibited increased sensitivity to CDDP, confirming its involvement in CDDP-induced 
cellular response. As Kpnβ1 expression and localization was unaffected by CDDP in cervical cancer 
cells, this suggests that Kpnβ1 in CDDP-induced response occurs via other mechanisms. 
 
4.2.5. The role of p53 and p21 in the INI-43 and CDDP combination treatment 
Both p53 and p21 proteins are highly investigated factors in cancer, and their significance in cancer 
and response to chemotherapeutic agents have been repeatedly demonstrated. To elucidate 
whether, and how, these proteins may play a role in CDDP response, and furthermore, whether the 
enhanced CDDP effects in INI-43 pre-treated cells involve these two proteins, we examined the 
effects of p21 and p53 knock-down on cellular response to single and combination treatments. The 
knock-down was confirmed for both p21 and p53 48 hours post transfection, which is the time point 
when cells receive treatments in subsequent experiments (Fig. 4.8.A).  
 
4.2.5.1. p21 protects cells from CDDP-induced cell death while p53 does not affect CDDP-induced 
cell death in SiHa cells 
We first examined cell viability after CDDP treatment in p21 or p53 knock-down cells. We found that 
p21 knock-down cells showed increased sensitivity to CDDP treatment, indicated by the significant 
decrease in cell viability compared to the control cells after CDDP treatment (Fig. 4.8.B). p53 knock-
down, on the other hand, did not affect CDDP-induced reduction in cell viability (Fig. 4.8.C). To 
examine whether the decrease in cell viability was associated with apoptosis, we investigated PARP  
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Figure 4.8. CDDP sensitivity in p21 or p53 knock-down SiHa cells. SiHa cells were transfected with 30 nM of 
control siRNA (si-ctrl), p21 targeting siRNA (si-p21) or p53 targeting siRNA (si-p53) and knock-down was confirmed 
by western 48 hours post transfection, GAPDH was included for loading control (A). Cell viability in p21 knock-
down and p53 knock-down cells were examined after 48 hours of 30 µM and 60 µM CDDP treatment by MTT 
assay, and viable cells were normalized to the viability of untreated cells in each transfection group (B and C). 
CDDP-induced PARP cleavage was examined in p21 and p53 knock-down cells by western blot, with GAPDH as the 
loading control (D). Results shown are mean ± SEM of experiment conducted in triplicates (B and C) and repeated 
at least two independent times (B - D), *p < 0.05.  
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cleavage using western blot. This showed that after a 48 hour CDDP treatment, p21 knock-down 
cells exhibited increased levels of cleaved PARP compared to the control cells, whereas p53 showed 
similar levels of cleaved PARP to the control cells (Fig. 4.8.D). These results indicated that in CDDP-
treated SiHa cells, the decrease in cell viability observed in p21 knock-down cells was a result of 
increased apoptosis. Furthermore, it confirmed the cell viability result for p53 knock-down cells, as 
no increased PARP cleavage was observed compared to si-ctrl transfected cells. These data suggest 
that p21 exerts a protective effect against CDDP-induced cell death, but p53 appears to not have a 
role in response to CDDP as a single treatment. 
 
4.2.5.2. INI-43 induced enhancement in CDDP-cytotoxicity is dependent on p53 function 
Next, the role of p21 and p53 in the enhancement of cell death in combination treatment was 
investigated. The degree of reduction in cell viability as a result of combination treatment were 
compared to single treatment for each knock-down via MTT assays. Cells with p21 or p53 knock-
down, together with the control cells were treated with CDDP only or 5 µM INI-43 and CDDP for 48 
hours, and cell viability was monitored using the MTT reagent. To quantify the enhancement of cell 
death associated with the combination treatment, the results were normalized to viability of cells 
receiving the CDDP single treatment. As expected, significant reduction in cell viability was observed 
for the control cells receiving the combination treatment, compared to single treatment (Fig. 4.9.A). 
In p21 knock-down cells, the degree of reduction in cell viability observed in combination treatment 
was more prominent than the control cells (Fig. 4.9.A). In p53 knock-down cells, however, cell 
viability was similar between single and combination treatment (Fig. 4.9.A). Examination of PARP 
cleavage is in accordance with these results - while the control cells showed moderate increase in 
PARP cleavage in combination treatment compared to single treatment, the degree of increase in 
cleaved PARP was more substantial in p21 knock-down cells, and no difference in PARP cleavage was 
observed between single and combination treatment in p53 knock-down cells (Fig. 4.9.B). 
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Densitometrical quantification of cleaved PARP relative to total PARP for single and combination 
treatments at 60 µM CDDP confirmed these interpretation (Fig. 4.9.C). 
 
 
  
Figure 4.9. The effect of p21 and p53 knock-down on INI-43 enhanced CDDP sensitivity in SiHa cells. p21 and 
p53 knock-down SiHa cells were subjected to single CDDP or combined INI-43 plus CDDP treatment for 48 hours, 
followed by cell viability determination (A) and PARP cleavage evaluation (B and C). Cell viability was determined 
using the MTT assay, and to compare the degree of increase in cell death as a result of the combination 
treatment, viability was normalized to the cells receiving single CDDP treatment (A). PARP cleavage was 
investigated via western blot as an indication of apoptosis, with GAPDH as loading control (B). Densitometrical 
quantification of cleaved PARP relative to total PARP and normalized to GAPDH for the 60 µM CDDP treated cells 
(C). Results shown are mean ± SEM of experiments performed in triplicates (A), and repeated at least two 
independent times (A and B), *p < 0.05. 
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These results show that in p21 depleted cells, single CDDP treatment led to increased apoptosis 
compared to control cells. Furthermore, the degree of increase in cell death between single and 
combination treatment was more pronounced in p21 knock-down cells compared to control cells. 
These suggest a protective role for p21 in both single and combination treatment-induced cell death, 
as its inhibition resulted in increased cell death for both treatments. On the other hand, p53 appears 
not to have a role in the single CDDP induced cell death, as its inhibition resulted in similar CDDP 
sensitivity to the control cells. However, the combination treatment result suggests that p53 
function is required for the enhanced CDDP cytotoxicity when cells are pre-treated with INI-43, as in 
p53 knock-down cells, the combination treatment no longer showed greater killing effects. 
 
4.2.5.3. INI-43 pre-treatment stabilized p53 via Kpnβ1 inhibition 
We next questioned the mechanism of action of INI-43, which enabled p53 to become a 
requirement for CDDP-induced apoptosis. We considered the possibility that INI-43 pre-treatment 
stabilized p53 protein, thereby allowing p53 to induce downstream pathways when subsequently 
exposed to CDDP. 
 
To test this, we examined the levels of p53 in cycloheximide (CHX) treated cells. CHX is an inhibitor 
of protein synthesis, therefore the changes in p53 levels after CHX treatment directly reflect the rate 
of degradation. Cells were either treated with DMSO (control) or 5 µM INI-43 for 2 hours, consistent 
with the time and concentration used in the combination treatment prior to CDDP exposure. 
Proteins were harvested at various time points following CHX treatment, and p53 levels were 
measured. Western blot analysis showed an increase in p53 stability in INI-43 treated cells, which 
was indicated by the prolonged presence of p53 (Fig. 4.10.A). Densitometrical scanning of p53 levels 
relative to GAPDH were then used to calculate the half-life of p53, which showed a 3.4-fold increase 
from 7 minutes to 24 minutes (Fig. 4.10.B). To confirm that p53 stabilization by INI-43 treatment is  
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associated with Kpnβ1 inhibition, we examined p53 levels in Kpnβ1 knock-down cells after 
treatment with CHX. Similar to the INI-43 treated cells, Kpnβ1 knock-down cells sustained p53 for 
longer periods after CHX treatment, with a half-life of 68 minutes compared to the 24 minutes in the 
control cells. This represented a 2.8-fold increase in the calculated half-life in Kpnβ1 knock-down 
cells (Fig. 4.10.C and D). Although the absolute values for p53 half-life in the control cells differed in 
the two experiments, this is likely an experimental variation. In both experiments, however, 
approximately 3-fold increase in the half-life of p53 were observed when compared to their 
respective controls (Fig. 4.10.E), suggesting that INI-43 pre-treatment in SiHa cells stabilized p53, and 
that this stabilization is associated with Kpnβ1 inhibition. 
 
Figure 4.10. The effect of INI-43 treatment and Kpnβ1 inhibition on p53 stability. The half-life of p53 was 
examined in INI-43 treated (A and B) and Kpnβ1 knock-down cells (C and D). Cells were incubated with DMSO or 5 
µM INI-43 for two hours (A); or transfected with 20 nM si-ctrl or si-Kpnβ1 for 48 hours (C), followed by treatment 
with 50 µg/mL cycloheximide (CHX). Proteins were harvested from each treatment at the indicated time points 
after CHX treatment, and analyzed for p53 content by western blot, with GAPDH as the loading control (A and C). 
Quantitative analysis of p53 protein was carried out by densitometrical scanning, and band intensities were 
plotted in log scale relative to p53 at time = 0 min for INI-43 treated (B) and Kpnβ1 knock-down cells (D). p53 
protein half-life was determined using the equation (Log2)/[slope]. Results shown are representative of 
experiments performed at least twice. The fold increase in p53 stability is shown for the representative 
experiment  in both INI-43 treated and si-Kpnβ1 transfected cells, normalized to their respective controls (E). 
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So far, our results suggest differing roles for p53 and p21 in the CDDP-response pathway in cervical 
cancer cells. While p53 appears not to be involved in CDDP single treatment induced apoptosis, p21 
was found to counteract this process. Furthermore, the enhancement of CDDP cytotoxicity by INI-43 
was opposed by p21, but promoted by p53. 
 
We next investigated whether INI-43 enhanced CDDP cytotoxicity via elevating p53 or repressing 
p21 levels. SiHa cells were subjected to single or combination treatment as previously described for 
24 hours, and p53 and p21 levels were determined via western blotting. The result showed that in 
cells treated with single CDDP, a decrease in p21 level and increase in p53 level were observed (Fig. 
4.11.A). Surprisingly, in cells treated with both INI-43 and CDDP, we observed elevated levels of p21 
compared to cells receiving CDDP only, suggesting that the enhanced CDDP cytotoxicity in the 
combination treatment was not mediated through repression of p21 (Fig. 4.11.A). On the other hand, 
p53 levels were similar between single and combination treated cells. This suggest that the 
transcription or translation of p53 is likely repressed in the combination treated cells to maintain 
constant p53 levels as the rate of p53 degradation is slowed. 
 
To investigate whether the stabilization of p53 represented increased p53 activity even though 
global increase in p53 levels was not observed, we examined the expression of Mcl-1 in single and 
combination treated cells, as Mcl-1 is transcriptionally repressed by p53419. Western blot analysis 
showed that at 30 µM and 60 µM CDDP concentrations, lower Mcl-1 levels were observed in INI-43 
pre-treated cells compared to non-pre-treated cells (Fig. 4.11.B). These result suggest that INI-43 
pre-treatment enhanced CDDP sensitivity in SiHa cells via stabilizing p53, which associated with the 
repression of the pro-survival factor Mcl-1 known to be negatively regulated by p53. 
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Figure 4.11. Expression of p53, p21, and the p53-downstream target Mcl-1 in response to single CDDP and 
combined INI-43 plus CDDP treatments. SiHa cells were subjected to single or combination treatment as 
previously described for 24 hours. Proteins were harvested and analyzed with western blot for p53 and p21 
expression, with β-tubulin as the loading control (A). Mcl-1 expression was measured via western blot for single 
and combination treatment, with GAPDH as the loading control (B). Densitometrical quantification was conducted 
and expressed as protein of interest relative to their respective loading controls, and normalized to the untreated 
samples for both experiments. Results shown are representatives of experiments performed two independent 
times. 
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4.2.6. The effect of single CDDP treatment and INI-43 plus CDDP combination treatment 
on Nuclear Factor Kappa B (NFκB) 
NFκB is a transcription factor best known for its role in the pro-inflammatory signalling pathway. In 
response to environmental stimuli, it relocates into the nucleus where it activates the transcription 
of various genes. It is generally considered a pro-survival factor420, and has been shown to contribute 
to CDDP-resistance in many cancers421, 422. NFκB has been reported to enter the nucleus in a 
Kpnβ1/Karyopherinα-dependent manner169, 270, 423, and we have previously found INI-43 to inhibit 
NFκB nuclear import333. As NFκB is an oncogenic factor known to mediate CDDP resistance, and that 
its nuclear entry is reliant on Kpnβ1, we investigated the effect of combination INI-43 and CDDP 
treatment on NFκB. 
 
4.2.6.1. CDDP induced nuclear localization of p50 and p65, which is repressed by INI-43 pre-
treatment 
To investigate the activity of NFκB, we examined the localization of two subunits, p50 and p65, after 
cells were treated with CDDP or INI-43 plus CDDP as previously described. Immunofluorescence and 
fluorescent microscopy analysis showed that in the untreated cells, p50 stained with similar 
intensities in the nucleus and cytoplasm, indicating an even distribution between the two cellular 
compartments. In cells subjected to 30 µM CDDP treatment, p50 localization became more nuclear 
compared to untreated cells, and in cells receiving pre-treatment with 5 µM INI-43 followed by CDDP, 
p50 exhibited predominantly cytoplasmic distribution (Fig. 4.12.A). p50 fluorescence intensities were 
measured and expressed as nuclear fluorescence relative to cytoplasmic fluorescence (p50 
Fc(Nu/Cy)), which showed a significant increase in single CDDP treated cells compared to untreated 
cells, and a significant decrease in combination treated cells compared to single treated cells (Fig. 
4.12.B). Analysis of p65 localization showed a strong cytoplasmic localization in the untreated cells, 
and treatment with CDDP increased p65 nuclear accumulation, resulting in some cells showing 
nuclear p65 distribution and some cells showing even distribution. Pre-treatment with INI-43 
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decreased the CDDP-induced nuclear accumulation of p65, leading to predominant cytoplasmic 
localization (Fig. 4.12.C and D).  
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Figure 4.12. Cellular localization of NFκB p50 and p65 in response to single and combination treatment. SiHa 
cells were subjected to single or combination treatment for 24 hours, followed by fixation. NFκB-p50 (A) and 
NFκB-p65 (C) localization were then analyzed using immunofluorescence and fluorescent microscopy. A 
representing field of view is shown for each treatment. Fluorescence intensities were quantified using ImageJ and 
expressed as nuclear fluorescence relative to cytoplasmic fluorescence (Fc(Nu/Cy)) for p50 (B) and p65 (D). 
Results shown are mean ± SEM of 6 cells, *p < 0.05 (B and D).  
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These findings were independently confirmed using protein fractionation and western blot analysis, 
which showed similar results. There was an increase of nuclear p50 and p65 when cells were 
subjected to CDDP-only treatment, however, if the cells had received INI-43 prior to CDDP treatment, 
a reduction in CDDP-induced nuclear localization of p50 and p65 were observed, compared to those 
receiving CDDP only (Fig. 4.13). Nuclear p65 however, did not return to basal levels in the INI-43 pre-
treated cells, as higher levels were still observed in the nuclear fraction after the combination 
treatment compared to the untreated cells. This is possibly due to alternative importing activities by 
other members of the Karyopherin family169. 
 
  
Figure 4.13. Nuclear p50 and p65 levels in SiHa cells treated with single CDDP or combination of INI-43 plus 
CDDP. SiHa cells were subjected to single and combination treatment as previously described for 24 hours, 
followed by nuclear protein extraction. Nuclear protein samples were analyzed for p50 and p65 levels, and TBP 
was used as the nuclear loading control. β-tubulin was included to confirm that clean nuclear lysates were 
obtained in comparison to a cytoplasmic protein sample 'C'. The experiment was repeated three independent 
times.  
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 4.2.6.2. INI-43 pre-treatment decreased the levels of CDDP-induced NFκB target gene expression  
To investigate whether the altered localization of p50 and p65 translated into functional significance, 
we examined the expression of three downstream targets of NFκB, namely cyclinD1, c-Myc, and X-
chromosome linked inhibitor of apoptosis (XIAP), which are all known to be involved in CDDP-
induced response424-428. Western blot analysis revealed that, with the exception in XIAP, single CDDP 
treatment led to increased levels of both cyclinD1 and c-Myc (Fig. 4.14.A). Furthermore, the levels of 
cyclinD1, c-Myc and XIAP were all repressed in a concentration dependent manner in combination 
treated cells, compared to CDDP only treated cells (Fig. 4.14.A). As both cyclinD1 and c-Myc have 
been reported to confer chemoresistance by increasing the cell's DNA repair capacity429, 430, we 
examined whether their decreased expression in INI-43 pre-treated cells had an impact on CDDP-
induced DNA damage. The level of γH2AX after 24 hours treatment with CDDP or INI-43 plus CDDP 
were measured using western blot, and the result showed increased γH2AX levels in the cells 
receiving combination treatment compared to single treatment (Fig. 4.14.B), suggesting increased 
DNA damage in these cells. 
 
Taken together, these results suggest that in response to CDDP-induced DNA damage, NFκB 
relocates into the nucleus where it increased expression of target genes such as cyclinD1 and c-Myc. 
Pre-treatment of cells with INI-43 attenuated NFκB response by repressing its nuclear entry, as well 
as repressing p50 expression. This could consequently lead to decreased levels of cyclinD1 and c-
Myc, and possibly XIAP resulting in enhanced DNA damage and apoptosis.  
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Figure 4.14. Expression of NFκB target genes cyclin D1, c-Myc and XIAP; as well as DNA damage marker γH2AX 
in SiHa cells subjected to single and combination treatment. SiHa cells were treated with CDDP only or a 
combination of INI-43 plus CDDP for 24 hours, followed by western blot analysis to determine levels of cyclinD1, 
c-Myc and XIAP (A). To examine the impact of decreased cyclinD1 and c-Myc expression on DNA damage, γH2AX 
expression was determined via western blot (B). β-tubulin was included for loading control. Results shown are 
representative  of two independent experiments. 
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4.2.7. Kpnβ1 over-expression sensitized HeLa cells to CDDP 
So far we have shown that Kpnβ1 inhibition via siRNA or INI-43 restored CDDP sensitivity in SiHa cells, 
with alterations in various molecular pathways involved in survival and apoptosis. These results 
suggest that the function of Kpnβ1 is important in CDDP-induced cellular response and may 
contribute to CDDP resistance. This led us to question whether increasing the expression of Kpnβ1 
(and thereby its function) could increase the cells' tolerance to CDDP. To investigate this, we used 
the CDDP-sensitive and Kpnβ1 over-expressing cell line, HeLa-pEFIRES-Kpnβ1-GFP and the control 
cell line HeLa-pEFIRES-GFP, of which the former was previously shown to express approximately 
twice as much Kpnβ1 as the control GFP expressing cells (see Fig. 2.9 in Chapter 2). 
 
4.2.7.1. Kpnβ1 over-expressing cells exhibited increased sensitivity to CDDP 
CDDP sensitivity in the Kpnβ1-overpressing and control cells were first assessed by examining CDDP 
IC50, which was 12.0 µM in Kpnβ1 over-expressing cells compared to 19.8 µM in the control cells (Fig. 
4.15.A and B), suggesting increased CDDP sensitivity in Kpnβ1 over-expressing cells. Examination of 
cell viability confirmed these results, whereby significant decrease in cell viability was observed in 
Kpnβ1 over-expressing cells compared to control cells at all concentrations of CDDP (Fig. 4.15.C).  
 
To determine whether the increased sensitivity to CDDP treatment in the Kpnβ1 over-expressing 
cells was associated with increased apoptosis, we investigated PARP cleavage in both cell lines after 
CDDP treatment via western blotting. The result showed enhanced PARP cleavage in Kpnβ1 over-
expressing cells compared to the control cells when treated with the same concentration CDDP (Fig. 
4.15.D), which was confirmed by densitometrical quantification (Fig. 4.15.E). This suggest that the 
enhanced decrease in cell viability of Kpnβ1 over-expressing cells observed after CDDP treatment 
associated with increased apoptosis.  
148 
 
 
 
 
 
 
 
A B 
C 
D
\
D 
E 
149 
 
 
 
 
 
 
 
 
 
4.2.7.2. Effect of CDDP on p53, p21, Mcl-1 and γH2AX in Kpnβ1 over-expressing cells 
Having shown earlier that inhibition of Kpnβ1 in combination with CDDP treatment led to alterations 
in p53, p21, Mcl-1 and γH2AX, we next explored effects of CDDP treatment on these proteins in 
Kpnβ1 over-expressing cells. Examination of p53, p21 and Mcl-1 showed that CDDP treatment led to 
similar trends of expression in these proteins in both cell lines, with increased p53 levels and 
decreased p21 and Mcl-1 levels in a concentration-dependent manner. The changes were, however, 
more prominent in Kpnβ1 over-expressing cells compared to the control cells (Fig. 4.16). 
Furthermore, Kpnβ1 over-expressing cells showed higher p53 levels and lower p21 and Mcl-1 levels 
without CDDP treatment, suggesting that Kpnβ1 over-expressing cells are more sensitive to 
apoptotic signals. As Kpnβ1 over expression has been reported to cause mitotic abnormalities and 
induce genomic instability, we investigated DNA damage marker γH2AX after CDDP treatment in 
comparison to the control cells. Western blot analysis showed enhanced γH2AX elevation in Kpnβ1 
over-expressing cells compared to the control cells, indicative of enhanced DNA damage in these 
cells.  
 
These results indicate that over-expression of Kpnβ1 enhanced CDDP sensitivity by enhancing DNA 
damage effects; as well as amplifying the effects of apoptotic factor p53 and suppressing anti-
apoptotic factors p21 and Mcl-1. This was a surprising finding, as inhibition of Kpnβ1 increased the 
sensitivity of cervical cancer cells to CDDP treatment, we postulated that over-expression might have 
Figure 4.15. CDDP sensitivity in Kpnβ1-over expressing cells. CDDP IC50 was determined for HeLa-pEFIRES-GFP 
(GFP) and HeLa-pEFIRES-Kpnβ1-GFP (Kpnβ1-GFP) cells (A). Results shown are the mean ± SEM of 4 independent 
experiments. A representing IC50 determination plot is shown (B), results are mean ± SEM of 6 replicates. Cell 
viability for the control and Kpnβ1 over-expressing cells were analyzed after 48-hour CDDP treatment via MTT 
assay, and results were normalized to viability of the untreated cells (C). Results shown are mean ± SEM of 6 
replicates, and the experiment was repeated 4 independent times, *p < 0.05. PARP-cleavage was analyzed as an 
indication of apoptosis in both cell lines after 48-hour CDDP treatment, GAPDH was included as the loading 
control (D). The results were quantified densitometrically (E), and the experiment was repeated two independent 
times. 
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a rescue effect. Our data, however, show that Kpnβ1 over-expression sensitized cancer cells to CDDP 
similarly to that observed in Kpnβ1 inhibited cells, suggesting interfering with Kpnβ1 expression in 
both directions disadvantaged cervical cancer cells to CDDP treatment. 
 
 
  
Figure 4.16. Levels of p53, p21, Mcl-1 and γH2AX in control and Kpnβ1 over-expressing cells after CDDP 
treatment. HeLa cells over-expressing Kpnβ1-GFP or GFP were treated with CDDP for 24 hours followed by 
western blot analysis to determine levels of γH2AX, p53, p21 and Mcl-1. GAPDH was included as loading control, 
and the experiment was repeated two independent times. 
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4.3. Discussion 
In this chapter we report that sub-lethal concentrations of INI-43 effectively enhanced CDDP-
induced apoptosis, as shown by decreased cell viability and increased apoptosis. These findings were 
observed in both CDDP-sensitive (HeLa) and CDDP-resistant (SiHa) cell lines. Kpnβ1 knock-down 
experiments showed similar results to that of INI-43 pre-treated cells, whereby CDDP sensitivity was 
significantly enhanced. This suggest that INI-43 acts in a manner similar to Kpnβ1 knock-down. We 
concluded that Kpnβ1 functions in the pro-survival pathway, and speculated that its over-expression 
can possibly increase CDDP resistance. To our surprise, Kpnβ1 over-expressing HeLa cells showed no 
survival advantage in comparison to the control GFP-expressing cells, but instead were more prone 
to CDDP-induced apoptosis. Although unexpected, this result could possibly explain why HeLa cells 
did not elevate Kpnβ1 levels in response to CDDP, since this proved to confer no advantage for cell 
survival. Whilst we have previously shown that Kpnβ1 inhibition genetically or pharmacologically 
induced cervical cancer cell death128, 333, others have reported that exogenously expressed Kpnβ1 
induced mitotic abnormalities, resulting in genomic instability282, 286. This could provide an 
explanation as to why Kpnβ1 over-expressing cells exhibited increased CDDP sensitivity. It is likely 
that cancer cells require a fine balance in Kpnβ1 expression, and that artificial perturbation of this 
fine balance in either directions could have deleterious effects on cell survival.  
 
To understand the mechanism of action underlying the increased CDDP sensitivity observed in the 
combination treated cells, we investigated various proteins that are known to be involved in CDDP 
response; including p21, p53 and NFκB. The roles of p21 and p53 in CDDP-induced apoptosis were 
elucidated using knock-down experiments, and CDDP-induced alterations in NFκB localization was 
evaluated.  
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Evaluating the roles for p53 and p21 is challenging, as these proteins have been reported to support 
both pro- and anti-apoptotic effects of these cell cycle regulators. The role of p21 as a pro-apoptotic 
factor has been reported by various groups, including Chen et al., who have demonstrated that the 
upregulation of p21 enhanced apoptosis in ovarian cancer cells subjected to combination treatment 
incorporating CDDP431. Stordal and Davey showed decreased p21 promoted small cell lung cancer 
survival when challenged with DNA damage432, and Taguchi et al. reported increased p21 expression 
in correlation with CDDP sensitivity in head and neck squamous cell carcinoma433. On the other hand, 
there are also substantial evidence suggesting that p21 can oppose apoptosis, conferring drug 
resistance. For instance, He et al. reported increased p21 in association with CDDP resistance in 
oesophageal squamous carcinoma through kinase-7434, and other downstream kinases which are 
positively regulated by p21, including both PAK1 and PAK4, which have also been shown to increase 
cancerous phenotypes and CDDP resistance435, 436. p53, on the other hand, has been widely accepted 
as a tumour suppressor protein important for guarding the genome and regulating apoptosis. 
However, evidence are emerging to demonstrate that p53 can also promote oncogenesis in various 
cases437-439. These findings are suggestive that both p21 and p53 are involved in CDDP resistance and 
CDDP-induced apoptosis, yet their roles in the apoptotic pathway may not be absolute, and varies in 
each case. 
 
To determine the role of p21 in our model system, we inhibited p21 expression via siRNA and 
examined cellular response to CDDP single treatment and INI-43 plus CDDP combination treatment. 
Our results suggest that p21 exhibited a protective role against cell death induced by both single and 
combination treatments. Interestingly, we found p21 levels to be elevated in the combination 
treatment compared to the single treatment, which seemingly contradicts the increased apoptosis 
observed in the combination treatment. We proposed the possibility that the combination 
treatment caused molecular alterations in numerous pathways, including both pro- and anti-survival. 
However, as the net outcome was greater killing effect, the activation of apoptotic pathways is likely 
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more potent than anti-apoptotic pathways. This finding also proposes a potential for co-targeting 
both Kpnβ1 and p21 in combination with CDDP, which further enhanced apoptosis compared to 
Kpnβ1 inhibition and CDDP. 
 
The siRNA mediated p53 knock-down experiment demonstrated its pro-apoptotic role in our model 
system, but only in the combination treatment. We then showed that this was achieved through 
increased p53 stability by INI-43 pre-treatment or Kpnβ1 knock-down, which associated with 
increased responsiveness to CDDP treatment. SiHa is a HPV16 positive cell line harbouring the viral 
oncogenes E6440, which has been reported to directly associate with p53 and induce its 
degradation441. This results in the highly unstable p53, which is supported by our observation where 
p53 level is rapidly diminished after CHX treatment. Furthermore, stabilization of p53 has also been 
observed in HPV16 and HPV18 positive CaSki cells after transfection with si-Kpnβ1300, and 
interestingly, inhibition of CRM1 via KPT-185 or LMB has been shown to stabilize p53 in other cancer 
models346, 442. Together with our findings, these data suggest that interfering with the nuclear 
transport system in both directions may have stabilizing effect on p53. It is likely that under normal 
conditions in SiHa cells, p53 is rapidly degraded making the p53-associated apoptotic pathway less 
accessible to CDDP-induced DNA damage response. This is supported by our finding that p53 
inhibition did not alter CDDP sensitivity in SiHa cells. INI-43 pre-treatment stabilized p53, thereby 
making p53 activity available for apoptotic induction when cells were subsequently treated with 
CDDP. This could also explain why the combination treatment does not augment apoptosis in C33A 
cells, as C33A cells contain mutant p53 which is non-functional443.  
 
Although INI-43 pre-treatment moderately stabilized p53, we did not observe global increase in p53 
levels in the combination treatment compared to single treatment. This suggests that p53 levels are 
maintained in the cells even though it was stabilized after INI-43 pre-treatment. Previous work from 
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our laboratory, however, showed that lethal concentrations of INI-43 (≥10 µM), as well as siRNA-
mediated Kpnβ1 knock-down increased cellular p53 levels, suggesting that greater inhibition of 
Kpnβ1 does lead to increased global p53 levels**. This was however, not observed at the sub-lethal 
dose of INI-43 used in our experiments. We theorize that even though the overall p53 level was not 
increased by INI-43 at 5 µM, it is the enhanced stability of p53 that associated with increased 
apoptosis in combination treated cells. The increased p21 levels as well as decreased Mcl-1 levels in 
INI-43 treated cells may be supporting evidence of this, as p53 is known to positively regulate p21 
and repress Mcl-1419, 444. Furthermore, the elevated caspase-3/7 activities observed in the 
combination treatment could be associated with the decreased level of Mcl-1, as Mcl-1 is known to 
promote survival by inhibiting events preceding mitochondrial release of cytochrome C445. Whilst the 
link between Kpnβ1 inhibition and p53 stabilization is demonstrated in our results, further 
experiments should be carried out to determine how nuclear import inhibition leads to p53 
stabilization, and whether this is mediated through interfering with HPV E6 activity.  
 
NFκB is an important response factor to a variety of stress-signals, including CDDP induced DNA 
damage446. Under such conditions, NFκB is activated and relocates into the nucleus where it 
promotes the transcription of various genes involved in DNA repair and survival447. Its pro-survival 
and anti-apoptotic effects were first demonstrated by Wang et al., shedding light on NFκB as a 
contributor to chemoresistance448-450. Subsequently, various groups have reported similar findings 
where increased chemosensitivity was observed after NFκB inhibition (for details, see review by 
Nakanishi and Toi, 2005310, 451-453). As NFκB is reliant on Kpnβ1/Karyopherinα for nuclear entry, we 
addressed the possibility that the enhanced sensitivity to CDDP observed in Kpnβ1 inhibited cells 
may involve inhibiting NFκB nuclear entry and activities. Supporting this, we found that INI-43 
exhibited inhibitory effects on CDDP-induced nuclear import of NFκB, as well as the expression of its 
transcriptional targets cyclinD1, c-Myc and XIAP. Both c-Myc and XIAP are oncoproteins known to 
                                                          
**
Stowell, C. "Identification of Nuclear Import Inhibitors That Display Anti-cancer activity." University of Cape Town, 2011 
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promote cell survival and are frequently dysregulated in cancer. c-Myc confers chemoresistance via 
suppressing Bridging Integrator 1 (BIN1), an inhibitor of PARP-1 involved in DNA repair activity. c-
Myc thus allow increased tolerance to DNA damage, thereby conferring CDDP resistance429. XIAP 
promotes survival by directly binding to and inhibiting the activities of caspase-3, caspase-7 and 
possibly caspase-9454, 455. While cyclinD1 is best known for driving cell cycle from G1 to S phase456, 
more recent work by Jirawatnotai et al. have demonstrated that cyclinD1 is also involved in DNA 
damage repair in association with Rad51430, and that cyclinD1 inhibition impaired repairing capacity, 
leading to sensitization of cancer cells to CDDP457. Our results showed that INI-43 may indirectly 
repress the levels of these DNA-repair and anti-apoptotic proteins via decreasing NFκB nuclear 
import, and thus its transcriptional activity. We also found that at the same concentration of CDDP, 
cells pre-treated with INI-43 showed enhanced levels of γH2AX compared to non-pre-treated cells. 
This result could be explained in two ways; firstly, it could suggest that Kpnβ1 inhibition augmented 
the DNA-damaging capacity of CDDP, so that a fixed amount of CDDP is able to cause more harm in 
INI-43 pre-treated cells compared to control cells. Alternatively, we speculate that INI-43 pre-
treatment impaired DNA repair response (potentially through decreasing levels c-Myc and cyclinD1), 
and as a result, these cells require more time to repair DNA damage. The elevated levels of γH2AX as 
a result of DNA damage is thus sustained in these cells 24 hours after treatment, while the cells 
receiving CDDP only were able to execute the repair more rapidly, allowing levels of γH2AX to fall 
after 24 hours. In support of our finding, Olive and Banath have reported that cells which retained 
γH2AX 24 hours after CDDP treatment correlated with their failure to survive and form colonies in 
clonogenic assays458, and we similarly found that the enhanced cell death observed in the 
combination treatment correlated with higher γH2AX levels 24 hours after treatment. Interestingly, 
with opposing roles in apoptosis, NFκB and p53 have been shown to mutually antagonize the 
transcriptional activity of each other459, 460, suggesting that INI-43 pre-treatment may impair NFκB 
mediated survival pathways by preventing its nuclear entry, as well as through stabilizing p53. 
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Taken together, we have shown here that Kpnβ1 inhibition sensitized cervical cancer cells to CDDP 
treatment, and we propose that the combined use of INI-43 and CDDP may be an effective approach 
for anti-cancer treatment. This is mediated through stabilization of p53 and preventing NFκB nuclear 
localization, leading to alterations in various downstream targets such as XIAP, c-Myc, and Mcl-1. 
These proteins are known to confer CDDP resistance in a variety of cancers, and their inhibition 
through genetic or pharmacological approaches have been demonstrated to increase sensitivity to 
chemotherapeutic agents461-467. The abrogation of enhanced cell death in combination treated cells 
via p53 knock-down suggest that p53 is likely upstream of NFκB induced survival response. 
Interestingly, CRM1 inhibition via LMB has similarly been demonstrated to enhance CDDP sensitivity 
in p53-wildtype cervical cancer cells468, suggesting that p53 may play a crucial role in nuclear 
transport inhibition induced CDDP sensitivity. 
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CHAPTER 5 
CONCLUSION 
5.1. Main conclusions 
The nuclear transport machinery in eukaryotic cells serve vital functions important for normal 
cellular processes, and abnormalities in this system is linked to pathogenesis such as cancer. The 
active participant in this system, the Karyopherins have shown therapeutic potentials in recent 
studies with the majority of the investigations revolving around the Exportin CRM1. In this study, we 
addressed the feasibility of targeting nuclear import associated with Kpnβ1, via the use of a small 
molecule INI-43, and investigated two main areas: the anti-cancer effect of nuclear import inhibition 
using a cell culture and an in vivo model system; and the effect of nuclear import inhibition on CDDP 
sensitivity in cancer cells in culture. The former provides evidence for the potential of INI-43 as a 
single agent in cancer treatment, while the latter sets the ground work for its combined use with 
other chemotherapeutic agents in current practice. 
 
The anti-cancer effects of INI-43 were evident through a series of cell culture based assays. These 
included its negative impact on cancer cell viability, survival, and proliferative activities under 
different growth conditions. In particular, the ability of cancer cells to grow anchorage-
independently is an indication of anoikis resistance, which is associated with invasiveness and 
metastasis469. The ability of INI-43 to inhibit cancer growth of this nature is an indication that INI-43 
could be effective at treating tumours with invasive and migratory properties. Genetic manipulations 
to alter Kpnβ1 levels showed that while Kpnβ1 knock-down induced apoptotic events in cancer cells 
similar to that observed after INI-43 treatment, Kpnβ1 over-expression was able to partially reverse 
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this. The molecular events associated with INI-43 induced cell death were mitochondrial release of 
cytochrome C and PARP cleavage, indicating that cell death was mediated through the intrinsic 
mitochondrial pathway, which were similarly observed in Kpnβ1 knock-down cancer cells300. These 
findings further demonstrate that Kpnβ1 inhibition and INI-43 treatment triggered similar cellular 
events and phenotypes, supporting that INI-43 induced-cancer cell death is mediated through Kpnβ1.  
 
 
INI-43 appeared less toxic to non-cancer cells, with IC50 values 2-3 fold higher in non-cancer 
fibroblast cells compared to cancer cells. At concentrations between 10 µM and 15 µM, INI-43 
inhibited cancer cells by 100% whilst not affecting non-cancer cells. The selectivity of INI-43 may 
derive from the increased reliance of cancer cells on Kpnβ1 function296; which could be its nuclear 
import function in interphase cells and/or its mitotic involvement in dividing cells. As Kpnβ1 
inhibition with siRNA and INI-43 both induced apoptosis related to G2/M cell cycle arrest300, 333, it is 
likely that the apoptotic event is at least due partly to interference of the mitotic functions of Kpnβ1. 
Interestingly, the mechanism of cell death and selectivity of nuclear import inhibition is similarly 
observed in CRM1 inhibited cells, implying that altered nuclear transport in both directions caused 
similar deleterious effects on cancer cells238.  
 
Liver microsome and toxicology analyses of INI-43 revealed moderate stability and tolerability in 
athymic nude mice of up to 50 mg/kg, although 50 mg/kg may not be the maximum tolerated dose. 
The approved use of Ivermectin for treating parasitic infections, a compound with recently identified 
nuclear import inhibitory effects further demonstrates the systemic safety of nuclear import 
inhibitors. The promising data obtained from in vitro and toxicology studies prompted further 
experimentation in preclinical models, where the three dimensional development of tumours and 
interactions with its microenvironment is recapitulated. We showed that in the ectopic xenograft 
mouse model, intraperitoneally administered INI-43 hindered tumour growth, and the effects were 
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more pronounced in CaSki and WHCO6 cells. Both CaSki and KYSE30 tumours developed necrosis, a 
characteristic of aggressive tumours that strongly correlates to invasiveness353. INI-43 treatment in 
mice bearing those tumours showed reduced necrotic occurrence, suggesting that INI-43 may 
potentially be effective at treating aggressive epithelial neoplasm, although further experimental 
validation is needed. The selective anti-cancer effects of INI-43 in vitro and in vivo adds significance 
to its clinical potentials, yet further modification of its chemical structure may be necessary, as INI-
43 is a compound with low solubility, which may compromise its deliverance systemically. 
Nonetheless, our findings show that INI-43 could be a useful lead parent compound for future 
generations of Kpnβ1 inhibitors with cancer therapeutic purposes.  
 
As current anti-cancer treatment frequently employ the use of multiple chemotherapeutic agents, 
we examined the possibility of using INI-43 in combination with CDDP, a widely available first-line 
drug used in treating various cancers including small cell-lung cancer, ovarian cancer and cervical 
cancer. This compound was chosen for analysis in combination with INI-43 as it is a DNA-damaging 
agent, which meets the criteria where two agents used in combination should not have overlapping 
mechanisms of action. We hypothesized that nuclear trafficking of proteins is an important response 
under DNA damage conditions, and may play a role in drug resistance. Crippling this mechanism 
could therefore produce favourable outcomes in cancer cells less responsive to CDDP. Studies in the 
ovarian cancer model revealed elevated levels and altered localization of Kpnβ1 in response to CDDP 
treatment, suggesting that Kpnβ1 is responsive to DNA damage. Similar observations were made in 
HEK293 cells, where hydrogen-peroxide stress evoked a response in Kpnβ1 and its transport 
activity384, suggesting that Kpnβ1 is involved in stress response in general. 
 
As INI-43 has been shown to inhibit nuclear translocation of Kpnβ1 within 45-minute of treatment, 
and that 1.5-hour treatment was sufficient to impede nuclear import of Kpnβ1 cargoes333, the 
combined treatment of INI-43 and CDDP was designed with 2-hour INI-43 pre-treatment at a sub-
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lethal concentration (5 µM) followed by exposure to CDDP. Using this treatment protocol, both 
ovarian cancer and cervical cancer cells showed increased sensitivity to CDDP compared to cells 
which didn't receive the INI-43 pre-treatment. In both cancer models, this was attributed to 
increased apoptosis, which correlated with increased caspase-3/7 activity in SiHa cells, indicative of 
an escalation in the intrinsic apoptotic pathway. Furthermore, siRNA mediated Kpnβ1 knock-down in 
both cancer models led to increased CDDP sensitivity, illustrating that Kpnβ1 directly contributed to 
CDDP resistance. 
 
In the combination treatment regimen, the dose of INI-43 used (5 µM) was not sufficient to cause 
cell death on its own, yet in combination it significantly enhanced CDDP-induced cell death in both 
cancer models, suggesting a synergistic relationship between the two drugs. CI determination in SiHa 
cells confirmed this, where the majority of the combinations produced superior killing effects 
compared to the additive effects of either drugs used on its own. These findings suggest that this 
combinatory pair may have potential and warrants further research. 
 
In the ovarian cancer cell lines OVCAR4 and OVCAR5, CDDP treatment induced Kpnβ1 expression 
and nuclear localization, although whether this results in increased transport rates remain to be 
investigated. The enhanced apoptotic activities observed in the combination treatment correlated 
with a decrease in CDDP-induced nuclear Kpnβ1 accumulation, suggesting that the nuclear 
localization of Kpnβ1 may promote survival in cancer cells under stress conditions. Our findings 
suggest that Kpnβ1 associated activities favour the survival of ovarian cancer cells when exposed to 
CDDP. This was similarly observed in cervical cancer cells, although Kpnβ1 itself did not show a 
significant increase in nuclear localization or expression after CDDP treatment. It is possible that 
other regulatory mechanisms exist in HeLa cells that prevents the uncoordinated elevation in Kpnβ1 
levels in response to CDDP, as this has been shown to cause mitotic disadvantages in this cell line282, 
286. Although increased Kpnβ1 levels was not observed in cervical cancer cells in response to CDDP, 
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the increase in nuclear accumulation of the Kpnβ1 cargo NFκB-p50 and NFκB-p65 suggest that there 
was a change in substrate specificity or increase in Kpnβ1 activity in response to CDDP. Associated 
with this, an increase in cyclinD1 and c-Myc levels were observed in response to CDDP, both of 
which are transcriptionally regulated by NFκB424-428. INI-43 pre-treatment decreased the CDDP-
induced nuclear localization of NFκB presumably by interfering with Kpnβ1 activity, and the 
expression of both cyclinD1 and c-Myc were accordingly reduced. These findings provides a possible 
explanation to the enhanced CDDP sensitivity, whereby INI-43 decreases the activation of pro-
survival factors like NFκB by preventing their nuclear entry. 
  
Using the cervical cancer cell line SiHa, we found that siRNA mediated p53 inhibition abrogated the 
enhanced cell death observed in the combination treatment. This suggest that the enhanced cell 
death observed in the combination treatment compared to the single treatment may in part result 
from p53 activity. We hypothesized that a change in p53 stability may account for the differences 
observed between single and combination treatment, and in support, we found an increase in p53 
stability in the presence of INI-43. Kpnβ1 knock-down experiments further demonstrated that INI-43 
induced p53 stability was a result of Kpnβ1 inhibition. We also speculate that there may be a overlap 
between the p53 and NFκB pathway, as both proteins negatively regulate the transcriptional activity 
of each other459. The decreased levels of NFκB-target genes in INI-43 treated cells could thus result 
from a combined effect of decreased NFκB nuclear localization as well as p53 stabilization. 
Furthermore, the combination treatment was ineffective at sensitizing C33A to CDDP, a p53 mutant 
cell line, suggesting that the presence of wildtype p53 may be the determining factor for the 
synergistic interaction between INI-43 and CDDP in cervical cancer cells. 
 
The involvement of p53 in the responsiveness to the combination treatment for ovarian cancer cell 
lines OVCAR4 and OVCAR5 remains unclear, as contradicting evidence exist in literature regarding 
the p53 status for these two cell lines470, 471. However, if either cell lines harbour a mutant p53, this 
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would suggest an alternative, p53-independent mechanism for the enhanced cell death observed in 
combination treatment of these cells. 
 
The decreased expression of both cyclinD1 and c-Myc associated with sustained γH2AX expression 
24 hours after CDDP treatment. This could be an indication of enhanced DNA damage or prolonged 
DNA damage repair. As Kpnβ1 is also known to transport various cargoes involved in DNA repair, the 
enhanced level of γH2AX could result from the weakened DNA damage repair capacity as Kpnβ1 
inhibition would prevent the nuclear entry of these cargoes. A decrease in other pro-survival factors, 
including XIAP and Mcl-1 were also observed in INI-43 pre-treated cells, which correlated with 
elevated apoptosis. The fact that p53 knock-down abrogated the ability of INI-43 to sensitize cancer 
cells to CDDP suggest that p53 is likely the key regulator in this network of events, and that the 
changes observed in c-Myc, XIAP and Mcl-1, NFκB and cyclinD1 is likely dependent on p53 activities 
in SiHa cells.  
 
Whilst the enhanced killing effects of the combination treatment are linked to suppression of various 
anti-apoptotic factors, we also observed elevation of p21, which showed pro-survival effects. We 
speculate that the combined use of INI-43 and CDDP, as opposed to CDDP only, elicited alterations in 
numerous cellular events, some of which promoted cell death and others antagonizing it. However, 
the net outcome of enhanced cell death compared to the single use of CDDP demonstrated the 
feasibility of combining nuclear import inhibition and CDDP. Additionally, these results suggest a 
potential for targeting p21 and Kpnβ1 simultaneously in combination with CDDP, which further 
improved treatment outcome in SiHa cells. 
 
We demonstrated that the combined use of INI-43 and CDDP achieved greater killing effects 
compared to CDDP alone, which occurred through alteration of multiple cellular events. Amongst 
these, p53 appears to be an important mediator for the enhanced killing in the combination 
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treatment in the cervical cancer model. The role of p53 in the combination treatment in other 
cancer models should, however be determined empirically using cells with known p53 status. If the 
benefit of this combination treatment is dependent on the presence of wildtype p53, this approach 
would then be more effective at treating cancers with lower occurrence of p53 mutations, such as 
cervical cancer. The main etiology for cervical cancer is HPV infection, where the viral E6 protein 
directly inactivates p53, thereby alleviating the selection pressure for loss-of-p53 function in this 
type of cancer. Indeed, mutations in p53 is observed more frequently in HPV negative cervical cancer 
than HPV positive cervical cancer (70.8% versus 36.4%)472. Other cancers known to present with low 
p53 mutation events include myeloid leukemia and skin squamous cell carcinoma472, which could 
potentially be treated using this approach. However, if OVCAR4 and OVCAR5 are p53 mutant cells, 
our data suggest that INI-43 could sensitize cancer cells to CDDP via alternative pathways 
independent of p53, and that this approach could be effective at treating cancers with non-
functional p53.  
 
In conclusion, our study provides evidence for nuclear import inhibition as a novel class of anti-
cancer targets. This is illustrated through the use of INI-43, a potential inhibitor of Kpnβ1 which 
targeted cancer cells and sensitized cancer cells to CDDP. We propose that further development of 
this compound may result in clinically useful anti-cancer therapies. On the other hand, coupling 
nuclear import inhibition to current therapeutic regimens could significantly enhance cancer cell 
death, or alternatively, the same treatment outcome could be achieved with lower doses of CDDP, 
thereby easing the undesired side effects associated with CDDP. 
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5.2. Summary of key findings 
1. At concentrations around 10 µM, the small molecule INI-43 inhibited proliferation and induced 
apoptosis in cancer cells whilst having minimal effect on non-cancer cells proliferation in vitro.  
 
2. The effects of INI-43 are likely mediated through interfering with Kpnβ1 function, as both INI-43 
treatment Kpnβ1 knock-down induced similar phenotypes, and Kpnβ1 over-expression partially 
reversed the cancer-killing effect of INI-43. 
 
3. INI-43 decreased tumour growth in both cervical and oesophageal cancer in xenograft mouse 
models. 
 
4. INI-43 sensitized ovarian cancer cells to CDDP treatment, which correlated with decreased nuclear 
localization of Kpnβ1. 
 
5. INI-43 sensitized cervical cancer cells to CDDP treatment synergistically, and the enhanced CDDP 
sensitivity is associated with p53 activity and repression of various anti-apoptotic factors including 
Mcl-1, c-Myc and XIAP. 
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5.3. Future experiments 
Recommended future work include dissecting out the mechanism by which INI-43 induces cancer 
cell apoptosis, and to conduct comparable cell viability assays using more suitable controls such as 
non-cancer epithelial cells. As we speculate and have data to suggest that INI-43 acts by interfering 
with Kpnβ1 function, further experiments to support this could include examining the effects of INI-
43 on localization of cargoes known to be exclusively ferried by Kpnβ1 (such as SREBP1316). 
Moreover, as Kpnβ1 also play important roles in many mitotic events282, 286, the effects of INI-43 on 
mitotic processes should be investigated, including spindle assembly, chromosome segregation, 
nuclear envelope degradation and reformation. Investigating the effect of INI-43 on other members 
of the Karyopherin family known to co-operate with Kpnβ1 in importing cargoes (such as 
Karyopherinα) could provide more insight into understanding how INI-43 affects Kpnβ1. 
 
The interaction between INI-43 and Kpnβ1 could be confirmed by targeted mutation in the predicted 
binding region of INI-43 to Kpnβ1, i.e. amino acids 331-363. Other experiments to confirm direct 
binding of INI-43 to Kpnβ1 is currently being investigated in our laboratory through circular 
dichroism, fluorescence resonance energy transfer and isothermal titration calorimetry. As discussed 
earlier, the pharmacokinetic and pharmacodynamic properties of INI-43 is another area to focus on, 
including examining the absorption, distribution and excretion of INI-43 in a living system. For 
extensive in vivo testing, the structure of INI-43 could be modified to improve its chemical property 
such as solubility.  
 
The combination treatment of INI-43 and CDDP have generated promising results, and could be 
furthered by testing in an in vivo system such as in xenograft mouse models. The mechanism by 
which INI-43 stabilizes p53 should be addressed, these experiments include investigating the effects 
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of INI-43 on p53 and other proteins known to be involved in determining p53 stability (such as HPV 
E6 and MDM2). The combination treatment should also be tested in a suitable non-cancer system to 
address whether the enhanced killing effect is specific to cancer. 
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CHAPTER 6 
MATERIALS AND METHODS 
6.1. Materials  
6.1.1. Cell lines  
The following cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, 
MD, USA): human cervical carcinoma cell lines, HeLa (HPV18), CaSki (HPV16 and HPV18), SiHa 
(HPV16) and C33A (HPV negative); and normal breast skin fibroblasts CCD-1068SK. Oesophageal 
carcinoma cell lines WHCO5 and WHCO6 were originally derived from South African patients with 
oesophageal squamous cell carcinoma, and were acquired from Prof. R. Veale (University of 
Witwatersrand)473. KYSE30 was established by Shimada et al. and were purchased from German 
Resource Centre for Biological Materials, DSMZ GmbH (Braunschweig, Germany)474. Normal skin 
fibroblasts FG0 and DMB were obtained from the Department of Medicine, University of Cape Town. 
All the ovarian epithelial carcinoma cell lines; including A2780, OVCAR3, OVCAR4, OVCAR5, OVCAR8, 
SKOV3 and CP70, as well as the immortalized ovarian surface epithelial cell line T29 were provided 
by Prof. M. Birrer (Harvard Medical School, MA, USA), and were originally obtained as previously 
described475-477.  
 
6.1.2. siRNA (Kpnβ1, p53, p21) 
Inhibition of gene expression was achieved using small-interfering RNA (siRNA). All siRNAs were 
purchased as lyophilized powders from Santa Cruz Biotechnology (Santa Cruz, CA, USA), including 
Kpnβ1 siRNA (sc-35736), p21 (sc-29427), p53 (sc-29435) and the control siRNA (sc-37007). The 
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lyophilized powder was resuspended in RNase-free water to a concentration of 10 µM and stored at 
-20OC.  
 
6.1.3. Compounds 
6.1.3.1. Inhibitor of Nuclear Import-43 (INI-43) 
Inhibitor of Nuclear Import-43 (INI-43, chemical name 3-(1H-benzimidazol-2-yl)-1-(3-
dimethylaminopropyl)pyrrolo[5,4-b]quinoxalin-2-amine)) was purchased in powder form from 
Chembridge (ZINC identification number 20547783, San Diego, CA, USA) and MolPort Chemicals 
(MolPort-000-492-602, Riga Latvia). The compound was dissolved in DMSO to a stock concentration 
of 10 mM and stored at -20OC.  
 
6.1.3.2. Ivermectin 
Nuclear import inhibitor Ivermectin was purchased from Sigma-Aldrich (St Louis, MO, USA) and 
dissolved in DMSO to a stock concentration of 50 mM and stored at -20OC. 
 
6.1.3.3. Importazole 
Nuclear import inhibitor Importazole was purchased from Sigma-Aldrich (St Louis, MO, USA) and 
dissolved in DMSO to a stock concentration of 50 mM and stored at 4OC. 
 
6.1.3.4. CDDP 
Cisplatin (CDDP) was purchased as a powder form from Sigma-Aldrich (St Louis, MO, USA), and 
dissolved in 0.9% NaCl to a concentration of 1 mg/mL. Solutions were filter sterilized through a 0.22 
µm filter and kept at room temperature protected from light.  
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6.1.3.5. Doxycycline 
Doxycycline (Dox) was purchased as a powder form from Sigma-Aldrich (St Louis, MO, USA), and 
dissolved in water to a concentration of 10 mg/mL. The solution was filter sterilized through a 0.22 
µm filter and kept at -20OC protected from light. 
 
6.1.3.6. Puromycin 
Puromycin was purchased as a powder form from Calbiochem (Merck), and dissolved in water to a 
concentration of 10 mg/mL. The solution was filter sterilized through a 0.22 µm filter and kept at -
20OC protected from the light. 
 
6.1.4. Plasmids  
6.1.4.1. pHIV7-TetR-IRES-GFP-shRNA 
To conditionally inhibit the expression of Kpnβ1 in cancer cells, the lentiviral construct for 
doxycycline-inducible shRNA expression, the pHIV7-TetR-IRES-GFP (pTIG) plasmid was used. The 
construct pTIG-shRNA-Kpnβ1 (pTIG-shKpnβ1) was cloned using the pTIG-shRNA-TBX2 (pTIG-shTBX2) 
as the starting material (see section 6.2.9), which was a kind gift from A/Prof. S. Prince (University of 
Cape Town, South Africa). The pTIG plasmid was originally designed by A/Prof. M. Weinberg 
(University of Witwatersrand, South Africa, see Appendix Fig. A.2)338. The control plasmid used in 
these experiments, pTIG-scrambled sequence (pTIG-scr) was a kind gift from Dr A. Cooper and 
A/Prof. S. Prince. 
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6.1.4.2. pEFIRES-GFP plasmids 
Kpnβ1 over-expressing HeLa cells and control cells (HeLa-pEFIRES-Kpnβ1-GFP and HeLa-pEFIRES-GFP) 
were established using the pEFIRES-GFP construct as previously described333. The pEFIRES plasmid 
was kindly provided by Yosef Shaul (Weizmann Institute of Science, Isreal)478, and the Kpnβ1 
sequence was released from the pEGFP-Kpnβ1 plasmid kindly provided by Prof. P. Lavia (Institute of 
Molecular Biology and Pathology, CNR National Research Council, Rome, Italy)282. Cloning of the 
pEFIRES-Kpnβ1-GFP, and establishment of the pEFIRES stable cell lines were achieved by Dr P. van 
der Watt and Dr K. Hadley. 
 
6.1.4.3. pQC-NLS-mCherry IX 
Kpnβ1 activity was assessed in ovarian cancer cells using the pQC-NLS-mCherry IX construct 
purchased from Addgene Repository, and a kind gift from Connie Cepko (plasmid #37354)479. 
 
6.1.5. Antibodies  
The following antibodies used for the western blot and immunofluorescence experiments were 
purchased from Santa Cruz Biotechnology: rabbit anti-Kpnβ1 (H300, sc-11367), rabbit anti-β-tubulin 
(H-235, sc-9104), mouse anti-GAPDH (0411, sc-47724), rabbit anti-GFP (FL, c-8334), rabbit anti-PARP-
1 (H-250, sc-7150), rabbit anti-TBP (TFIID, N-12, sc-204), rabbit anti-p21 (H-164, sc-756), rabbit anti-
Mcl-1 (H-260, sc-20679), rabbit anti-NFκB p50 (H-119, sc-7178), rabbit anti-NFκB p65 (H-286, sc-
7151), mouse anti-cyclinD1 (HD11, sc-246) and rabbit anti-c-Myc (N-262, sc-764). Other antibodies 
used for western blot experiments include mouse anti-cytochrome C (Clone 7H8.2C12, 556433, BD 
Pharmingen, San Diego, CA, USA), rabbit anti-Peroxiredoxin-3 (Prdx-3, raised against synthetic 
peptide corresponding to amino acids 241-256 of human Prdx-3, p1247, Sigma), rabbit anti-Histone 
H3 (D1H2, raised against carboxy terminus of human histone H3 protein #4499, Cell Signal), rabbit 
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anti-phospho-Histone H2A.X (γH2AX, Ser139, 20E3, #9718, Cell Signal), anti-cleaved PARP (Asp214, 
D64E10, #5625, cell signal), mouse anti-XIAP (raised against human XIAP amino acid 268-426, 
610763, BD Biosciences) and mouse anti-p53 (DO-7, raised against recombinant human wildtype p53, 
M7001, DakoCytomation, Glostrup, Denmark). Secondary antibodies used were Goat anti-Rabbit IgG 
(H + L)-HRP Conjugate (#1706515, Bio-Rad), Goat anti-Mouse IgG (H + L)-HRP Conjugate (#1706516, 
Bio-Rad), Goat anti-Rabbit IgG (H + L), FITC conjudate (#65-6111, Thermofisher Scientific), Alexa 
Fluor 647 Chicken anti-Rabbit IgG antibody (#A-21443, Molecular Probes), and Cy3-conjugated Goat 
anti-Rabbit (#111-165-144, Jackson ImmunoResearch). 
 
6.1.6. Animals 
Animal ethics approval was obtained from the Faculty of Health Sciences Animal Ethics Committee, 
University of Cape Town, South Africa (reference number 012/009) for all animal experiments. Male 
and female athymic nu/nu mice (UCT 21) of 4 - 6 weeks age were obtained from the animal breeding 
unit (Health Sciences, University of Cape Town, South Africa) and all procedures were carried out in 
strict accordance with the guidelines of the Animal Ethics Committee, University of Cape Town. The 
mice were housed 6 per cage in autoclaved polysulfone cages in a room maintained at constant 
temperature and humidity. Mice were housed under 12-hour light and darkness cycles and were fed 
a regular autoclaved chow diet with water containing antibiotics and multi-vitamins.  
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6.2. Methods 
6.2.1. INI-43 mass and purity confirmation 
To ensure the identity and quality of INI-43 used in this study, INI-43 was dissolved in 100% DMSO 
(Sigma) and analyzed by reverse-phase high performance liquid chromatography tandem mass 
spectrometry. INI-43 was separated on a 2.1 mm x 150 mm column (Kinetex C18, particle size 2.6 µM) 
using a gradient flow, from 5 mM ammonium formate (pH 3) in 5% acetonitrile to 95% acetonitrile, 
at an eluent flow rate of 0.4 mL/min. Detection was accomplished using a diode array detector (DAD) 
coupled to an AB SCIEX 4000 QTRAP MS and equipped with electrospray positive ionization capacity 
(Turbo VTM ion source).The sample volume was 300 μL, and the acquisition mode was single 
quadrupole full scan, scanning from m/z 100 to 500 at 1 sec/scan. The target compound was 
detected at 33.33 μM. Analyst 1.5.2 software was used for instrument control and data acquisition.  
 
6.2.2. Cell culture 
6.2.2.1. Medium requirements 
The cervical cancer, oesophageal cancer, and normal skin fibroblasts cell lines (HeLa, CaSki, SiHa, 
C33A, WHCO5, WHCO6, KYSE30, CCD-1068SK, DMB and FG0) were maintained in Dulbecco's 
Modified Eagle's Medium (DMEM, Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 
100 U/mL penicillin, 100 µg/mL streptomycin and 10% Fetal Calf Serum (Gibco, Life Technologies, 
Carlsbad, CA, USA). The HeLa-pEFIRES stable cell lines were maintained in full growth medium 
supplemented with 1.5 µg/mL Puromycin (Calbiochem, Merck). The ovarian cell lines (A2780, 
OVCAR3, OVCAR4, OVCAR5, OVCAR8, SKOV3, CP70 and T29) were maintained in RPMI-1640 
(Invitrogen Life Technologies) supplemented with 10% Fetal Calf Serum (Gibco, Life technologies, CA, 
USA), 1% L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin. All cells were cultured at 
37OC in a humidified chamber with 5% CO2.  
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6.2.2.2. Subculturing cells 
Cells grown in a 10 cm tissue culture dish were washed with PBS before trypsinization with 4 mL of 
trypsin-EDTA solution. After detachment, the trypsin-EDTA-cell suspension was neutralized with the 
addition of 4 mL fresh culture medium. Cell suspension were centrifuged at 250 x G for 
approximately 5 minutes at room temperature or 4OC to pellet the cells. The supernatant was 
aspirated off and cells were resuspended in fresh culture medium at appropriate volumes and 
placed in new culture dishes. 
 
6.2.2.3. Freezing and thawing cells 
For long term storage, cells grown to approximately 80% confluency were collected by trypsinization, 
neutralization and centrifugation as above described. After aspiration, cell pellet was resuspended in 
pre-chilled freezing medium at a concentration of approximately 1 x 106 cells per mL freezing 
medium. Cells were transferred into cryotubes and kept at -80OC for two weeks before placing it in 
the liquid nitrogen.  
 
To revive the cells, 1 mL frozen cell suspension was thawed to 37OC in a waterbath and rapidly added 
to 9 mL fresh growth medium in a 10 cm culture dish.  
 
6.2.2.4. Mycoplasma checks  
To ensure that the cells were free of mycoplasma contamination, cells were routinely checked for 
mycoplasma as follows: cells were grown in penicillin-free and streptomycin-free culture medium for 
3-4 days, and plated onto coverslips. Cells were fixed and stained with Hoechst fluorescent DNA-
binding stain before mounting and visualization on a Zeiss Axiovert 200 Fluorescent Microscope (Carl 
Zeiss, Jena, Germany). 
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6.2.3. Performing the single (CDDP) and combination (INI-43 and CDDP) treatments 
To assess whether nuclear import inhibition via INI-43 treatment had an effect on CDDP sensitivity in 
cancer cells, we investigated the single CDDP treatment and combination of INI-43 and CDDP 
treatment. All combination treatments were achieved by pre-treating cells with INI-43 for 2 hours, 
followed by CDDP treatment without removing INI-43 from the media. This was achieved through 2 
serial steps - a pre-treatment using half of the total media volume with 1 x INI-43 concentration for 2 
hours, followed by a second treatment using half the total media volume with 1 x INI-43 
concentration and 2 x CDDP concentration. For treatment with 5 µM INI-43 and 30 µM CDDP in a 96-
well plate where the total media volume was 100 µL, the cells were first treated with 50 µL media 
containing 5 µM INI-43 for 2 hours, followed by addition of another 50 µL media containing 5 µM 
INI-43 and 60 µM CDDP, giving a final total volume of 100 µL, with 5 µM INI-43 and 30 µM CDDP. The 
control cells were subjected to exactly the same procedure, except equivalent volumes of DMSO 
were administered in place of INI-43.  
 
6.2.4. Half inhibitory concentration (IC50) determination 
The IC50 for the different agents were determined as follows: cells were plated at 5000 cells/well in a 
96-well dish and left overnight to adhere. Cells were then treated with the agent of interest at 
ranging concentrations for 48 hours, followed by addition of the MTT reagent (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, Sigma) for four hours. Crystals were 
solubilized using Solubilization Reagent for 24 hours. The absorbance, which is indicative of cell 
viability were measured at OD595nm using a Biotek microplate spectrophotometer (Winooski, VT, 
USA), and the IC50 value was calculated by plotting the [Fa/(1-Fa)] in log scale against log drug 
concentration, where Fa = 
100 - % viable cells relative to the untreated
100
. The half inhibitory concentration was 
calculated using the formula IC50 = 10
x-intercept. 
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6.2.5. Cell viability assay 
Cell viability was examined after incubation with drug of interest for a period of 48 hours unless 
otherwise stated. Briefly, cells were seeded to settle overnight. After drug treatment for the 
appropriate time period, MTT reagent was added at 1/10 total volume for 4 hours, and crystals were 
solubilized with Solubilization Reagent for approximately 24 hours. Cell viability was then 
determined by absorbance at OD595nm as previously described. 
  
6.2.6. Proliferation assay 
To assay for cell proliferation, cells were seeded in 96-well plates at 1000 cells/well. After 
attachment, cells were treated with INI-43 at various concentrations, and viable cells were examined 
using the MTT reagent and Solubilization Reagent as previously described, every 24 hours for a 
period of 5 days.  
 
6.2.7. Clonogenic assay  
Cells were seeded sparsely (1000 to 2000 cells per 35 mm dish), followed by INI-43 treatment the 
next day. Cells were incubated in the presence of INI-43 for 24 hours, before the drug-containing 
media is replaced with fresh growth media. The viable cells were left to proliferate and form 
colonies with the growth media replenished every 48 hours, until the control cells have formed 
colonies with approximately 50 cells per colony. Cells were rinsed with 2 mL PBS and fixed with 2 mL 
Fixation Solution for 5 minutes at room temperature. Colonies were stained with 1 mL 0.5% Crystal 
Violet Solution for 2 hours at room temperature, after which crystal violet solution was removed, 
and the plates were rinsed in tap water. The plates were left to air-dry overnight before images were 
captured using a standard camera.  
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6.2.8. Anchorage-independent proliferation assay 
Anchorage-independent proliferation of cancer cells were assayed as previously described480. Briefly, 
10 000 cells were resuspended in 100 µL full growth media containing INI-43 and 1% methylcellulose 
(Sigma) and plated in triplicates per well of a 96-well plate. Prior to plating, 96-well dishes were 
coated with 100 µL poly-(HEMA) (Sigma) per well for at least 16 hours to prevent cell adhesion. 
Colonies were monitored daily, and upon the control cells reaching reasonable colony sizes, the 
colonies were stained with MTT reagent (Sigma) for several hours at 37OC. Colonies were 
photographed using brightfield microscope with the Moticam 2500 camera (Motic, British Columbia, 
Canada) on a Zeiss Telaval microscope.  
 
6.2.9. Cloning of the pTIG- plasmids 
To conditionally inhibit the expression of Kpnβ1, an inducible shRNA system was employed. Three 
Kpnβ1 targeting shRNAs (shKpnβ1-1, shKpnβ1-2 and shKpnβ1-3) were separately cloned into the 
pHIV7-TetR-IRES-GFP-shRNA vector (pTIG), which expresses shKpnβ1 under the control of the 
tetracycline/doxycycline-inducible U6 promoter. The starting material, pTIG-shTBX2 was digested 
with restriction enzyme BamHI, which cleaved the plasmid into three segments of 7539bp, 1388bp 
and 1038bp (Fig. 6.1). The 1038bp fragment which contained the U6 promoter and the shTBX2 was 
then separated from the other fragments by electrophoresis on a 1% agarose gel (Fig. 6.2.A), and 
purified using the Wizard® SV Gel and PCR clean-up system (Promega). Using this fragment as the 
template, primers were designed for PCR to amplify the U6 promoter, with the shKpnβ1 sequence 
incorporated into the reverse primer (Fig. 6.1). Restriction sites NotI and SphI were included into the 
forward primer (1038_forward) and reverse primer (1038_reverse), respectively, along with a few 
extra base pairs for restriction enzyme digestion (Fig. 6.1). The PCR product was confirmed by 
electrophoresis to be the right size of approximately 350 bp on a 2% agarose gel (Fig. 6.2.B), and 
purified using the Wizard® SV Gel and PCR clean-up system (Promega). The PCR product and the  
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Figure 6.1. Cloning of the doxycycline inducible pHIV7-TetR-IRES-GFP-shRNA-Kpnβ1 (pTIG-shKpnβ1) using the 
pTIG-shTBX2 plasmid. The pTIG-shTBX2 plasmid was digested with BamHI to release a 1038 bp fragment 
containing both the U6 promoter and shTBX2. Using this fragment as a PCR template, primers were designed with 
restriction sites NotI and SphI, and the shKpnβ1 sequence was incorporated into the reverse primer to amplify 
PCR product containing the U6 promoter and the shKpnβ1 sequence. The PCR product and pTIG-shTBX2 were 
then both digested with NotI and SphI independently, followed by ligation to produce pTIG-shKpnβ1. 
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Figure 6.2. Cloning of the doxycycline inducible pHIV7-TetR-IRES-GFP-shRNA-Kpnβ1 (pTIG-shKpnβ1) using the 
pTIG-shTBX2 plasmid. Gel electrophoresis of BamHI digested pTIG-shTBX2, with the 1038bp fragment containing 
the U6 promoter and shTBX2 (A). Gel electrophoresis of the PCR product ran using the 1038 bp fragment from the 
BamHI digested pTIG-shTBX2, and the 1038_forward and 1038_reverse primers (B). Alignment of cloning product 
and target sequence in the U6 promoter (blue dotted line) and shKpnβ1-1 region (red solid line), confirming the 
sequence identity.  
 
 
A B 
C 
179 
 
pTIG-shTBX2 plasmid were then both digested with NotI and SphI, followed by ligation of the two 
fragments together (Fig. 6.1). The resultant plasmid was transformed into competent E.coli JM109 
cells (Promega), and prepared on large scale using the Maxiprep Kit (Qiagen). Resulting plasmid were 
then confirmed by sequencing and showed 100% match to the target sequence (Fig. 6.2.C). Details 
regarding the above mentioned steps were as follows:  
 
(i) Primer sequences: 
Forward primer: 
5’ – GATCGAATTCGGATCCGCGGCCGC*AAGGTCGGGCAGGAAGAGGGCC -3’ 
Reverse primer: 
5’ – GTCAACGCAGCATGC**(shRNA sequence)GATCTCTATCACTGATAGGGA -3’ 
shRNA sequences: 
shKpnβ1-1 
5’ - AAAAAACAGCAAACTTCAGGTAACTTCTCTTGAAAGTTACCTGAAGTTTGCTG -3’ 
shKpnβ1-2 
5’ – AAAAAAGCGGCGCAGAAGTTCCTGGTCTCTTGAACCAGGAACTTCTGCGCCGC – 3’ 
shKpnβ1-3 
5’ – AAAAAAGGATGTTCCAAAGCACAGCTCTCTTGAAGCTGTGCTTTGGAACATCC – 3’ 
*GCGGCCGC – NotI restriction site 
**GCATGC – SphI restriction site  
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(ii) Restriction enzyme digestion were all performed at 37OC for 1 hour per µg of DNA. 
 
(iii) The agarose gels were prepared by adding 1 g (for 1%) or 2 g (for 2%) of agarose powder (Sigma) 
into 100 mL TAE buffer, followed by microwave heating until completely dissolved. The solution was 
left at room temperature to reach approximately 60OC, followed by addition of 5 µL of 10 mg/mL 
ethidium bromide. The solution was then poured into the gel tank to set. DNA materials with loading 
dye were loaded into the wells and electrophoresed at 90-100 V for a time period sufficient to 
separate the DNA fragment, alongside a molecular weight marker. 
  
(iv) DNA clean-up and purification from PCR reactions and agarose gels were achieved using the 
Wizard® SV Gel and PCR clean-up system (Promega); and the large-scale plasmid preparation from 
E.coli were achieved using Maxiprep Kit (Qiagen). Both were used according to the manufacturer's 
instructions. 
 
(v) PCR was performed in a total volume of 50 µL with 20 pmole of each of the primers, 200 µM 
dNTP, 2 mM MgSO4, 1 U of Taq pfu DNA polymerase (Fermentas), 5% DMSO and 2 ng template DNA 
in sterile water. PCR conditions were denaturation at 95OC for 5 minutes; followed by 35 cycles of 
30-second denaturation at 95OC, 30-second annealing at 50.5OC, 3-minute elongation at 72OC; and a 
final elongation at 72OC for 15 minutes. The annealing temperature was chosen based on empirical 
testing, and the temperature cycles were performed using the GeneAmpPCR machine (PCR System 
2700, Applied Biosystems). 
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(vi) Ligation was performed using 500 ng linearized pTIG vector and 30 ng insert (U6-shKpnβ1), 2.5 U 
T4 DNA ligase (Promega) in a total reaction volume of 20 µL. Reaction was incubated at room 
temperature for 16 hours. 
 
(vii) Transformation was performed by addition of the entire ligation product into 50 µL of 
competent E.coli JM109 (Promega) and mixed by flicking. The tubes were placed on ice for 20 
minutes, followed by a heat shock in a 42OC waterbath for 2 minutes. The tube was placed back on 
ice for another 2 minutes, and 450 µL of LB was added. The cells were incubated at 37OC for 1 hour 
with 150 rpm shaking. A volume of 100 µL from the transformation reaction was then plated onto 
selective LA plates containing 100 µg/mL ampicillin, and the plates were incubated at 37OC overnight. 
Viable colonies indicated the successful uptake of plasmid DNA. 
 
(viii) The BigDye® Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems) was used to confirm 
the sequence of the clones, where all procedures performed were in strict accordance with the 
manufacturer’s instructions and temperature cycles were performed using the GeneAmpPCR 
machine (PCR System 2700, Applied Biosystems). DNA was cleaned up by ethanol precipitation and 
the DNA pellet was electrophoresed at the Human Genetics department (Health Sciences faculty, 
University of Cape Town). 
 
6.2.10. siRNA and plasmid transfection (siRNA, pEFIRES, pTIG, mCherry) 
To insert siRNA into cells, the transfection reagent Transfectin (Bio-Rad) or LipofectamineR 2000 
Reagent (Invitrogen Life Technologies) were used for cervical and ovarian cancers, respectively. 
Transfection mixes were prepared according to the final siRNA concentration and size of dish been 
transfected. Generally, for transfection of 20 nM siRNA, 1 µL of Transfectin or 0.9 µL of 
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LipofectamineR 2000 Reagent per mL total media volume were used. Cells were generally seeded in 
10 cm dishes on day 0, followed by transfection on day 1. On day 2, the transfected cells were sub-
cultured into smaller dishes for the subsequent experiments, unless otherwise stated. For si-Kpnβ1 
transfection (20 nM) in a 10 cm dish, 10 µL Transfectin was added to 800 µL DMEM and incubated at 
room temperature for 5 minutes. A volume of 20 µL 10 µM si-Kpnβ1 was then added to the mix and 
gently mixed by flicking the tube. The mixture was incubated at room temperature for 15 - 20 
minutes, and added dropwise to the cells in 5 mL penicillin-free and streptomycin-free growth media, 
giving a final siRNA concentration of 20 nM. For transfection of si-p21 and si-53 (30 nM) in the same 
size dish, 15 µL Transfectin and 30 µL of 10 µM siRNA were used. After 5 - 6 hours of incubation, the 
transfection mix-containing media was replaced with fresh growth media containing penicillin and 
streptomycin. For transfection of 20 nM si-Kpnβ1 using LipofectamineR 2000 Reagent in ovarian 
cancer cells, 9 µL of LipofectamineR 2000 Reagent was gently mixed with 1.5 mL DMEM and 
incubated at room temperature for 5 minutes, after which 20 µL of 10 µM si-Kpnβ1 diluted in 1.5 mL 
DMEM was added. The transfection mix were gently tapped and incubated at room temperature for 
20 minutes, and all 3 mL were then added dropwise to cells in the 10 cm dish containing 7 mL 
penicilline-free and streptomycin-free growth media. Successful knock-down is verified via western 
blotting 48 hours after transfection. 
 
For transfection of the pTIG series of plasmid, the transfection reagent GencCellinTM Transfection 
Reagent (Celtic Molecular Diagnostics, South Africa) was used. Briefly, 4 µL of GencCellinTM 
Transfection Reagent was used per µg of plasmid DNA transfected. For transfection in a 60 mm 
culture dish, 2 µg of pTIG plasmid was diluted in 200 µL DMEM, to which 8 µL of GencCellinTM 
Transfection Reagent was added. The mixture was vortexed for 2 - 3 seconds, and incubated at room 
temperature for 15 minutes, after which the mixture was added dropwise to the cells giving a final 
DNA concentration of 500 ng/mL. 
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For transfection of the pQC-NLS-mCherry-IX plasmid in ovarian cancer cells, LipofectamineR 2000 
Reagent was used. Cells were seeded in 24-well plates in total volumes of 300 µL, followed by 
transfection of 800 ng pQC-NLS-mCherry-IX using 3 µL of LipofectamineR 2000 Reagent, each diluted 
in 50 µL of DMEM and the rest of the procedure is identical to above-described.  
 
6.2.11. Protein harvest from cultured cells and quantification 
To analyze protein levels under various conditions, proteins were harvested from cells. Depending 
on the question addressed in each experiment, proteins were harvested from different cellular 
fractions.  
 
All buffers and solutions used in protein extraction procedures were added with 1 x complete 
protease inhibitor cocktail (Roche, Basel, Switzerland) and 0.1 M Sodium Orthovanadata (Na3VO4) to 
inhibit phosphatases prior to use.  
 
6.2.11.1. Whole cell lysates from live cells 
To analyze protein expression in viable cells, whole cell lysate were extracted using the RIPA buffer 
on ice. Cells were grown and subjected to the required treatment for a period of time. Before 
protein extraction, cells were washed with ice-cold PBS twice, followed by addition of RIPA buffer. 
The RIPA buffer-cell mix was scraped from the dish and placed into eppendorf tubes. The lysates 
were then sonicated for 3 - 5 seconds to shear the DNA strands, which were then removed together 
with other cellular debris by centrifugation at 10 000 x G for 10 minutes. The supernatant containing 
the proteins were then placed into new pre-chilled eppendorf tubes, and the entire procedure was 
performed strictly on ice. Protein samples were stored at -80OC until ready for quantification and 
western blotting.  
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6.2.11.2. Whole cell lysates from live and dead cells 
To analyze PARP cleavage as an indication of apoptosis, lysates from both live and dead cells were 
extracted. After the required treatment for the required time (generally 48 hours, unless otherwise 
stated), the culture media containing the floating dead cells were collected into a falcon tube and 
pelleted by centrifugation at 250 x G for 5 minutes. The dead-cell pellet and the viable adherent cells 
were both washed twice in ice-cold PBS, followed by addition of RIPA. Proteins from the live and 
dead cells were then combined, and subsequently subjected to sonication and centrifugation as 
previously described. The entire procedure was performed strictly on ice. 
 
6.2.11.3. Mitochrondrial fractionation 
To investigate the mitochondrial release of cytochrome C after INI-43 treatment, cells were grown 
and treated with INI-43 in 10 cm dishes. After the required length of incubation period, cells were 
washed twice in cold PBS, followed by lysis in Subcellular Fractionation Buffer and passed through a 
25 Ga needle ten times. The samples were then incubated on ice for 20 minutes, and centrifuged at 
720 x G for 5 minutes. The supernatant was further centrifuged at 10 000 x G, and the pellet was 
washed in Subcellular Fractional Buffer and passed ten times through a 25 Ga needle again, followed 
by centrifugation at 10 000 x G. The resulting pellet containing the mitochondrial material was 
resuspended in RIPA buffer, and stored at -80OC until ready for analysis.  
 
6.2.11.4. Nuclear and cytoplasmic fractionation 
To examine the changes in nuclear content of certain proteins after CDDP and INI-43 treatment, the 
nuclear proteins were harvested separately from the cytoplasm. Cells were grown in 10 cm dishes 
and subjected to the required treatment. At time of harvesting, cells were washed twice in ice-cold 
PBS, and collected by trypsinization as previously described. The cell pellets were resuspended in 
Harvest Buffer on ice for 5 minutes, followed by centrifugation at 1000 x G for 10 minutes which 
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separated the cytoplasmic fraction (supernatant) and the nuclear fraction (pellet). The cytoplasmic 
fraction was centrifuged again at 14 000 x G for 15 minutes, and the supernatant stored at -80OC. 
The nuclear pellet was washed in Buffer A, and centrifuged at 1000 x G for 5 minutes. The pellet was 
then resuspended in Buffer C and vortexed for 15 minutes at 4OC to extract the nuclear protein, 
followed by centrifugation at 14 000 x G for 10 minutes. The supernatant containing the nuclear 
protein was moved into a new eppendorf and stored at -80OC. 
 
All protein samples were quantified in 96-well plates using the BCA Protein Assay Kit (Pierce, Thermo 
Scientific, Rockford, IL, USA), according to the manufacturer's instructions. The absorbencies at 
OD595nm were determined using a Biotek microplate spectrophotometer (Winooski, VT, USA), 
alongside the BSA protein standards.  
 
6.2.12. Western blot analysis 
6.2.12.1. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and protein 
transfer 
SDS-polyacrylamide gels were prepared with 4% stacking gel on top of the 7.5% - 15% resolving gel. 
1-50 µg of protein samples were heat denatured in the presence of 1 x Laemmli Loading Dye at 95OC 
for 5 minutes, and loaded into the wells of the stacking gel. The protein molecular weight marker, 
Kaleidoscope (Bio-Rad) was loaded alongside to determine the size of the proteins. Samples were 
electrophoresed at 150 V-180 V for a period of time sufficient to separate the protein of interest, 
using the Bio-Rad Mini Protein II System (Bio-Rad, Hercules, CA, USA). Following electrophoresis, 
proteins were transferred onto a HybondTM-ECLTM nitrocellulose membrane (Amersham Biosciences, 
Buckinghamshire, U.K.) using a tank transfer system (Bio-Rad) at 100V for 70 minutes.  
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6.2.12.2. Immunoblotting and chemiluminescent detection 
After transfer, the nitrocellulose membranes were blocked in 5% (w/v) fat-free milk prepared in 
TBST at room temperature for 1 hour. Membranes were then incubated with the primary antibody 
(refer to Table 6.1 for antibody conditions) at 4OC overnight with shaking. The membranes were then 
washed 3 x 10 minutes in TBST with shaking, and the secondary antibody was applied for 1 - 3 hours 
at room temperature with shaking. The membranes were again washed 3 x 5 minutes, where after 
the antibody was detected using the Lumiglo, Lumiglo Reserve (KPL, Inc., Gaithersburg, MD, USA) or 
Super SignalTM West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) depending on the 
strength of the signal. The chemiluminescent light emission was detected by exposing X-ray films 
(AGFA) to the nitrocellulose membrane for a period of time, followed by immersing the film in 
developer (AGFA G128), water, then fixative (AGFA G333C) and water.  
 
6.2.12.3. Stripping and reprobing blots 
For stripping and reprobing, membranes were immersed in Stripping Buffer for 10 - 20 minutes, 
replacing with fresh Stripping Buffer halfway. Membranes were then washed in PBS 2 x 10 minutes, 
followed by 2 x 5 minutes in TBST, after which blocking and incubation with primary antibody can 
proceed. 
 
6.2.13. Immunofluorescence  
To analyze the cellular distribution of proteins, cells were grown on glass coverslips and subjected to 
the appropriate treatments. Cells were then washed twice in ice-cold PBS, and fixed in 4% 
paraformaldehyde prepared in PBS for 10 minutes at room temperature. The cells were then 
washed with PBS, and permeabilized by a 5 minute incubation with 0.5% Triton-X-100 prepared in 
PBS at room temperature. After one wash in PBST, the  cells  were blocked  using  Blocking Buffer for 
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Table 6.1. Antibody concentrations and incubation conditions for western blot analysis 
Primary antibody 
Primary antibody 
conditions 
Secondary antibody 
Secondary antibody 
conditions 
Substrate 
Rabbit anti-Kpnβ1 
(Santa Cruz) 
1:2000, 5% milk 
Goat anti Rabbit 
(Bio-Rad) 
1:5000, TBST 
Lumiglo 
Super Signal 
Mouse anti-GAPDH 
(Santa Cruz) 
1:10000, TBST 
Goat anti Mouse 
(Bio-Rad) 
1:5000, 5 % milk 
Lumiglo 
Super Signal 
Rabbit anti-β-tubulin 
(Santa Cruz) 
1:1000, TBST 
Goat anti Rabbit 
(Bio-Rad) 
1:5000, TBST 
Lumiglo 
Super Signal 
Rabbit anti-GFP (Santa 
Cruz) 
1:1000, TBST 
Goat anti Rabbit 
(Bio-Rad) 
1:5000, TBST Lumiglo 
Rabbit anti-PARP-1 
(Santa Cruz) 
1:1000, 5% milk 
Goat anti Rabbit 
(Bio-Rad) 
1:5000, TBST Lumiglo 
Rabbit anti-TFIID (TBP) 
(Santa Cruz) 
1:1000, TBST 
Goat anti Rabbit 
(Bio-Rad) 
1:5000, TBST Lumiglo 
Rabbit anti-p21 (Santa 
Cruz) 
1:200, 5% milk 
Goat anti Rabbit 
(Bio-Rad) 
1:5000, TBST Lumiglo  
Rabbit anti-Mcl-1 
(Santa Cruz) 
1:250, TBST 
Goat anti Rabbit 
(Bio-Rad) 
1:5000, TBST Lumiglo 
Rabbit anti-NFκB p50 
(Santa Cruz) 
1:5000, TBST 
Goat anti Rabbit 
(Bio-Rad) 
1:5000, 5% milk Lumiglo 
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Table 6.1. Antibody concentrations and incubation conditions for western blot analysis (continued) 
 
Rabbit anti-NFκB 
p65 (santa cruz) 
1:5000, 5% milk Goat anti Rabbit 1:5000, 5% milk 
Lumiglo 
Reserve 
Mouse anti-cyclinD1 
(santa cruz) 
1:250, 2.5% milk Goat anti Mouse 1:2500, 5% milk 
Lumiglo 
Reserve 
Mouse anti-c-Myc 
(santa cruz) 
1:200, 5% milk Goat anti Mouse 1:2000, 5% milk Lumiglo 
Mouse anti-
cytochrome C (BD 
Pharmingen) 
1:250, TBST Goat anti Mouse 1:2500, 5% milk 
Lumiglo 
Reserve 
Rabbit anti-
Peroxiredoxin-3 
(Sigma) 
1:4000, TBST Goat anti Rabbit 1:5000, TBST Lumiglo 
Rabbit anti-Histone 
H3 (D1H2) (cell 
signal) 
1:5000, TBST Goat anti Rabbit 1:5000, TBST 
Lumiglo 
Super Signal 
Rabbit anti-
Phospho-Histone 
H2A.X (ser139) (cell 
signaling) 
1:500, TBST Goat anti Rabbit 1:5000, TBST 
Lumiglo, 
Super Signal 
Mouse anti-p53 
(Dako) 
1:500, TBST Goat anti Mouse 1:2000, 5% milk Lumiglo 
Rabbit anti-Cleaved 
PARP (cell signal) 
1:1000, 5% BSA Goat anti Rabbit 1:5000, 5% milk Super Signal 
Mouse anti-XIAP 
(BD Biosciences) 
1:500, TBST Goat anti Mouse 1:2000, 5% milk Lumiglo 
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15 minutes at 37OC (Blocking Buffer: 5% Normal Horse Serum (Sigma) and 0.2% Gelatin from cold 
water fish skin (Sigma) prepared in 1 x PBST). After blocking, cells were incubated with the primary 
antibody and secondary antibody diluted in Blocking Buffer or 1% BSA (Table 6.2), each for 60 
minutes at 37OC with 3 x 5 minute PBST washes in between. The cells were washed one final time 
with PBST at room temperature, and the nuclei were labelled with 500 ng/mL DAPI. The slides were 
mounted and coverslipped, and images were visualized using a Zeiss Inverted Fluorescence 
Microscope under 100 x oil immersion. For confocal imaging, a spinning disk confocal microscopy 
(Nikon Ti2000 and Yokugawa CSU-X1) was used. Images were acquired using a EMCCD camera 
(Hamamatsu).  
 
Table 6.2. Antibody concentrations and incubation conditions for immunofluorescence  
 
Primary antibody 
Primary 
antibody 
conditions 
Secondary antibody 
Secondary 
antibody 
conditions 
Cell lines 
Rabbit anti Kpnβ1 
(Santa Cruz)  
1:400, blocking 
buffer 
Goat anti Rabbit IgG, 
FITC conjugate 
(Thermofisher 
Scientific) 
1:200, blocking 
buffer* 
Ovarian cancer 
cell lines 
Rabbit anti Kpnβ1 
(Santa Cruz)  
1:400, blocking 
buffer 
Alexa Fluor 647 
Chicken anti Rabbit 
IgG (Molecular 
Probes) 
1:200, blocking 
buffer* 
Ovarian cancer 
cell lines 
Rabbit anti Kpnβ1 
(Santa Cruz)  
1:100, 1% BSA in 
PBST 
Cy3 Goat anti Rabbit 
(Jackson 
ImmunoResearch) 
1:300, 1% BSA in 
PBST 
Cervical cancer 
cell lines 
Rabbit anti NFκB 
p50 (Santa Cruz) 
1:200, 1% BSA in 
PBST 
Cy3 Goat anti Rabbit 
(Jackson 
ImmunoResearch) 
1:300, 1% BSA in 
PBST 
SiHa 
Rabbit anti NFκB 
p65 (Santa Cruz) 
1:200, 1% BSA in 
PBST 
Cy3 Goat anti Rabbit 
(Jackson 
ImmunoResearch) 
1:300, 1% BSA in 
PBST 
SiHa 
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6.2.14. Microsomal assay 
To determine the metabolic stability of INI-43, human liver microsome (pool of 50, mixed gender, 
Batch number H0610, Lot number 1110413, Xenotech) and mouse liver microsome (pool of 600 
male Mouse BALB/c, Batch number M3000, Lot number 0810197, Xenotech) were used to set up 
reactions containing 0.5 mg/mL microsomes, 10 μM INI-43 and 5 mM MgCl2 made up to 475 μL with 
0.1 M phosphate buffer. Reactions were initiated by adding 1 mM co-factor NADPH and incubated at 
37OC for 30 minutes. The reaction was stopped by adding equal volumes of pre-chilled acetonitrile to 
precipitate the proteins. The samples were vortexed and centrifuged, and supernatant was filtered 
through a 0.22 μm filter. The centrifuged and filtered samples of microsomal incubations were then 
analysed by HPLC-MS/MS to determine the remaining concentrations of the parent compound. A 
reverse-phase high performance liquid chromatography (HPLC) on a high-pressure chromatogram 
(Agilent 1200 Rapid Resolution, 600 bar, USA) with a diode array detector (DAD) coupled to an AB 
SCIEX 4000 QTRAP MS, equipped with a Turbo VTM ion source and a 2.1 mm x 150 mm column 
(Kinetex C18, particle size 2.6 µM) were used. The column was eluted in a gradient flow, from 5 mM 
ammonium formate (pH 3) in 5% acetonitrile to 95% acetonitrile, at an eluent flow rate of 0.4 
mL/min. Analyst 1.5.2 software was used for instrument control and data acquisition. Lightsight 
2.2.1 software was used for metabolite identification and data processing. The % INI-43 remaining 
were calculated using the formula % INI-43 remaining = 
peak area after incubation
peak area at T=0
 x 100, and the projected 
half-life (T1/2) was determined using the formula T1/2 (minutes) = absolute(
ln 2 x  incubation time 
ln  
%remaining
100
 
) as 
previously described481.  
 
6.2.15. INI-43 toxicology analysis 
To confirm that INI-43 is suitable for testing in nude mice, toxicology studies were performed. 
Experiments were initiated with low dose INI-43 (1 mg/kg), where twelve mice were randomized 
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into the control and test group of 6 each. The test mice received 1 mg/kg INI-43 dissolved in DMSO, 
and the control mice received an equivalent amount of DMSO. INI-43 and DMSO were delivered via 
intraperitoneal injections every 48 hours for a duration of 28 days, through which the animals’ 
wellbeing and body mass were monitored daily. At the end of the experiment, the mice were 
euthanized by halothane overdose and autopsies were performed for regular checks. The liver was 
then removed and weighed, and sent for pathological examination. After confirming that the mice 
were tolerant to 1 mg/kg INI-43, intermediate dose at 10 mg/kg were tested, followed by high dose 
at 50 mg/kg. All experiments were carried out in identical format.  
 
6.2.16. Tumour formation analysis 
To optimize the conditions for tumour induction in nude mice using xenografted cancer cells, nine 
mice were used for each of the cell lines HeLa, CaSki, WHCO6 and KYSE30. Mice were divided into 
three groups of 3, receiving 5, 7.5 and 10 million cancer cells via subcutaneous injections. Cells for 
inoculation were prepared by culturing in 15 cm dishes until approximately 80% confluent. Cells 
were harvested by trypsinization, washed twice in ice-cold PBS and resuspended in PBS to a final 
concentration of 25 000 cells/µL, 37 500 cells/µL and 50 000 cells/µL. A volume of 200 µL cell 
suspension was subcutaneously implanted into the hind flanks of each nude mice, equivalent to 5 
million, 7.5 million and 10 million cells, respectively. The mice were monitored daily for wellbeing 
and tumour development, where the tumour length and width were recorded using a calliper. 
Tumour volume was calculated using the formula tumour volume (mm3) = 
length x width x width
2
. For 
irregularly shaped tumours, length refers to the longest diameter and width refers to the shortest 
diameter. Upon the tumour length reaching 20 mm, appearance of necrosis in the tumour tissues, or 
observation of distress in the mice, whichever occurred first, the animal was euthanized by 
halothane overdose and the endpoint of each experiment was marked by the death of the last 
mouse in that group. 
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6.2.17. Tumourigenesis assay 
The tumourigenesis assay was carried out using the cervical cancer cell line CaSki and oesophageal 
cancer cell lines WHCO6 and KYSE30. Cancer cells (5 x 106 per mouse) were subcutaneously 
implanted into the hind flanks of nude mice as previously described. Once the tumours had reached 
a palpable size, drug treatment was initiated. Tumour bearing mice were randomized into two 
groups of six each, and dosed intraperitoneally with either the vehicle control (DMSO) or INI-43 (50 
mg/kg), every 2-3 days for 3 (WHCO6 and KYSE30) or 4 (CaSki) weeks. The WHCO6 and KYSE30 
tumours grew more rapidly, and either reached 20 mm or developed necrosis before the pre-
scheduled 4-week experimental duration, and hence had to be euthanized earlier. Tumours were 
measured on day 0 (first treatment) and twice a week thereafter, using a calliper as previously 
described. At the end of each studies, tumours were dissected out, weighed and photographed.  
 
6.2.18. Combination index determination 
To elucidate the nature of the combined use of INI-43 and CDDP (i.e. synergistic, additive or 
antagonistic), the Chou-Talalay method was employed. Briefly, cells were seeded in 96-well plates at 
5000 cells per well in five replicates. The cells were then subjected to INI-43 only, CDDP only or a 
combination of INI-43 and CDDP as previously described. The concentration of drugs used are 
summarized in Appendix Table 7.1, where three ratios were tested, 1 INI-43 : 3 CDDP, 1 INI-43 : 4 
CDDP and 1 INI-43 : 5 CDDP. Cells were incubated in the presence of drugs for 48 hours, after which 
cell viability for each treatment were determined using the MTT reagent and Solubilization Reagent. 
Cell viabilities for each treatment were normalized to the untreated, and converted to Fa as 
previously described. The Fa values were then used to calculate the CI values using the CompuSyn 
software (ComboSyn, Inc., Paramus, NJ), and plotted against Fa.  
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6.2.19. Caspase-3/7 activity 
SiHa cells were seeded in 96-well plates and treated with DMSO or INI-43 for 2 hours, followed by 
CDDP at various concentrations for 48 hours. Caspase-3/7 activity was monitored using the Caspase-
GloR 3/7 assay, according to the manufacturer's instructions. Luminescence was measured using the 
VeritasTM microplate luminometer (Promega) and normalized to cell viability measured by the MTT 
performed in parallel.  
 
6.2.20. p53 half-life determination 
To determine the half-life of p53 in INI-43 treated and Kpnβ1 knock-down cells, SiHa cells were 
treated with 5 µM of INI-43 for two hours or transfected with si-Kpnβ1 for 48 hours, consistent with 
the pre-treatment prior to CDDP exposure. Cells were then treated with 50 µg/mL cycloheximide 
(CHX), where after proteins were harvested at 0, 15, 30, 45, 60 and 90 minutes. Proteins were 
quantified by the BCA kit (Pierce), as previously described, and p53 expression were examined via 
western blotting. Resulting protein bands were densitometrically quantified by ImageJ, followed by 
normalization to p53 band intensity at time = 0. The band intensities were plotted in log scale 
relative to time, and the half life T1/2 was calculated using the following equation T1/2 (minutes) = 
Log2
[slope]
 , where [slope] is the absolute value of the gradient of the linear trendline drawn.  
 
6.2.21. Statistical analysis 
Experiments were performed in triplicates, quadruplicates, 5 or 6 replicates, and expressed as the 
mean ± standard error of the mean (SEM), unless otherwise stated. All in vitro experiments were 
performed at least two independent times. For data analysis, the Student's t-test (unpaired or paired) 
was performed with a p value of <0.05 considered statistically significant. For the in vivo experiments, 
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changes in mice's body mass and liver mass were analyzed using non-parametric Mann-Whitney U 
test, and a p value of <0.05 was considered statistically significant. 
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6.3. Solutions 
6.3.1. Tissue culture solutions 
 Trypsin-EDTA 
 0.5 g Trypsin 
 8 g NaCl 
 1.45 g Na2HPO4.2H2O 
 0.2 g KCl 
 0.2 g KH2PO4 
 10 mM EDTA, pH 8.0 
 Adjust volume to 1 L with PBS 
 
 Cell-freezing media 
 90% Growth media 
 10% DMSO 
 
 MTT reagent (IC50, viability and proliferation assays) 
 100 mg MTT 
 20 mL PBS 
 Vortex and incubate in 37OC waterbath for 15 minutes  
 Filter sterilize through 0.22 µm filter 
 Store at 4OC protected from light for a maximum period of one month 
 
 Solubilization Reagent (IC50, viability and proliferation assays) 
 25 g SLS 
 Adjust volume to 250 mL with dH2O 
 Add 76.6 µL concentrated HCl 
 
 Fixation Solution (clonogenic assay) 
 12.5 mL glacial acetic acid 
 87.5 mL methanol 
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 Crystal Violet Solution (clonogenic assay) 
 500 mg crystal violet 
 25 mL methanol 
 75 mL dH2O 
 
 1% methylcellulose growth media (anchorage-independent colony formation assay) 
 1 g methylcellulose powder 
 Autoclave 
 100 mL pre-warmed complete growth media 
 Vortex and shake at 4OC overnight 
 
 Poly-(HEMA) solution (anchorage-independent colony formation assay) 
 2.4 g poly(2-hydroxyethyl methacrylate) 
 200 mL 96% ethanol 
 Dissolve with constant stirring in 65OC waterbath 
 
6.3.2. Protein solutions 
6.3.2.1. Protein extraction solutions 
Prior to use, complete protease inhibitor cocktail (Roche, Basel, Switzerland) and Sodium 
Orthovanadate (Na3VO4) were added to a final concentration of 1 x and 0.1 M respectively, to all 
protein extraction solutions. 
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 RIPA Buffer (50 mL) 
      Volume   Final concentration 
 5 M NaCl    1.5 mL   150 mM 
 1 M Tris, pH 7.5    2.5 mL   50 mM 
 Triton-X-100    0.5 mL   1% (v/v) 
 Sodium deoxycholate   0.5 g powder  1% (w/v) 
 10% SDS    0.5 mL   0.1% (v/v) 
 500 mM EGTA    0.2 mL   2 mM 
 500 mM EDTA    0.2 mL   2 mM 
 500 mM NaF    5 mL   50 mM 
 100 mM Na2P2O7   2.5 mL   5 mM 
 ddH2O to 50 mL 
 
 Subcellular Fractionation Buffer (Mitochondrial protein extraction, 50 mL) 
 4.28 g Sucrose 
 1 mL 1 M HEPES (pH 7.4) 
 5 mL 100 mM KCl  
 7.5 μL 1 M MgCl2 
 100 μL 500 mM EDTA 
 100 μL 500 mM EGTA 
 Up to 50 mL with dH2O 
 
 Harvest Buffer (Nuclear protein extraction, 50 mL) 
 500 μL 1 M HEPES pH 7.9 
 2.5 mL 1 M NaCl 
 10 μL 500 mM EDTA 
 250 μL Triton-X-100 
 Up to 50 mL with dH2O 
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 Buffer A (Nuclear protein extraction, 50 mL) 
 500 μL 1 M HEPES pH 7.9 
 500 μL 1 M KCl 
 10 μL 500 mM EDTA 
 10 μL 500 mM EGTA 
 Up to 50 mL with dH2O 
 
 Buffer C (Nuclear protein extraction, 50 mL) 
 50 μL 1 M HEPES pH 7.9 
 2.5 mL 1 M NaCl 
 5 μL 100 mM EDTA 
 5 μL 100 mM EGTA 
 100 μL 5% NP-40 
 Up to 5 mL with dH2O 
 
6.3.2.2. Western Blot solutions 
 4% Stacking Gel 
 1.25 mL 1 M Tris-Cl, pH 6.8 
 100 µL 10% SDS 
 1.3 mL 30% Acrylamide 
 7.3 mL dH2O 
 120 µL 10% APS 
 12 µL Temed 
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 Resolving Gel 
Component 7.5% 10.0% 12.5% 15.0% 
ddH2O 7.3 mL 5.7 mL 4.3 mL 2.3 mL 
1 M Tris pH 8.8 7.5 mL 7.5 mL 7.5 mL 7.5 mL 
30% acrylamide 5 mL 6.6 mL 8 mL 10 mL 
10% SDS 100 µL 100 µL 100 µL 100 µL 
10% APS 350 µL 350 µL 350 µL 350 µL 
TEMED 35 µL 35 µL 35 µL 35 µL 
 
  
 4% Laemmli Loading Dye (10 mL) 
 2.5 mL 1 M Tris-Cl, pH 6.8 
 3 mL 20% SDS 
 0.5 mL 0.1% Bromophenol Blue 
 4 mL Glycerol 
 
Prior to use, 50 μL of β-mercaptoethanol was added into 450 μL of the dye solution and kept at 
room temperature for a maximum period of 1 month 
 
 1 x Running Buffer 
 2.9 g Tris 
 14.4 g Glycine 
 1 g SDS 
 Up to 1 L with dH2O 
 
 1 x Transfer Buffer 
 3.03 g Tris 
 14.4 g Glycine 
 500 mL dH2O 
 200 mL Isopropanol/Methanol 
 Up to 1 L with dH2O  
200 
 
 TBST 
 6.05 g Tris 
 8.77 g NaCl 
 800 mL dH2O 
 Adjust pH to 7.5 
 500 μL Tween-20 
 Up to 1 L with dH2O 
 
 Stripping Buffer 
 15 g glycine 
 1 g SDS 
 10 mL Tween-20 
 Adjust pH to 2.2 
 up to 1 L with dH2O 
 
6.3.3. DNA solutions 
 TE Buffer 
 1 mL 1 M Tris-Cl, pH 8.0 
 200 μL 500 mM EDTA, pH 8.0 
 98.8 mL dH2O 
 
 TAE Buffer 
 4.84 g Tris 
 1.14 mL Glacial acetic acid 
 2 mL 500 mM EDTA 
 Up to 1 L with dH2O 
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6.3.4. Bacterial solutions 
 Luria Broth (LB) 
 10 g Tryptone 
 5 g Yeast Extract 
 10 g NaCl 
 950 mL dH2O 
 Adjust to pH 7.0 with 5 N NaOH 
 Up to 1 L with dH2O 
 Autoclave 
 
 Luria Agar (LA) 
 10 g Tryptone 
 5 g Yeast Extract 
 10 g NaCl 
 15 g Agar 
 Up to 1 L with dH2O 
 Autoclave 
 
 Ampicillin (10 mg/mL) 
 1 mg Ampicillin 
 10 mL dH2O 
 Filter sterilize using 0.22 µm filter 
 Stored at -20OC 
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6.3.5. Others 
 4% Paraformaldehyde (Immunofluorescence) 
 40 g paraformaldehyde 
  900 mL PBS 
 Heat to approximately 60OC with constant stirring 
 Raise pH by adding 1 N NaOH dropwise, until solution clears 
 Up to 1 L with PBS 
 Filter sterilize 
 
 Mowiol Mounting Solution 
 2.4 g Mowiol-488 
 6 g Glycerol 
 6 mL dH2O 
 Stir vigorously 
 12 mL 200 mM Tris-Cl, pH 8.5 
 Heat to 60OC with stirring for 10 minutes 
 Remove undissolved particles by centrifugation at 5000 x G for 15 minutes 
 Store at -20OC 
 Prior to use, dissolve 2.5 mg of n-propyl gallate in 1 mL thawed Mowiol by vortexing 
 
6.3.6. General 
 PBS 
 8.0 g NaCl 
 0.2 g KCl 
 0.24 g KH2PO4 
 1.44 g Na2HPO4 
 800 mL dH2O 
 Adjust to pH 7.4 with HCl 
 Up to 1 L with dH2O 
 Autoclave 
203 
 
 PBST 
 1 L PBS 
 2 mL Tween-20 
 
 0.5 M EDTA 
 186.12 g Na2EDTA-2H2O 
 800 mL dH2O 
 Adjust to pH 8.0 with NaOH 
 Up to 1 L with dH2O 
 Autoclave 
  
 0.5 M EGTA 
 190.18 g EGTA 
 800 mL dH2O 
 Adjust to pH 8.0 with NaOH 
 Up to 1 L with dH2O 
 Autoclave 
 
 1 M Tris-Cl 
 121 g Tris base 
 800 mL dH2O 
 Adjust to pH 8.0 with conc. HCl 
 Up to 1 L with dH2O 
 Autoclave 
 
 1 M HEPES 
 238.80 g HEPES 
 800 mL dH2O 
 Adjust to desired pH using KOH pellets 
 Up to 1 L with dH2O 
 Filter sterilize 
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APPENDIX I 
INI-43 IC50 determination plots in additional ovarian cancer cell lines 
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INI-43 IC50 determination plots in additional oesophageal cancer cell lines 
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INI-43 IC50 determination plots in additional non-cancer cell lines 
 
 
 
  
Figure A.1. INI-43 IC50 determination in ovarian cancer, oesophageal cancer and non-cancer fibroblast cell lines. 
Five-thousand cells were seeded per well in 96-well plates and allowed to settle overnight. Cells were then 
treated with INI-43 at various concentrations, and viable cells were assayed 48 hours later using the MTT reagent 
as previously described. Cell viability was standardized to the untreated cells, and plotted as log [Fa/(1-Fa)] 
against INI-43 concentration in log scale as previously described. Results shown are mean ± SEM of experiments 
performed in 5 replicates repeated at least two independent times.  
 
231 
 
APPENDIX II 
 
  
Figure A.2. pHIV7-TetR-IRES-shRNA-Kpnβ1 (pTIG-shKpnβ1). The conditional shRNA expressing plasmid 
containing the shKpnβ1 under the control of the tetracycline/doxycycline-inducible U6 promoter, spanned by NotI 
and SphI restriction sites. The plasmid also contains IRES for expression of GFP as a selection marker in eukaryotic 
cells, and Ampicillin resistance gene (AmpR) for selection in bacterial cells.  
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APPENDIX III 
 
  
Figure A.3. pQC-NLS-mCherry-IX. The pQC construct which constitutively expressed the NLS-tagged mCherry 
fluorescent protein under the control of the CMV promoter. 
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APPENDIX IV 
Table A.1. Combination Index determination: CDDP and INI-43 concentrations used in cell viability 
assays 
 
CDDP (µM) 
INI-43 (µM) 
1INI-43:3CDDP 1INI-43:4CDDP 1INI-43:5CDDP 
3 1 0.75 0.6 
7.5 2.5 1.875 1.5 
15 5 3.75 3 
22.5 7.5 5.625 4.5 
30 10 7.5 6 
45 15 11.25 9 
  
Table A.1. CDDP and INI-43 concentrations used in determining the nature of interaction between the two 
drugs. Cells were subjected to treatment with single INI-43, single CDDP or a combination of INI-43 and CDDP. 
The combination treatment was carried out where the ratio of the two drugs remain constant in each 
experiment, and the INI-43 to CDDP ratios tested were 1:3, 1:4 and 1:5.  
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